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“Kites rise highest against the wind, not with it.” 
― Sir Winston Churchill 
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ABSTRACT 
Parkinson’s disease (PD) is a chronic neurodegenerative disorder characterized by progressive loss 
of nigrostriatal dopamine neurons and propagating Lewy body pathology. Dopamine depletion in 
the striatum gives rise to the cardinal motor symptoms of PD. Current PD medications are based 
on replenishing striatal dopamine and provide symptomatic relief to the motor deficits. However, 
troublesome adverse effects and diminished efficacy complicate their long-term use. There is a 
great unmet medical need for a therapy that could slow or halt the progression of the disease. 
Neurotrophic factors (NTFs) are secreted proteins that promote neuronal growth, differentiation 
and survival. They are able to prevent the progression of neurodegeneration and restore aberrant 
neuronal function in a variety of preclinical models of PD. Nonetheless, outcomes from clinical 
trials have been disappointing. The purpose of this work was to characterize the effects of cerebral 
dopamine neurotrophic factor (CDNF), mesencephalic astrocyte-derived neurotrophic factor 
(MANF) and novel small molecule receptor tyrosine kinase RET agonists (BT13 and BT44) on 
nigrostriatal dopamine system and support their preclinical development as potential 
neurotrophic therapies of PD. 
To further clarify the functional effects of glial cell line-derived neurotrophic factor (GDNF), CDNF 
and MANF in the normal rat brain, microdialysis measurements were performed after a bolus 
injection of NTFs into the striatum. We saw augmented stimulus-evoked dopamine release and 
elevated dopamine turnover in the striatum of MANF-injected rats. GDNF injection increased in 
vivo tyrosine hydroxylase (TH) and catechol-O-methyltransferase activity and decreased 
monoamine oxidase A activity. These data are relevant when considering exogenously 
administered NTFs as a potential therapeutic approach for PD, since they have to be compatible 
with the existing dopaminergic medications of the patients. 
We also investigated the distribution properties of 125I-labeled and unlabeled CDNF after a nigral 
injection to intact rats. CDNF readily diffused into the brain areas surrounding the injection site 
and colocalized with TH-immunoreactive neurons in the substantia nigra. We did not detect active 
transportation of CDNF to distal brain areas. This characterization provides valuable insights into 
the selection of optimal delivery site and protocol for CDNF therapy. 
Our in vitro assays showed that RET agonists BT13 and BT44 were able to induce RET 
phosphorylation and activate downstream pro-survival signaling cascades Akt and ERK. They also 
supported the survival of cultured midbrain dopamine neurons from wild-type, but not from RET 
knockout, mice. The functional effects of BT13 and BT44 were evaluated in a unilateral 6-
hydroxydopamine rat model of PD, where both compounds alleviated amphetamine-induced 
turning behavior. BT44 also showed potential to restore striatal TH-immunoreactive fibers. As 
blood-brain barrier penetrating compounds, BT13 and BT44 serve as promising leads that can be 
further developed into a disease-modifying therapy for PD. 
 
TIIVISTELMÄ 
Parkinsonin tauti on etenevä hermorappeumasairaus, jolle on ominaista aivojen mustatumakkeen 
dopamiinihermosolujen tuhoutuminen ja Lewyn kappaleiden esiintyminen aivoissa. 
Dopamiinihermosolujen tuhoutuminen johtaa aivojuovion dopamiinivajeeseen, joka saa aikaan 
Parkinsonin taudille ominaiset liikehäiriöt. Taudin nykyinen lääkitys perustuu dopamiinivajeen 
korjaamiseen ja on luonteeltaan oireita lievittävää. Pitkäaikaiskäytössä lääkkeet menettävät 
tehoaan ja johtavat hankaliin haittavaikutuksiin. Taudin kulkua hidastavalle hoidolle onkin suuri 
tarve. Hermokasvutekijät ovat hermosolujen kasvua, erilaistumista ja selviytymistä edistäviä 
proteiineja. Niiden on osoitettu estävän dopamiinihermosolujen tuhoutumista ja korjaavan niiden 
häiriintynyttä toimintaa useissa kokeellisissa Parkinson-malleissa. Kliinisissä kokeissa testattujen 
hermokasvutekijähoitojen teho on kuitenkin jäänyt puutteelliseksi. Tämän väitöstyön 
tarkoituksena oli selvittää CDNF:n (dopamiinisolujen hermokasvutekijä) ja MANF:n (keskiaivojen 
astrosyyttiperäinen hermokasvutekijä) sekä uusien, RET-tyrosiinikinaasia aktivoivien 
pienmolekyylien BT13:n ja BT44:n vaikutuksia aivojen dopamiinijärjestelmään ja samalla tukea 
niiden prekliinistä kehitystä mahdolliseksi Parkinsonin taudin kulkuun vaikuttavaksi hoidoksi. 
Ensimmäisessä osatyössä selvitimme aivojuovioon annostellun GDNF:n (gliasolulinjaperäinen 
hermokasvutekijä), CDNF:n ja MANF:n aiheuttamia toiminnallisia muutoksia terveen rotan 
aivoissa käyttämällä hyväksi mikrodialyysimenetelmää. Havaitsimme MANF:n lisäävän stimuloitua 
dopamiinin vapautumista ja dopamiinin aineenvaihduntaa aivojuoviossa. GDNF injektio 
puolestaan lisäsi dopamiinia syntetisoivan tyrosiinihydroksylaasientsyymin aktiivisuutta. Lisäksi se 
vaikutti dopamiinia metaboloivien entsyymien toimintaan lisäämällä katekoli-O-
metyylitransferaasin ja vähentämällä monoamiinioksidaasin aktiivisuutta. Nämä löydökset 
auttavat sovittamaan mahdollisia hermokasvutekijähoitoja yhteen Parkinson-potilaiden 
käyttämien dopaminergisten lääkkeiden kanssa. 
Toisessa osatyössä tutkimme CDNF:n leviämisominaisuuksia terveen rotan aivoissa 
mustatumakkeeseen kohdistuneen annostelun jälkeen. CDNF levisi laajalle injektiokohtaa 
ympäröivään aivokudokseen ja oli havaittavissa mustatumakkeen dopamiinihermosoluissa. 
Merkkejä CDNF:n aktiivisesta kuljetuksesta kaukaisemmille aivoalueille ei havaittu. Tämä tutkimus 
tarjoaa arvokasta lisätietoa CDNF:n optimaalisen annostelutavan määrittämiseksi. 
Kolmannessa ja neljännessä osatyössä osoitimme BT13:n ja BT44:n aktivoivan soluja suojaavat 
Akt- ja ERK-signalointireitit sekä edistävän viljeltyjen dopamiinihermosolujen selviytymistä. Kun 
BT13:n ja BT44:n vaikutuksia tutkittiin Parkinsonin taudin eläinmallissa rotilla, molempien 
yhdisteiden havaittiin lievittävän kokeessa mitattua liikehäiriötä. BT44 osoitti myös viitteitä 
dopaminergisia hermosäikeitä korjaavasta vaikutuksesta. Veri-aivoesteen läpäisevät BT13 ja BT44 
ovatkin lupaavia johtolankamolekyylejä, joita edelleen optimoimalla voisi olla mahdollista kehittää 
uusi Parkinsonin taudin etenemistä hidastava hoito.  
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Parkinson’s disease (PD) is a debilitating neurological disorder with increasing prevalence in aging 
populations. The cardinal motor symptoms of PD arise from the progressive degeneration of 
nigrostriatal dopamine neurons and the resultant dopamine depletion in the dorsal striatum (Kalia 
and Lang 2015; McGregor and Nelson 2019). This causes imbalance in the excitability of the direct 
and indirect striatal projection pathways within the basal ganglia leading to inadequate activation 
of the motor cortex and impaired motor functions. The underlying pathological processes of PD 
are incompletely understood, but they seem to be associated with neuroinflammation and the 
presence of intracellular protein inclusions called Lewy bodies. 
There is no cure for PD. The current treatments provide symptomatic relief mainly to the motor 
symptoms by increasing dopaminergic activity within the dorsal striatum (Armstrong and Okun 
2020). With the progression of the disease, however, the therapies gradually lose their effects and 
start to be accompanied by troublesome adverse effects such as motor fluctuations, dyskinesias 
and psychiatric symptoms. The dopaminergic treatments have minor effects on disabling non-
motor symptoms of PD and, importantly, they are unable to halt the neurodegenerative processes 
underlying the disease. Thus, a disease-modifying therapy remains an urgent unmet medical need 
for PD.  
Our brain has an innate capacity to reorganize its structure, neuronal connections and functions 
in response to intrinsic and extrinsic stimuli (Cramer et al. 2011). These dynamic adaptations, 
commonly called neuroplasticity, have a pivotal role in the proper function of the nervous system. 
Neurotrophic factors (NTFs) are small secreted proteins that regulate almost all aspects of 
neuroplasticity including neurogenesis, neuronal development and maintenance and, 
importantly, the survival and recovery of neurons (Paratcha and Ledda 2008). Therefore, NTFs 
serve as promising candidates for developing disease-modifying therapies for neurodegenerative 
disorders such as PD. 
There are four major families of NTFs, two of which, GDNF family ligands and CDNF/MANF family 
of NTFs, are of special interest in this thesis. Glial cell line-derived neurotrophic factor (GDNF) is 
the founding member of GDNF family ligands and was identified in 1993 based on its survival-
promoting effects on cultured midbrain dopamine neurons (Lin et al. 1993). Thereafter, intensive 
research efforts have uncovered the signaling mechanisms of GDNF as well as its robust survival 
promoting and regenerative effects on midbrain dopamine neurons both in vitro and in animal 
models of PD. 
Cerebral dopamine neurotrophic factor (CDNF) and mesencephalic astrocyte-derived 
neurotrophic factor (MANF) form structurally and functionally distinct family of NTFs (Lindholm et 
al. 2007; Petrova et al. 2003). They have also shown strong neurotrophic properties on midbrain 
dopamine neurons promoting their survival and repair in vitro and in animal models of PD. Their 
precise mechanism of action, however, has remained undetermined thus far. Being endoplasmic 




subsequent unfolded protein response (UPR). As inflammation and ER stress responses are closely 
linked with each other, their neuroprotective effects may be due to regulation of 
neuroinflammation in the brain. 
Following promising outcomes in preclinical experiments, intracranial GDNF application 
proceeded into clinical trials with PD patients. These trials suggest a favorable safety profile for 
the NTF therapies together with some promising efficacy outcomes, yet none of the randomized, 
placebo-controlled trials met their primary endpoints (Nutt et al. 2003; Lang et al. 2006; Whone 
et al. 2019). The varying success in the clinical trials has raised questions about the optimal dosing 
paradigm and protein therapy related challenges. NTFs are, for example, unable to cross the 
blood-brain barrier (BBB), and thus require intracranial delivery increasing treatment-related risks 
and costs. A small molecule that mimics the effects of NTFs on degenerating dopamine neurons 
and is suitable for systemic administration would be an attractive drug candidate for PD. 
In the present study, we pursued new insights into the biological effects of intrastriatally injected 
CDNF and MANF on dopamine synthesis, release and metabolism in the normal rat brain in order 
to gain better understanding of their therapeutic applicability for degenerative brain diseases. We 
also further elucidated the spreading properties of CDNF in the rat brain after intranigral injection 
which is highly relevant information in terms of finding the optimal sites of administration. Lastly, 
we investigated two novel small molecule RET agonists, their signaling properties and 
neuroprotective effects on nigrostriatal dopamine neurons in a neurotoxin-induced rat model of 
PD. These agonists serve as promising lead compounds that may open avenues in the search of a 
BBB-penetrating neurotrophic therapy for PD. 
The literature review will first give an overview of neuroplasticity and NTFs, their structure, 
expression and signaling mechanisms, focusing on GDNF family ligands, CDNF/MANF family of 
NTFs and NTF mimetics. Then, the organization and functions of the basal ganglia circuitry will be 
reviewed together with dopamine projection pathways, modulatory effects and lifecycle in the 
brain. Finally, PD and preclinical and clinical studies of NTFs in PD will be described.  




2 REVIEW OF THE LITERATURE 
2.1 Neuroplasticity and neurotrophic therapies 
In this thesis, neurotrophic therapies refer to a concept of utilizing endogenous NTFs or similarly 
acting small molecule compounds (i.e. NTF mimetics) to induce neuroplasticity changes in the 
central nervous system (CNS). Neurotrophic therapies are considered as potential disease-
modifying treatments for various neurological disorders. 
2.1.1 Neuroplasticity  
The brain has traditionally been considered as a static organ, without turnover of neurons or 
capacity for repair after neuronal insults. However, it has a fundamental ability to reorganize its 
structure, connections and function in response to intrinsic and extrinsic stimuli (Cramer et al. 
2011). These long-lasting and bidirectional alterations are of crucial importance for neuronal 
development and brain functions, e.g. learning. Developmental and environmental changes, 
diseases and therapeutic interventions induce adaptive neuroplastic changes which take place at 
many levels. During normal development, newborn neurons that are not functionally integrated 
into neural circuits are eliminated through selective apoptosis (Castrén and Hen 2013). It has been 
estimated, that up to 60% of the neurons originally generated die in most neuronal populations 
(Oppenheim 1991). This naturally occurring cell death is regulated by NTFs that promote the 
survival and maturation of neurons. 
At cellular level, the morphology of mature neurons can be modified through arborization and 
pruning of axonal and dendritic branches and spines (Castrén and Hen 2013). The synapse-
containing branches are more likely stabilized whereas spines lacking a synapse are readily 
pruned. The number of synapses is regulated dynamically through synaptogenesis and elimination 
of inactive synapses. At functional level, long-term potentiation (LTP) increases the synaptic 
strength, whereas long-term depression (LTD) suppresses it in inactive synapses. Active 
information transfer in LTP enhances the synaptic function and protects the synapse from pruning.  
Growth factors, especially NTFs, have been shown to play a key role in regulating the dynamic 
adaptations in the neuronal connections and functions which are crucial for the proper function 
of the nervous system (Paratcha and Ledda 2008; Bothwell 2014; Lu et al. 2014; Levy et al. 2018). 
NTFs control almost all processes relating to the neuroplasticity including neural stem cell 
proliferation, migration and differentiation of neuroblasts, growth and survival of neurons, neurite 
outgrowth, formation of synapses and LTP. In addition, numerous transcriptional and epigenetic 
mechanisms regulate the expression of effector genes involved in neuroplasticity (Castrén and 
Hen 2013). 
Brain resident innate immune cells, microglia, are also prominent players in the regulation of brain 
homeostasis and neuronal plasticity (Block and Hong 2005; Sierra et al. 2010; Kettenmann et al. 
2013; Wake et al. 2013). Reactive microglia are primarily responsible for immune reactions in the 
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CNS in response to an infection or neuronal injury. Resting microglia, instead, are responsible for 
the surveillance and elimination of presynaptic terminals and dendritic spines in a process termed 
synaptic pruning. Microglia also release various substances such as adenosine triphosphate (ATP), 
NTFs and cytokines which regulate neuroinflammation, programmed cell death, neurogenesis, 
neuronal repair and synaptic connectivity. In addition, microglia phagocytose apoptotic cells and 
newborn neural progenitor cells. These functions contribute to the maturation, plasticity and 
homeostasis of neuronal circuits during development and adulthood. 
New neurons are continuously supplied to the hippocampus and olfactory bulb in most mammals 
throughout life conferring plasticity to these neuronal circuits (Falk and Frisén 2005; Steiner et al. 
2019). The newborn hippocampal neurons derive from local stem cells residing in the subgranular 
zone (SGZ) of the dentate gyrus, whereas neurons added to the olfactory bulb are derived from a 
neurogenic niche in the subventricular zone (SVZ) of the lateral ventricle wall from where they 
migrate along the rostral migratory stream (RMS). Innovative research strategies have 
demonstrated that substantial neurogenesis occurs also in the germinal areas of the adult human 
brain. The incorporation of 5-bromo-3'-deoxyuridine (BrdU), a synthetic nucleotide injected to 
cancer patients for diagnostic purposes, into the DNA of the dividing cells (Eriksson et al. 1998) or 
retrospective analysis of radioactive 14C incorporated into the genomic DNA as a consequence of 
increased atmospheric levels of 14C produced by nuclear weapon tests during the Cold War 
(Spalding et al. 2005) has enabled these research achievements. Measuring the level of nuclear-
bomb-test-derived 14C in the neuronal DNA Spalding and coworkers revealed extensive 
neurogenesis of hippocampal cells also in adult humans (Spalding et al. 2013). Similarly, 
retrospective 14C-dating has revealed that a substantial number of newborn interneurons 
continuously integrates into the striatum (Ernst et al. 2014). In humans, neuroblasts arising from 
the SVZ provide a source for striatal neurons instead of migrating to the olfactory bulb via RMS. 
2.1.2 Neurotrophic factors 
NTFs are endogenous proteins secreted by a variety of tissues in the body (reviewed in Huang and 
Reichardt 2001; Airaksinen and Saarma 2002). Importantly, NTFs support the survival of neurons 
and help them to recover from injuries making them a promising therapeutic strategy not only for 
the management of neurodegenerative disorders, such as PD, Alzheimer's disease (AD) and 
amyotrophic lateral sclerosis (ALS), but also for the treatment of neuronal traumas, e.g. spinal cord 
injury. There appears to be a shortage of NTFs in neurodegenerative diseases; for example in PD 
patients, decreased expression of GDNF, brain-derived neurotrophic factor (BDNF) and ciliary 
neurotrophic factor (CNTF) have been reported in the surviving neurons of the substantia nigra 
(SN) (Mogi et al. 1999; Parain et al. 1999; Howells et al. 2000; Chauhan et al. 2001). Apart from 
their important effects on the development and maintenance of neurons, NTFs also exert several 
essential functions outside the nervous system in non-neural tissues. 
2.1.2.1 Neurotrophic hypothesis  
Mature neurons have highly polarized morphology; they consist of a cell body containing the 
nucleus and other organelles, dendrites receiving synaptic input from neighboring cells, and one 




long axon, which ends in presynaptic terminals. According to the classical neurotrophic hypothesis 
the target tissue of neuronal innervation secretes limiting quantities of NTFs which are  
transported retrogradely along the axon to the cell body where they suppress apoptosis of the 
innervating neuron (Hamburger 1939, 1934; Hamburger and Levi-Montalcini 1949). In this way, 
NTF secretion by the target organ ensures the balance between the size of the target and the 
number of innervating neurons. During development, most neuronal populations are initially 
overproduced. Neuronal target fields, however, produce NTFs in amounts that are not sufficient 
for all neurons. The lack of target-derived NTFs drives the neurons without proper connections 
with the target organ into programmed cell death, thus, regulating the innervation density of the 
organ. The main caveat of the abovementioned hypothesis is that it has been demonstrated to 
hold true almost exclusively in the peripheral nervous system (PNS). In the CNS, the relationship 
between target-derived NTFs and neuronal survival appears to be more complex because 
neighboring cells also can provide trophic support to neurons through paracrine secretion and a 
neuron might be able to secrete NTFs itself through an autocrine loop (Cerchia 2006). In addition, 
the classical neurotrophic hypothesis has been broadened since some neuronal populations seem 
to depend on several different NTFs regulating concurrently or sequentially the target organ 
innervation (Davies 1996). 
2.1.2.2 Characteristics and families of NTFs 
Structurally mature NTFs proteins consist of approximately 100-160 amino acids and contain 
typically several conserved disulphide bridges between cysteine residues enabling closely related 
conformations within different NTF families (Ibáñez 1998; Airaksinen et al. 1999; Airaksinen and 
Saarma 2002; Lindholm and Saarma 2010; Bothwell 2014). Like most other secreted polypeptides, 
NTFs are synthetized and packaged into secretory vesicles in the rough ER. NTFs can be secreted 
from various neuronal and non-neuronal cells in the CNS and PNS. NTFs are commonly produced 
in the form of a precursor protein. The signal sequence is cleaved either intracellularly in secretory 
vesicles or by extracellular proteases producing mature NTFs. Mature NTFs usually form non-
covalently associated dimers that bind to transmembrane receptor tyrosine kinases which in turn 
initiate intracellular signaling cascades resulting in trophic effects (Ibáñez 1998). 
NTFs known today can be divided into four major families (Bothwell 2014; Ibáñez and Andressoo 
2017; Lindahl et al. 2017): 
1. neurotrophins including nerve growth factor (NGF), BDNF, neuorotrophin-3 (NT-3) and 
neuorotrophin-4 (NT-4) 
2. GDNF family ligands (GFLs) including GDNF, neurturin (NRTN), artemin (ARTN), persephin 
(PSPN), and a distant member growth and differentiation factor-15 (GDF-15, also known 
as macrophage-inhibiting cytokine-1, MIC-1) 
3. neurotrophic cytokines (=neurokines) including CNTF, cardiotrophin-1, leukemia inhibitory 
factor, neuropoietin, oncostatin M, cardiotrophin-like cytokine, interleukin 6 (IL-6), IL-11 
and IL-27 
4. CDNF/MANF family of NTFs. 
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Two of these families, GFLs and unconventional CDNF/MANF family of NTFs are in the focus of this 
thesis and will be discussed in more detail in the following chapters. Also, other trophic and growth 
factors, e.g. members of transforming growth factor β (TGF-β) superfamily, vascular endothelial 
growth factors, insulin-like growth factors and fibroblast growth factors (FGFs) are shown to have 
neurotrophic activities but those fall out of the scope of this thesis (Grothe and Timmer 2007; 
Zacchigna et al. 2008). 
2.1.3 GDNF family ligands  
GDNF was identified and isolated in 1993 based on its survival-promoting effects on ventral 
midbrain dopamine neurons (Lin et al. 1993). NRTN, ARTN and PSPN, the other three family 
members structurally similar to GDNF, were characterized within five years after the discovery of 
GDNF (Kotzbauer et al. 1996; Baloh et al. 1998; Milbrandt et al. 1998). GDF-15 is a distant member 
of the GFLs which functions as a  peripheral signal downregulating food intake, energy expenditure 
and body weight in response to tissue damage and stress (Bootcov et al. 1997; Böttner et al. 1999; 
Hsiao et al. 2000). GFLs are distant members of TGF-β superfamily. Together with their receptors 
they form one of the major neurotrophic networks in the nervous system regulating the 
development, maintenance and function of a variety of neurons and glial cells (Ibáñez and 
Andressoo 2017). GFLs, their receptors and binding preferences are summarized in Figure 2.1. 
2.1.3.1 Synthesis, structure and secretion of GFLs 
GFLs are synthesized in the form of a precursor protein preproGFL (Lin et al. 1993; Lonka-Nevalaita 
et al. 2010). The pre-sequence guides GFLs to the ER for secretion. During secretion GFLs form 
disulfide-bonded homodimers and can be modified by N-linked glycosylation (Lin et al. 1993; 
Lonka-Nevalaita et al. 2010; Piccinini et al. 2013). Proteolytic cleavage of proGFLs into mature GFL 
proteins takes place extracellularly by furin, PACE4, PC5A, PC5B and PC7. After secretion GFLs bind 
to heparan-sulphate side chains of extracellular matrix proteoglycans which limits their diffusion 
in brain parenchyma and increases their local concentration.  
GDNF, the founding member GFLs, is a ~20 kD, N-glycosylated protein consisting of 211 amino 
acids (Lin et al. 1993). The mature 134 amino acids long GDNF is formed after the cleavage of the 
pre- (19 amino acids) and pro- (58 amino acids) signaling sequences. The primary structure of 
GDNF contains seven conserved cysteine residues with the same relative spacing as in the other 
TGF-β superfamily members. The tertiary structure of GDNF is stabilized with three disulphide 
bridges that are formed between the cysteine residues. The one remaining cysteine connects two 
GDNF molecules with each other via a disulphide bridge forming GDNF homodimer. 





Figure 2.1. GDNF family ligands (GFLs) and their receptors. Glial cell line-derived neurotrophic factor 
(GDNF), neurturin (NRTN), artemin (ARTN), persephin (PSPN) and a distant member growth and 
differentiation factor-15 (GDF-15) bind preferentially to their cognate co-receptors GDNF family 
receptor α (GFRα) 1-4 and GDNF family receptor alpha-like (GFRAL), respectively, although cross-
binding occurs too. Thereafter, ligand-receptor complex binds to the common transmembrane 
receptor tyrosine kinase RET or neural cell adhesion molecule (NCAM), which initiate intracellular 
signaling cascades. GFLs can also directly bind to and signal through syndecan-3. Glycosyl 
phosphatidylinositol (GPI) -anchor attaches GFRα receptors to the plasma membrane (PM) and 
localizes them into lipid rafts. Primary phosphotylated tyrosine residues of RET, which serve as docking 
sites for the intracellular adaptor proteins, and the Ca2+-binding site in the middle of the four cadherin-
like domains of the extracellular RET are depicted in the figure. High affinity binding is indicated with 
solid lines and low affinity binding with dashed lines. Figure drawn by the author, inspired by Kramer 
and Liss (2015). 
2.1.3.2 RET-mediated signaling 
Mature GFL homodimers mediate their biological effects via a multicomponent receptor complex 
consisting of GDNF family receptor α (GFRα) and receptor tyrosine kinase RET (rearranged during 
transfection) (Airaksinen and Saarma 2002). A GFL first binds to its cognate GFRα co-receptor 
which dimerizes. Subsequently, GFL-GFRα complex recruits RET as a signal transducing receptor 
and triggers its homodimerization and autophosphorylation of its intracellular tyrosine kinase 
domain. Apart from RET, two alternative signaling receptors have been identified: neural cell 
adhesion molecule (NCAM) (Chao et al. 2003; Paratcha et al. 2003) and syndecan-3 (Bespalov et 
al. 2011). A summary of the known GFL signaling mechanisms is illustrated in Figure 2.2. 
RET was identified as the primary signaling receptor for GFLs in 1996 (Durbec et al. 1996a; Trupp 
et al. 1996; Vega et al. 1996; Worby et al. 1996). RET is a canonical single spanning transmembrane 
receptor tyrosine kinase. The extracellular region consists of four cadherin-like domains (CLD 1-4) 
with one Ca2+-ion between CLD2 and CLD3 that is required for ligand binding to RET (Anders et al. 
2001; Knowles et al. 2006). The cytoplasmic tyrosine kinase domain contains several tyrosine 
phosphorylation sites regulating the catalytic activities of RET (Myers et al. 1995; Tahira et al. 
1990). In most cases, the phosphorylated residues are Tyr905, Tyr1015, Tyr1062 and Tyr1096 which 
serve as docking sites for signal-transducing adaptor proteins (Coulpier et al. 2002; Arighi et al. 
2005). Alternative splicing of RET mRNA can produce three isoforms with varying length of the C-
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terminal tail (RET9, RET43 and RET51). RET9 and RET51 are the major isoforms and highly 
conserved in different species of vertebrates (Carter et al. 2001).  
Phosphorylation of the intracellular tyrosine residues of RET activates downstream signaling 
cascades including Ras/mitogen activated protein kinase (MAPK), phosphatidylinositol 3-kinase 
(PI3K)/Akt, phospholipase C-g (PLCg) and c-Jun N-terminal kinase (JNK) pathways (Takahashi 2001). 
Ras/MAPK pathway leads to the activation of transcription factor cAMP response element-binding 
protein (CREB) and regulates cellular proliferation, growth, differentiation, survival and 
neuritogenesis (Hayashi et al. 2000). PI3K/Akt pathway activates transcription factor NFkB and is 
primarily responsible for cellular survival, growth, migration and proliferation. 
RET is unable to bind GFLs in absence of the ligand-binding co-receptor GFRα (Jing et al. 1996; 
Treanor et al. 1996; Paratcha and Ledda 2008). The GFRα:s are a family of four glycosyl 
phosphatidylinositol (GPI) -anchored extracellular proteins, GFRα1-4, that serve as preferential 
receptors for GDNF, NRTN, ARTN and PSPN, respectively (Jing et al. 1996; Treanor et al. 1996; 
Baloh et al. 1997; Buj-Bello et al. 1997; Jing et al. 1997; Klein et al. 1997; Sanicola et al. 1997; 
Suvanto et al. 1997; Baloh et al. 1998; Naveilhan et al. 1998; Thompson et al. 1998; Trupp et al. 
1998; Widenfalk et al. 1998; Worby et al. 1998; Masure et al. 2000). In addition, GDNF family 
receptor alpha-like (GFRAL) was recently discovered as a co-receptor for GDF-15 (Emmerson et al. 
2017; Hsu et al. 2017; Mullican et al. 2017; Yang et al. 2017). It mediates GDF-15–GFRAL signaling 
via RET in the same way as the other GFL–GFRα complexes. Apart from the high-affinity binding 
to the cognate co-receptors, some low-affinity cross-reactivities between different GFLs and 
GFRα:s have been demonstrated in vitro as summarized in Figure 2.1 and Table 2.1.  
The GPI-anchor links GFRα:s to the plasma membrane and localizes them into lipid rafts, special 
subdomains of the plasma membrane (Tansey et al. 2000; Paratcha et al. 2001; Paratcha and 
Ibáñez 2002; Tsui et al. 2015). These cholesterol and sphingolipid-rich microdomains accumulate 
signaling proteins and thereby increase their interactions with each other. During receptor 
activation in cis, GFL homodimer first binds with high affinity to one of the GPI-anchored GFRα 
receptors which dimerizes (Airaksinen and Saarma 2002; Jing et al. 1996; Treanor et al. 1996) 
(Figure 2.2.A). Subsequently, GFL-GFRα complex recruits RET into the lipid raft. The relocation of 
RET into the lipid rafts potentiates downstream signal transduction through the receptor complex 
(Tansey et al. 2000). Through phosphorylated Tyr1062 residue, for example, RET associates with the 
adaptor protein FRS2 inside the lipid rafts and with SHC outside the rafts (Paratcha et al. 2001). 
Inside the lipid rafts, FRS2 first recruits Grb2 and Sos proteins which then leads to the activation 
of Ras/MAPK pathway (Melillo et al. 2001). Outside the lipid rafts, SHC can recruit either Grb2 and 
Gab proteins leading to the activation of PI3K/Akt pathway, or Grb2 and Sos proteins activating 
Ras/MAPK pathway (Besset et al. 2000; Hayashi et al. 2000). 
The GPI-anchor of GFRα receptor can also be cleaved by membrane-associated phospholipases or 
proteases which releases GFRα into the extracellular space and leads to the activation of RET in 
trans (Yu et al. 1998; Paratcha et al. 2001; Ledda et al. 2002). Soluble GFRα binds GFL in the 
extracellular space with high affinity after which the complex binds to and activates RET outside 
the lipid rafts where RET associates with SHC adaptor protein. Subsequently, RET is recruited into 




the lipid raft where it activates FRS2. The fact that GFRα receptors are much more widely 
expressed than RET, together with their ability to activate RET in trans, suggest non-cell-
autonomous functions for soluble GFRα during neuronal development and regeneration. 
Secretion of soluble GFRα by target tissues of RET-expressing neurons may act as a long-range cue 
that guides the growing axons. 
It should be noted, that RET signaling is under negative control which regulates the magnitude and 
duration of RET activation. A prevalent mechanism to control the downregulation of RET is 
through ligand-induced ubiquitination which leads to proteasomal degradation of the active 
receptor (Carniti et al. 2003; Scott et al. 2005). In response to ligand-mediated activation, RET can 
also be internalized from the plasma membrane into early endosomes via clathrin-mediated 
endocytosis (Richardson et al. 2006; Richardson et al. 2012; Crupi et al. 2015). The endocytosed 
GFL-GFRa-RET complex contributes to the retrograde GFL signaling, but finally receptor 
internalization terminates the extracellular signal transduction.  
2.1.3.3 NCAM-mediated signaling 
GFLs can also signal through NCAM independently of RET (Paratcha et al. 2003) (Figure 2.2.B). 
NCAM plays an important role in neurodevelopment, regeneration and synaptic plasticity by 
mediating cell adhesion to other cells and components of the extracellular matrix. GFLs, but not 
other NTFs, can bind directly to NCAM via its third Ig domain (Paratcha et al. 2003; Sjöstrand et al. 
2007; Nielsen et al. 2009). However, high-affinity binding of a GFL and downstream signaling 
through NCAM require the presence of GFRα co-receptor (Paratcha et al. 2003). Binding of GFL-
GFRα complex to NCAM activates intracellular Src family kinase Fyn and focal adhesion kinase 
(FAK) which, in turn, activate MAP kinases and cellular responses such as neurite outgrowth of 
hippocampal, cortical and midbrain neurons, survival of cultured dopamine neurons and 
stimulation of Schwann cell migration (Chao et al. 2003; Paratcha et al. 2003; Iwase et al. 2005; 
Cao et al. 2008a; Nielsen et al. 2009). GDNF has been shown to function as a chemoattractant 
factor for neuronal precursors migrating along the RMS and NCAM-mediated signaling seems to 
play a key role in this guidance process (Paratcha et al. 2006). A recent study suggested that NCAM 
can function as an alternative receptor also for ARTN (Ilieva et al. 2019). ARTN was shown to 
induce neuritogenesis by binding directly to NCAM and activating NCAM-associated signaling 
pathways in primary cerebellar neuron cultures.
  
 
Figure 2.2. Signaling mechanisms of GDNF family ligands (GFLs). (A) Signaling through receptor tyrosine kinase RET can occur in cis or in trans. During 
activation of RET in cis, GFL homodimer first binds to a glycosyl phosphatidylinositol (GPI) -anchored GDNF family receptor α (GFRα) which dimerizes (1). Then, 
GFL-GFRα complex recruits two RET molecules into the lipid raft of plasma membrane (PM) (2). This triggers dimerization of RET and autophosphorylation of 
its intracellular tyrosine residues which serve as docking sites for intracellular adaptor proteins (3). In trans signaling, the GPI-anchor of GFRα is cleaved by 
membrane-associated phospholipases (scissors) which releases soluble GFRα (sGFRα) into extracellular space. GFL binds with high affinity to sGFRα (1). GFL-
sGFRα complex activates RET outside of the lipid rafts (2). Subsequently, the receptor complex is recruited into the lipid raft (3). Inside the lipid rafts, 
phosphorylated RET associates with the adaptor protein FRS2 leading to the activation of Ras/MAPK pathway. Outside the rafts, RET interacts with SHC leading 
to the activation of PI3K/Akt pathway. GDNF can also activate intracellular Src family kinases (SFKs) signaling via GFRα1 independently of RET. (B) Neural cell 
adhesion molecule (NCAM) is an alternative signaling receptor for GFLs in cells lacking RET. GFL binds with high affinity to GFRα which dimerizes (1). Then, 
GFL-GFRα complex binds to transmembrane NCAM (2) leading to signal transduction via intracellular Src family kinase Fyn and focal adhesion kinase (FAK), 
and ultimately, the activation of MAP kinases (3). (C) Extracellular matrix-bound GFLs can also signal through a transmembrane heparan sulfate (HS) 
proteoglycan syndecan-3, independently of GFRα, RET or NCAM. Immobilized GFLs bind to the HS side chains of syndecan-3. The cytoplasmic domain activates 


























































































2.1.3.4 Signaling via syndecan-3 
The distribution of GDNF and NRTN in the brain parenchyma is restricted by binding to heparan 
sulfate proteoglycans of the extracellular matrix (Lin et al. 1994; Hamilton et al. 2001; Rickard et 
al. 2003; Piltonen et al. 2009; Bespalov et al. 2011). Bespalov and his colleagues  showed that 
immobilized, extracellular matrix-bound GDNF, NRTN and ARTN can also signal through a novel 
receptor, the transmembrane heparan sulfate proteoglycan syndecan-3, that is expressed on 
neuronal cells (Bespalov et al. 2011) (Figure 2.2.C). Immobilized GFLs bind with high affinity to the 
heparan sulfate side chains of syndecan-3 which activates intracellular SFK-mediated signaling 
cascades. As syndecan-3 has several heparan sulfate chains, one syndecan-3 can simultaneously 
bind multiple GFL homodimers acting as a high affinity and high capacity receptor for GFLs. GFL–
syndecan-3 interaction promotes hippocampal neurite outgrowth and migration of cortical γ-
aminobutyric acid (GABA) containing neurons, and thus may play a distinctive role in the 
embryonic development of these brain areas. In addition to direct intracellular signal 
transduction, syndecan-3, and other heparan sulfate proteoglycans, may modulate conventional 
signaling through GFRα-RET or NCAM by concentrating and presenting diffusible GFLs to the 
receptors. GFLs may have a dual mode of action: as diffusible soluble proteins, they prefer 
signaling via conventional receptors GFRα-RET and NCAM, whereas extracellular matrix-bound 
GFLs seem to signal through syndecan-3 independently of GFRα, RET or NCAM. 
2.1.3.5 Expression and functions of GFLs, GFRα:s and RET 
Following the initial observation of the effects of GDNF on midbrain dopamine neurons, several 
studies have shown its neurotrophic actions in other neuronal populations of the CNS and PNS. 
For example, GDNF supports the survival of noradrenergic neurons of the locus coeruleus (Arenas 
et al. 1995), basal forebrain cholinergic neurons (Williams et al. 1996), facial and spinal cord motor 
neurons (Henderson et al. 1994; Oppenheim et al. 1995; Yan et al. 1995) and peripheral 
sympathetic, parasympathetic and sensory neurons (Buj-Bello et al. 1995; Ebendal et al. 1995; 
Trupp et al. 1995). The biological effects on such a broad spectrum of neuronal populations 
suggest widespread expression of GDNF and its receptors throughout the CNS, PNS and non-
neuronal tissues. 
Although all GFLs activate the same downstream signaling pathways through RET, the selectivity 
in their biological effects is thought to be due to differential expression patterns of GFLs and their 
cognate GFRα co-receptors. GFL, GFRα and RET expression levels have been investigated using 
Northern blotting, in situ hybridization, RT-PCR and immunohistochemical techniques. The 
neuronal and non-neuronal expression of GFLs, GFRα:s and RET in developing and adult rodents 
together with their physiological main functions are summarized in Table 2.1. In general, the levels 
and temporospatial expression patterns of GFLs are strictly regulated (Mogi et al. 2001). GFLs and 
their receptors are more prominently expressed during embryonic development as compared to 
adult animals (Golden et al. 1999). In the mature brain, GFRα receptors show wider expression 
than GFLs or RET (Nosrat et al. 1997; Trupp et al. 1997; Ortega-de San Luis and Pascual 2016). 
When RET and GFRα are expressed in the same tissue, such as in the SN or spinal cord, the 
receptors are able to interact in cis. However, the expression pattern of GFRα co-receptors does 
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not always match with that of RET which suggests in trans mode of interaction between the 
receptors or that GFLs convey RET-independent signaling via alternative receptors as described 
above. 
Only GDNF and NRTN are expressed in the CNS of adult rodents which makes them to be of specific 
interest in regards of potential disease-modifying approaches for neurodegenerative diseases. 
Attempts to reveal the cellular basis of the relatively abundant expression of GDNF in postnatal 
striatum have shown that in the normal brain, neurons are the principal source of GDNF (Oo et al. 
2005). More precisely, GDNF is mainly synthesized by striatal interneurons (Bizon et al. 1999; 
Hidalgo-Figueroa et al. 2012). The vast majority (approximately 95%) of the GDNF-expressing cells 
in the striatum are parvalbumin (PV) -positive GABAergic interneurons and the remaining 5% are 
either cholinergic or somatostatin-positive interneurons.  
Upregulation of GDNF has been reported in several nigrostriatal injury models (Batchelor et al. 
1999; Liberatore et al. 1997; Yurek and Fletcher-Turner 2002, 2001). Upon injury, glial cells 
become the predominant source of GDNF as well as other growth factors like NGF, NT-3 and FGF 
(Bresjanac and Antauer 2000; Nakagawa and Schwartz 2004; Nakagawa et al. 2005; Chen et al. 
2006). The switch in the production of NTFs from neurons to glial cells may be part of the local 
mechanisms that aim to protect neurons and promote their regeneration. The cross-talk between 
damaged neurons and glia inducing the glial GDNF expression seems to be mediated via pro-
inflammatory cytokines IL-1b, IL-6, interferon-γ (IFN-γ), TNF-a and TNF-b, FGF (Appel et al. 1997; 
Verity et al. 1998; Verity et al. 1999; Kuno et al. 2006; Saavedra et al. 2007) and endothelin-1 
(Koyama et al. 2003a, 2003b). 
Endogenous GDNF does not affect the normal embryonic development of brainstem 
noradrenergic and midbrain dopaminergic neurons (Moore et al. 1996; Sánchez et al. 1996). 
However, the physiological role of endogenous GDNF in the maintenance of normal adult brain 
catecholaminergic neurons has remained poorly studied because of neonatal mortality of GDNF 
full knockout mice due to renal and ENS agenesis. Interestingly, there is an ongoing debate 
whether GDNF is vital or dispensable for the survival of catecholaminergic neurons of the 
substantia nigra pars compacta (SNpc) and the locus coeruleus (Enterría-Morales et al. 2020; 
Kopra et al. 2015; Kumar et al. 2015; Pascual et al. 2008; Pascual and López-Barneo 2015). In adult 
mice, GDNF overexpression from the native locus seems to exert trophic effects on the 
nigrostriatal dopamine system and enhance its function (Kumar et al. 2015).
 
 
Table 2.1. GDNF family ligands (GFL), GDNF family ligand receptors (GFRα) and RET: expression in rodents and physiological main functions. 





CNS: cortical areas, STR, NAcc, Hc, thalamic nuclei, 
hypothalamic nuclei, OB, olfactory tubercle, septum, midbrain, 
PAG, cerebellum, pons (incl. pedunculopontine nucleus and 
locus coeruleus), medulla, spinal cord, pituitary gland, pineal 
gland*, wall of the 4th ventricle 
PNS: sensory neurons, sympathetic neurons, Schwann cells 
Peripheral tissues: skeletal muscle, gonads, prostate, lung, 
liver, adrenal gland, stomach, intestine, spleen, heart, thymus, 
thyroid, salivary glands, skin, kidney*, bone*, teeth*, ear*, 
nose*, tongue*, eye*, urogenital system*, digestive system*, 
limb buds*, cartilage*, blood* 
 
 
• Originally discovered as a potent survival-promoting factor for embryonic 
midbrain dopamine neurons in culture 
• Essential for the prenatal development of ENS and kidneys 
• Essential for the development of peripheral sensory, sympathetic and 
parasympathetic neurons 
• Plays a crucial role in spermatogenesis 
• Supports the development and survival of spinal motoneurons, hindbrain 
noradrenergic neurons, midbrain dopamine neurons, basal forebrain 
cholinergic neurons and cerebellar Purkinje cells 
• May promote the insertion and stabilization of postsynaptic receptors in the 
neuromuscular junction 
• GDNF-/- genotype leads to perinatal death due to renal agenesis and the 
absence of enteric neurons   
(Lin et al. 1993), (Scharr et al. 1993), (Henderson et al. 
1994), (Springer et al. 1994), (Arenas et al. 1995), 
(Bowenkamp et al. 1995), (Buj-Bello et al. 1995), (Choi-
Lundberg and Bohn 1995), (Ebendal et al. 1995), (Li et al. 
1995), (Mount et al. 1995), (Oppenheim et al. 1995), 
(Springer et al. 1995), (Tomac et al. 1995), (Trupp et al. 
1995), (Yan et al. 1995), (Hellmich et al. 1996), (Moore et al. 
1996a), (Nosrat et al. 1996), (Pichel et al. 1996), (Sánchez 
et al. 1996), (Suvanto et al. 1996), (Vega et al. 1996), 
(Sainio et al. 1997), (Trupp et al. 1997), (Widenfalk et al. 
1997), (Enomoto et al. 1998), (Golden et al. 1998), 
(Heuckeroth et al. 1998), (Fundin et al. 1999), (Golden et al. 
1999), (Baudet et al. 2000), (Enomoto et al. 2000), (Garcès 
et al. 2000), (Meng et al. 2000), (Mikaels et al. 2000), 
(Worley et al. 2000), (Young et al. 2001), (Kramer et al. 
2006), (Naughton et al. 2006), (Wang et al. 2010), (Savitt et 
al. 2012), (Ortega-de San Luis and Pascual 2016) 
Neurturin 
(NRTN) 
CNS: cortical areas, STR, Hc, thalamic nuclei, hypothalamic 
nuclei, ventral midbrain, cerebellum, pituitary gland, septum*, 
brainstem nuclei*, pineal gland* 
PNS: sensory neurons, sympathetic neurons, retina 
Peripheral tissues: gonads, prostate, kidney, heart, bladder, 
urethra, skin, GI-tract, liver, lung, thymus, exocrine glands, 
skeletal muscle*, teeth*, digestive system*, sensory organs* 
• Originally identified on the basis of survival-promoting effects on sympathetic 
neurons in culture 
• Essential for the normal development and survival of parasympathetic 
neurons  
• Essential for the proper development, maintenance and function of ENS 
• Contributes to food digestion by ensuring proper intestinal motility and 
secretion of pancreatic enzymes and saliva 
• Promotes the survival and neurite outgrowth of spinal motoneurons and 
embryonic basal forebrain cholinergic neurons and survival of sensory 
neurons and midbrain dopaminergic neurons  
• NRTN-/- mice are viable and fertile, no gross developmental defects except 
ptosis due of lack of parasympathetic innervation of the lacrimal gland 
(Kotzbauer et al. 1996), (Klein et al. 1997), (Widenfalk et al. 
1997), (Golden et al. 1998), (Heuckeroth et al. 1998), 
(Horger et al. 1998), (Bilak et al. 1999), (Forgie et al. 1999), 
(Fundin et al. 1999), (Golden et al. 1999), (Heuckeroth et al. 
1999), (Jomary et al. 1999), (Rossi et al. 1999), (Taraviras et 
al. 1999), (Åkerud et al. 1999), (Baudet et al. 2000), 
(Enomoto et al. 2000), (Hiltunen et al. 2000), (Laurikainen et 
al. 2000), (Rossi et al. 2000), (Golden et al. 2003), (Rossi et 






CNS: not detected 
PNS: nerve roots of DRG*, immature Schwann cells*, 
sympathetic neurons*, along the routes of sympathetic 
neuroblast migration and along sympathetic axonal 
projections* 
Peripheral tissues: blood vessels (smooth muscle cells), 
esophagus*, stomach*, pancreas* 
• Originally identified as the ligand for the orphan GFRα3–RET receptor 
• Vascular-derived NTF crucial for the migration and axonal outgrowth of 
sympathetic neuroblasts and development of target tissue sympathetic 
innervation 
• Promotes the survival of sensory and midbrain dopamine neurons 
• Modulates the sensitivity of sensory neurons to noxious stimuli 
• ARTN-/- mice are viable and fertile, no gross developmental defects except 
ptosis due of lack of sympathetic innervation to the superior tarsus muscle 
(Baloh et al. 1998b), (Nishino et al. 1999), (Baudet et al. 
2000), (Rosenblad et al. 2000), (Andres et al. 2001), 
(Enomoto et al. 2001), (Honma et al. 2002), (Wang et al. 
2008), (McIlvried et al. 2010), (Nivlet et al. 2016) 
Persephin 
(PSPN) 
CNS: cortical areas*, Hc*, STR*, diencephalon*, midbrain*, 
pons*, medulla*, cerebellum*, spinal cord*, astrocytes* 
PNS: sympathetic neurons (SCG)*, sensory neurons (DRG)*, 
sciatic nerve*, optic nerve*, motoneurons* 
Peripheral tissues: fat tissue, adrenal gland, heart, kidney, 
liver, skin, spleen*, skeletal muscle*, bone*, testicle* 
In general, PSPN is expressed at very low levels in adult 
rodents 
• Originally discovered as the result of its homology to GDNF and NRTN 
• Regulates the function of thyroid C cells, their calcitonin production and bone 
formation in newborn and juvenile mice 
• May act as a circulating growth factor due to inability to bind heparan sulfate 
side chains of the extracellular matrix 
• Can modulate glutamate-mediated excitotoxicity in the CNS and supports the 
survival of motoneurons and sympathetic neurons 
• In vitro, promotes the survival and neurite outgrowth of embryonic midbrain 
dopamine and basal forebrain cholinergic neurons 
• PSPN-/- mice are viable and fertile, no gross developmental defects 
(Enokido et al. 1998), (Heuckeroth et al. 1998), (Jaszai et al. 
1998), (Milbrandt et al. 1998), (Tomac et al. 2002), (Åkerud 
et al. 2002), (Golden et al. 2003),  (Lindfors et al. 2006), 












CNS: cortical areas, STR, NAcc, Hc, OB, thalamic nuclei, 
hypothalamic nuclei, OT, amygdala, septum, habenular nuclei, 
ventral pallidum, midbrain (incl. SNpc, SNr, VTA and dorsal 
Raphe nucleus), PAG, cerebellum, pons (incl. 
pedunculopontine nucleus and locus coeruleus), spinal cord 
PNS: sensory neurons, Schwann cells, ENS, motoneurons, 
sympathetic neurons*, parasympathetic neurons*, retina* 
Peripheral tissues: gonads, prostate, GI-tract, liver, kidney, 
bladder, urethra, heart, lung, spleen, digestive system*, skin*, 
bone*, teeth*, skeletal muscle*, inner ear*, endocrine glands*, 
salivary glands* 
• Cognate co-receptor for GDNF 
• Shows low-affinity cross-reactivity with NRTN and ARTN in vitro 
• Association with NCAM potentiates high-affinity binding of GDNF to NCAM 
• Interaction with NCAM downregulates homophilic NCAM binding and cell 
adhesion 
• Ligand-induced cell adhesion molecule in the presence of GDNF 
• GFRα1-/- mice die early postnatally due to renal agenesis and deficits in the 
ENS 
(Baloh et al. 1997), (Jing et al. 1997), (Klein et al. 1997), 
(Nosrat et al. 1997), (Sanicola et al. 1997), (Trupp et al. 
1997), (Widenfalk et al. 1997), (Baloh et al. 1998b), 
(Cacalano et al. 1998), (Enomoto et al. 1998), (Glazner et al. 
1998), (Golden et al. 1998), (Masure et al. 1998), (Yu et al. 
1998b), (Fundin et al. 1999), (Golden et al. 1999), (Baudet et 
al. 2000), (Bennett et al. 2000), (Enomoto et al. 2000), 
(Hiltunen et al. 2000), (Mikaels et al. 2000), (Rossi et al. 
2000), (Garcès et al. 2001), (Sarabi et al. 2001), (Paratcha 
et al. 2003), (Sarabi et al. 2003), (Cho et al. 2004a), (Ledda 
et al. 2007), (Omodaka et al. 2014), (Ortega-de San Luis 







CNS: cortical areas, Hc, OB, thalamic nuclei, hypothalamic 
nuclei, OT, amygdala, septum, nucleus basalis of Meynert, 
midbrain (incl. SNpc, SNr, VTA and dorsal Raphe nucleus), 
PAG, cerebellum, brainstem (incl. locus coeruleus), spinal 
cord, pineal gland, pituitary gland, STR*, habenular nuclei* 
PNS: sensory neurons, sympathetic neurons, parasympathetic 
neurons, Schwann cells, ENS, retina, motoneurons* 
Peripheral tissues: gonads, GI-tract, heart, lung, spleen, 
thyroid gland, kidney, placenta, pancreas, urogenital system*, 
skin*, bone*, teeth*, skeletal muscle*, endocrine glands*, 
salivary glands*, sensory organs*  
• Cognate co-receptor for NRTN 
• Shows low-affinity cross-reactivity with GDNF in vitro 
• Association with NCAM potentiates high-affinity binding of NRTN to NCAM in 
vitro 
• GFRα2-/- mice are viable and fertile, but have ptosis and grow poorly due to 
deficits in the enteric and parasympathetic nervous system 
(Baloh et al. 1997), (Jing et al. 1997), (Klein et al. 1997), 
(Sanicola et al. 1997), (Widenfalk et al. 1997), (Golden et al. 
1998), (Horger et al. 1998), (Masure et al. 1998), (Naveilhan 
et al. 1998), (Trupp et al. 1998), (Yu et al. 1998b), (Fundin et 
al. 1999), (Golden et al. 1999), (Jomary et al. 1999), (Rossi 
et al. 1999), (Baudet et al. 2000), (Bennett et al. 2000), 
(Enomoto et al. 2000), (Hiltunen et al. 2000), (Mikaels et al. 
2000), (Rossi et al. 2000), (Garcès et al. 2001), (Paratcha et 
al. 2003), (Cho et al. 2004b), (Mabe et al. 2006), (Omodaka 
et al. 2014), (Ishida et al. 2016) 
GFRα3 
CNS: OB, Hc, cerebellum, expressed at low levels in the CNS 
PNS: sensory neurons, sympathetic neurons, Schwann cells, 
sympathetic neuroblasts*, peripheral nerves*, retina* 
Peripheral tissues: epidermis, thymus, heart, lung, intestine, 
pancreas, spleen, ovary, kidney, adrenal medulla*, skeletal 
muscle*, salivary gland*, liver* 
• Cognate co-receptor for ARTN 
• Shows low-affinity cross-reactivity with GDNF in vitro 
• GFRα3-/- mice are viable and fertile, no gross abnormalities other than ptosis 
 
(Baloh et al. 1998a), (Masure et al. 1998), (Naveilhan et al. 
1998), (Nomoto et al. 1998), (Trupp et al. 1998), (Widenfalk 
et al. 1998), (Worby et al. 1998), (Yu et al. 1998b), (Fundin 
et al. 1999), (Nishino et al. 1999), (Baudet et al. 2000), 
(Bennett et al. 2000), (Hiltunen et al. 2000), (Orozco et al. 
2001), (Honma et al. 2002), (Omodaka et al. 2014), (Wong 
et al. 2015), (Nivlet et al. 2016) 
GFRα4 
CNS: cortical areas, Hc, OB, habenular nuclei, ventral 
midbrain (incl. SNpc and VTA), cerebellum, spinal cord, 
pituitary gland 
PNS: sympathetic and parasympathetic ganglia 
Peripheral tissues: thyroid gland, parathyroid gland, adrenal 
medulla, heart, testicle 
• Cognate co-receptor for PSPN 
• Shows low-affinity cross-reactivity with NRTN in vitro 
• Association with NCAM potentiates high-affinity binding of PSPN to NCAM in 
vitro 
• GFRα4-/- mice are viable and fertile, no gross developmental defects 
(Enokido et al. 1998), (Lindahl et al. 2000), (Masure et al. 
2000), (Åkerud et al. 2002), (Paratcha et al. 2003), (Lindfors 
et al. 2006) 
RET 
CNS: dopamine neurons of midbrain (incl. SN and VTA), 
serotonergic neurons of dorsal Raphe nucleus, cholinergic 
neurons of basal forebrain, OB, thalamic and hypothalamic 
nuclei, amygdala, septum, PAG, cerebellum, pons (incl. locus 
coeruleus), cranial and spinal motoneurons, low levels in the 
STR 
PNS: ENS, sympathetic neurons, parasympathetic neurons, 
sensory neurons, retina 
Peripheral tissues: testicle, salivary gland, GI-tract, adrenal 
medulla, thyroid gland, heart, lymphoid organs, kidney*, inner 
ear*, teeth* 
• Transmembrane signaling receptor for GFL-GFRα complex 
• Ret gene originally discovered as an oncogene: gain-of-function mutations 
cause dominant cancer syndromes MEN2A, MEN2B and FMTC 
• Pivotal for the normal development and maintenance of ENS: loss-of-function 
mutations cause Hirschsprung’s disease (intestinal obstruction/ megacolon) 
• Essential for kidney organogenesis and spermatogenesis 
• Essential for the development of sympathetic and parasympathetic neurons 
• Promotes the survival, axonal guidance and maturation of motoneurons 
• Regulates long-term maintenance of the nigrostriatal dopamine system 
• RET-/- mice die at birth due to renal agenesis and deficits in the ENS 
(Takahashi et al. 1985), (Pachnis et al. 1993), (Schuchardt 
et al. 1994), (Tsuzuki et al. 1995), (Durbec et al. 1996b), 
(Schuchardt et al. 1996), (Trupp et al. 1996), (Nosrat et al. 
1997), (Trupp et al. 1997), (Glazner et al. 1998), (Golden et 
al. 1998), (Yu et al. 1998b), (Golden et al. 1999), (Taraviras 
et al. 1999), (Bennett et al. 2000), (Enomoto et al. 2000), 
(Garcès et al. 2000), (Hiltunen et al. 2000), (Lindahl et al. 
2000), (Enomoto et al. 2001), (Garcès et al. 2001), (Golden 
et al. 2003), (Jain et al. 2004), (Shakya et al. 2005), (Kramer 
et al. 2006), (Plaza-Menacho et al. 2006), (Kramer et al. 
2007), (Mijatovic et al. 2007), (Baudet et al. 2008), (Jijiwa et 
al. 2008), (Uesaka et al. 2008), (The Human Protein Atlas 
2020) 
CNS, central nervous system; PNS, peripheral nervous system; ENS, enteric nervous system; DRG, dorsal root ganglia; SCG, superior cervical ganglia; STR, striatum; NAcc, nucleus accumbens; 
Hc, hippocampus; GI, gastrointestinal; OB, olfactory bulb; OT, olfactory tubercle; PAG, periaqueductal gray; SNpc, substantia nigra pars compacta; SNr, substantia nigra pars reticulata; VTA, ventral 
tegmental area; FMTC, familial medullary thyroid carcinoma; MEN2, multiple endocrine neoplasia type 2 
* expression reported only during embryonic or early postnatal development, but not in adult rodent 
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2.1.4 CDNF/MANF family of neurotrophic factors 
More recently discovered NTFs, MANF and its paralog CDNF are structurally and functionally 
distinct from the classical NTFs (Petrova et al. 2003; Lindholm et al. 2007; Lindahl et al. 2017). 
MANF (also known as arginine-rich, mutated in early stage tumors; ARMET) and CDNF (also known 
as ARMET-like 1; ARMETL1) are both present in vertebrates, but invertebrates, including D. 
melanogaster and C. elegans, express only one homologous protein that is more closely related 
to MANF (DmMANF) (Palgi et al. 2009). Together CDNF and MANF form an evolutionary conserved 
family of NTFs that shows classical neurotrophic properties such as promoting the survival and 
repair of midbrain dopamine neurons in vitro and in animal models of PD, protecting cardiac 
myocytes and cortical neurons against ischemia, and enhancing peripheral nerve recovery in a 
sciatic nerve transection model (Petrova et al. 2003; Lindholm et al. 2007; Tadimalla et al. 2008; 
Airavaara et al. 2009; Voutilainen et al. 2009; Airavaara et al. 2010; Voutilainen et al. 2011; 
Airavaara et al. 2012; Glembotski et al. 2012b; Cheng et al. 2013a; Cordero-Llana et al. 2015a; Liu 
et al. 2018; Zhang et al. 2018a; Zhang et al. 2018b). 
During embryonic development, MANF signaling seems to be necessary for the proper neuronal 
differentiation, neuroblast migration and neurite outgrowth in the developing mouse brain (Tseng 
et al. 2018, 2017). In line, studies in D. melanogaster and C. elegans suggest an important role for 
DmMANF in the maturation and survival of dopamine neurons and in the maintenance of ER 
homeostasis (Palgi et al. 2009; Richman et al. 2018). In zebrafish, MANF knockdown causes a 
decrease in brain dopamine level and impairs the development of tyrosine hydroxylase (TH) 
expressing neurons (Chen et al. 2012). As for CDNF, knockout mice show age-dependent aberrant 
functions of the brain dopamine system such as slower dopamine reuptake via dopamine 
transporter (DAT) and increased amphetamine-induced dopamine release in the striatum (Lindahl 
et al. 2020). However, the number of dopamine neurons in the SN and dopamine level in the 
striatum remain unaltered. Interestingly, CDNF deficiency leads to age-dependent loss of enteric 
neurons in the submucosal plexus due to increased autophagy and neuronal degeneration. To 
date, the structure and expression pattern of CDNF and MANF are well-studied but their cell 
surface receptors and signaling pathways remain to be unraveled. 
2.1.4.1 Structure and secretion of MANF and CDNF 
CDNF and MANF are structurally unrelated to other NTFs. The amino acid sequences of mature 
human CDNF and MANF are 59% identical (Petrova et al. 2003; Lindholm et al. 2007; Lindahl et al. 
2017). Their primary structure contains an N-terminal signal sequence (pre-sequence) that directs 
them to the ER during protein synthesis and allow access to the secretory pathway. Cleavage of 
the pre-sequence results in a mature protein that can be secreted via the canonical COPII-
mediated ER-Golgi pathway (Apostolou et al. 2008; Oh-hashi et al. 2012; Norisada et al. 2016). 
Secreted CDNF and MANF seem to exert their trophic actions both in an autocrine and paracrine 
fashion but their binding to a transmembrane receptor has remained obscure until today 
(Apostolou et al. 2008; Lindahl et al. 2017). Although CDNF and MANF can be secreted, they are 
mostly retained intracellularly within the ER unlike classical NTFs that are exclusively secretory 
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proteins (Lindholm and Saarma 2010). In the ER, they seem to support protein folding and mitigate 
ER stress. 
Human MANF is a glycosylated protein consisting of 179 amino acids and having a molecular mass 
of 20 kDA (Figure 2.3A) (Petrova et al. 2003). Its primary structure contains a 21-amino acid-long 
signal sequence which is cleaved to form 158 amino acids long mature protein. The secondary 
structure of the protein is dominated by α-helices and random coils and virtually lacks β-sheets. 
Human CDNF is 187 amino acids long, glycosylated protein with a calculated molecular mass of 18 
kDa (Lindholm et al. 2007; Apostolou et al. 2008; Sun et al. 2011). CDNF has a signal sequence of 
26 amino acids, the cleavage of which forms a 161-amino acid-long mature protein. Similarly to 
MANF, the secondary structure of CDNF contains mostly α-helices. A characteristic feature of the 
primary structure of CDNF and MANF is eight conserved cysteine residues (Lindholm et al. 2007; 
Petrova et al. 2003). Four disulphide bridges are formed between the cysteine residues stabilizing 
the tertiary structure of the mature proteins. 
 
Figure 2.3. Schematic structure of human MANF and CDNF. (A) Schematic picture of the primary 
structure of human MANF and CDNF. The N-terminal (saposin-like) domain of MANF and CDNF is 
indicated in blue, and the C-terminal (SAP-like) domain in orange. Vertical yellow bars depict conserved 
cysteine residues, and they are numbered according to the sequence of mature protein. The formation 
of disulphide bridges is shown as black connecting lines below the sequence of MANF. The ER retention 
signals of MANF and CDNF (RTDL and KTEL, respectively) are marked with pink. (B) Solution structure 
of human MANF. MANF has two domains: saposin-like N-terminal domain containing five α-helices 
(α1-α5) and 310 helix in the linker region, and SAP-like C-terminal domain containing two α-helices (α6 
and α7). Yellow sticks show the formation of disulphide bridges in the tertiary structure. The CXXC 
motif (127CKGC130) and ER retention signal (155RTDL158) are indicated in the C-terminal domain. N - 
amino-terminus; C - carboxy-terminus. Adapted with permission from Elsevier: Neurobiology of 
Disease, Lindahl et al. (2017), © Elsevier 2016. 




The tertiary structures of CDNF and MANF closely resemble each other. They consist of two 
domains connected to each other with a flexible linker region (Lindholm et al. 2007; Parkash et al. 
2009; Hellman et al. 2011; Latge et al. 2015). N-terminal domain has a globular conformation 
containing five α-helices (α1-α5), 310 helix in the linker region and a hydrophobic core. Three out 
of four disulphide bridges are located in the N-terminal domain as depicted in Figure 2.3B. C-
terminal domain is partially unstructured; it contains two α-helices (α6 and α7) and one internal 
disulphide bridge between the two cystein recidues in CXXC motif (132CRAC135 in CDNF and 
127CKGC130 in MANF). This CXXC motif in the loop connecting the helices α6 and α7 seems to be 
important for the functionality of the proteins. Mätlik and coworkers  showed that mutating the 
CKGC motif abolishes the survival-promoting activity of MANF when overexpressed intracellularly 
in cultured sympathetic or sensory neurons, or when applied extracellularly in a rat model of focal 
cerebral ischemia (Mätlik et al. 2015). At the very end of the C-terminus, CDNF and MANF have 
conserved four amino acid sequences (158KTEL161 in CDNF and 155RTDL158 in MANF) which resemble 
the canonical ER retention signal KDEL (Glembotski et al. 2012; Henderson et al. 2013; Oh-hashi 
et al. 2012; Raykhel et al. 2007). Human has three KDEL receptors (KDELR1-3) that function in the 
Golgi. KDELRs recognize KDEL-like sequences in the C-terminus of proteins and mediate their 
retrograde trafficking from the Golgi back to the ER. Henderson and colleagues suggested that 
KDELRs, accumulated to the plasma membrane in ER-stressed cells, could mediate the cell surface 
binding of MANF (possibly CDNF too) through the interaction between the C-terminal RTDL 
sequence and KDELRs (Henderson et al. 2013). 
MANF retention to the ER is also dependent on another ER resident protein, glucose-regulated 
protein 78 kDa (GRP78; also known as binding immunoglobulin protein, BiP), the expression of 
which closely resembles the expression of MANF in mouse tissues (Mizobuchi et al. 2007; 
Glembotski et al. 2012; Oh-hashi et al. 2012). MANF interacts directly with GRP78 and the 
interaction has been shown to be calcium dependent. Depletion of ER calcium storages e.g. by 
thapsigargin, an inhibitor of SERCA (sarco/endoplasmic reticulum calcium transporting ATPase), 
triggers MANF secretion independently of the RTDL sequence. Taken together, if the ER calcium 
concentration is normal, both GRP78 and KDELR seem to participate in retaining MANF in the ER. 
Upon ER calcium depletion, MANF dissociates from GRP78 leading to its increased secretion 
although the interaction with KDELR remains unaffected. Thus, the RTDL sequence is anticipated 
to function as a weak retention motif fine-tuning the secretion of MANF. Overexpression of GRP78 
and KDELR1 in HEK293 cells similarly decreased the secretion of MANF and CDNF suggesting that 
the mechanisms regulating the secretion of CDNF and MANF are fundamentally similar 
(Glembotski et al. 2012; Oh-hashi et al. 2012; Henderson et al. 2013; Norisada et al. 2016). 
2.1.4.2 Expression of MANF and CDNF 
MANF is widely expressed both in neuronal and non-neuronal tissues starting from early stages of 
embryonic development until adulthood (Lindholm et al. 2008; Wang et al. 2014). 
Immunohistochemical studies show that in the rodent brain the expression of MANF is mainly 
neuronal (Lindholm et al. 2008; Shen et al. 2012; Wang et al. 2014). In the CNS of the adult mouse, 
MANF expression is abundant in several brain regions including the olfactory bulb, cortical areas, 
hippocampus, several hypothalamic and thalamic nuclei, pons, medulla, cerebellar Purkinje cells, 
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spinal cord and neural progenitors of the SVZ (Lindholm et al. 2008; Wang et al. 2014; Tseng et al. 
2018). In the striatum and SN, only low to intermediate levels of MANF were detected both from 
the adult brain and during embryonic development. In the SNpc, MANF immunofluorescency co-
localized with the TH-immunoreactive (ir) cells indicating MANF expression in dopamine neurons 
(Lindholm et al. 2008). However, MANF-positive neurons were more prevalent in the SN pars 
reticulata than in pars compacta. Wang and colleagues suggested that in the rat brain MANF 
expression is developmentally regulated with the expression being highest within the first two 
weeks after birth and decreasing upon aging (Wang et al. 2014). 
Apart from the CNS, MANF is broadly expressed in peripheral tissues of adult and embryonic mice 
(Mizobuchi et al. 2007; Lindholm et al. 2008; Lindahl et al. 2014). The expression is ample 
especially in secretory cells and tissues, including choroid plexus, pancreatic exocrine acinar cells 
and endocrine β cells, salivary glands, liver and testis, suggesting an important role of MANF in 
regulating protein homeostasis in cells with a high rate of protein production. Lower levels of 
MANF are detected in the lung, skeletal muscles, kidney and heart (Lindholm et al. 2008). The 
indispensable role of MANF for the survival and normal function of pancreas was shown in MANF 
knockout mice (Lindahl et al. 2014). MANF deficiency caused progressive loss of functional β cells 
and chronic UPR activation in pancreatic islets, resulting in insufficient insulin secretion, increased 
blood glucose level and diabetic phenotype. Importantly, MANF is widely expressed in spleen and 
different types of immune cells (Cheng et al. 2014; Liu et al. 2015b; Neves et al. 2016). For 
example, MANF levels in peripheral leukocytes and synovial tissues are highly up-regulated in 
response to arthritis or other inflammatory diseases (Chen et al. 2015). Recently, MANF expression 
has also been detected in human blood serum (Galli et al. 2016) as well as in rodent and human 
optic nerves and retina where it promotes the survival of retinal ganglion and photoreceptor cells 
(Gao et al. 2017a; Gao et al. 2017b; Lu et al. 2018).  
Similarly to MANF, CDNF transcripts are widely expressed both in the human and mouse brain as 
well as in peripheral non-neuronal tissues (Lindholm et al. 2007). The expression levels of CDNF, 
however, appear to be generally lower as compared to MANF. In immunohistochemical analyses, 
CDNF immunoreactivity was detected in somas where it co-localized with neuronal markers NeuN 
and Tuj1 indicating that the expression of CDNF is neuronal (Lindholm et al. 2007; Zhou et al. 
2016). In addition, CDNF was shown to co-localize with glial fibrillary acidic protein (GFAP), a 
marker for astrocytes, in rat primary hippocampal cell culture. In the adult mouse brain, CDNF-
positive cells were observed in the brain stem, including locus coeruleus, in the cortical layers II-
VI, in CA1 and CA3 pyramidal regions and dentate gyrus of the hippocampus and in the Purkinje 
cells of the cerebellum (Lindholm et al. 2007). In the SN, however, CDNF immunoreactivity was 
detected only in solitary cells which did not include TH-positive dopamine neurons. CDNF staining 
was weak also in the striatum. In postnatal P1 and P10 mouse brains, CDNF signal was detected in 
the hippocampus, thalamus, striatum and SN.	Relatively high CDNF levels were detected in the 
adult mouse heart, skeletal muscles and testis. Overall, the expression pattern of CDNF and MANF 
seems to partly overlap but the intensity of their expression differs. 




2.1.4.3 Two proposed mechanisms of action 
As described above, CDNF and MANF possess a two-domain protein structure (Parkash et al. 2009; 
Hoseki et al. 2010; Hellman et al. 2011; Latge et al. 2015). The domains are connected via a short 
polypeptide linker which allows them to move flexibly in relation to each other. The independent 
orientation of the domains may be an important feature in the mechanism of action of CDNF and 
MANF since the domains seem to exert distinct functions. 
Anti-apoptotic effect of MANF and CDNF 
The C-terminal domain of CDNF and MANF is homologous to the SAP (SAF-A/B, Acinus, and PIAS) 
domain of Ku70 (C-Ku70) (Hellman et al. 2011; Hoseki et al. 2010; Latge et al. 2015; Parkash et al. 
2009). Ku70 inhibits the cytoplasmic pro-apoptotic Bax (Bcl-2-associated X protein) via its SAP 
domain thereby preventing apoptosis (Sawada et al. 2003; Wolter et al. 1997). During apoptosis, 
Ku70 dissociates from Bax which is translocated into mitochondria where it promotes release of 
cytochrome c into the cytosol. Cytochrome c, in turn, activates caspases resulting in cell death 
(Green 2000). Owing to the structural homology with the SAP domain of Ku70, the C-terminal 
domain of CDNF or MANF may prevent apoptosis by regulating Bax and subsequent caspase 
activation (Hellman et al. 2011; Mei and Niu 2014). Direct interaction between CDNF or MANF and 
Bax, however, has not been detected suggesting that the neuroprotective activity against Bax-
dependent apoptosis is not mediated by a direct interaction of the proteins (Mätlik et al. 2015).  
The N-terminal domain of CDNF and MANF has a homologous structure with saposin-like proteins 
(SAPLIPs), a diverse family of lipid and membrane -interacting proteins with various cellular 
functions (Parkash et al. 2009; Hoseki et al. 2010; Hellman et al. 2011; Latgé et al. 2013; Latge et 
al. 2015). SAPLIPs are globular proteins containing four or five α-helices and two or three 
disulphide bridges (Bruhn 2005). Structurally N-CDNF and N-MANF are closest to the membrane-
lytic proteins granulysin and NK-lysin which contain several positively charged amino acid residues 
responsible for their binding to the negatively charged phospholipid heads of biological 
membranes (Parkash et al. 2009). Similarly, positively charged lysine and arginine residues on the 
surface of helices α3, α4 and α5 in N-CDNF and N-MANF may increase the membrane binding 
properties of the proteins. Lipid-binding could potentially mediate the initial cellular interaction 
and internalization of the proteins. Nevertheless, in spite of the structural propensity, lipid 
interactions of CDNF and MANF have not been demonstrated so far (Lindahl et al. 2017). 
Regulation of ER stress by MANF and CDNF 
Different cellular perturbations, for example the expression of mutated proteins or viral infections, 
can lead to the abnormal accumulation of unfolded or misfolded proteins in the lumen of ER. The 
misfolded proteins alter the function of ER and cause disturbances in cellular proteostasis referred 
to as ER stress (reviewed in Ron and Walter 2007; Dufey et al. 2014). In order to cope with protein 
folding alterations, ER stress triggers the activation of conserved cellular signaling cascades 
collectively known as UPR. UPR leads to adaptive responses that suppress protein translation and 
translocation into the ER, enhance protein folding capacity by increasing the production of 
molecular chaperones and degrading misfolded proteins. Altogether, these events aim to 
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attenuate unfolded protein load in the ER and restore the homeostasis. UPR related cytosolic 
signaling cascades are activated by dissociation of GRP78 from the luminal domain of three 
different ER transmembrane sensor proteins: inositol-requiring enzyme 1 (IRE1), protein kinase 
RNA-like ER kinase (PERK) and activating transcription factor 6 (ATF6). If ER stress becomes 
prolonged or too intense to be resolved with adaptive changes, UPR triggers apoptotic cell death 
mechanisms. ER stress and UPR play an important part in the pathophysiology of many 
neurodegenerative diseases, such as PD or AD, which are characterized by the aggregation of 
misfolded proteins in the brain (Hetz and Saxena 2017). 
CDNF and MANF have been shown to localize in the ER suggesting their function as ER stress and 
protein homeostasis regulating proteins (Apostolou et al. 2008; Cheng et al. 2013b; Mizobuchi et 
al. 2007; Tadimalla et al. 2008; Voutilainen et al. 2015). The promoter region of Manf gene 
contains two ER stress-responsive elements (ERSE I and ERSE II) which are recognized by ER stress-
inducible transcription factors activated ATF6 and spliced X-Box-Binding Protein 1 (XBP1s) 
enhancing MANF transcription (Lee et al. 2003; Yamamoto et al. 2004; Mizobuchi et al. 2007; Oh-
Hashi et al. 2013; Wang et al. 2018a). On the contrary, Cdnf gene has not been reported to contain 
such elements. MANF and CDNF expression levels are upregulated upon ER stress in various cell 
types in vitro and in vivo (Apostolou et al. 2008; Glembotski et al. 2012; Hartley et al. 2013; 
Mizobuchi et al. 2007; Tadimalla et al. 2008; Zhang et al. 2018). In physiological conditions, MANF 
and CDNF mostly localize to the luminal side of the ER, whereas under ER stress their secretion is 
enhanced which is an unconventional response for an ER stress-induced protein. 
The ER stress regulation of MANF and CDNF is proposed to be mediated through GRP78 and its 
downstream UPR signaling pathways (Lindahl et al. 2017). The hypothetical mechanism of MANF 
in the regulation of UPR is depicted in Figure 2.4. In a rat model of focal cerebral ischemia, for 
example, intraventricularly administered MANF was able to rescue the neuronal loss in the 
hippocampus and cortex and downregulate UPR by repressing the elevated levels of GRP78, 
phosphorylated IRE1 and cleaved caspase-3 (Yang et al. 2014). Similarly, exogenously 
administered CDNF protected against Aβ-induced synaptotoxicity by suppressing the increase of 
GRP78, phosphorylated JNK and cleaved caspase-3 in primary hippocampal cells (Zhou et al. 2016). 
In knockout mice, the lack of MANF led to chronic UPR activation in pancreatic islets and significant 
upregulation of GRP78, ATF4, CHOP and ATF6 (Lindahl et al. 2014). Recent findings by Yan and 
coworkers show that MANF binds to the nucleotide-binding domain of GRP78 and inhibits 
nucleotide exchange on GRP78 (Yan et al. 2019). Thus, MANF seems to promote protein folding in 




Figure 2.4. Proposed mechanism for unfolded protein response (UPR) regulation by MANF. (A) In the absence of endoplasmic reticulum (ER) stress, binding 
of glucose-regulated protein 78 kDa (GRP78) to the luminal domain of three ER transmembrane sensor proteins, activating transcription factor 6 (ATF6), 
inositol-requiring enzyme 1 (IRE1) and protein kinase RNA-like ER kinase (PERK), keeps them inactive. MANF is suggested to bind GRP78 in a Ca2+ dependent 
manner helping to keep the UPR sensor proteins inactive. KDEL receptor (KDELR) retains MANF in the ER via the C-terminal RTDL sequence. MANF may also 
be retrieved from the Golgi back to the ER by KDELR. (B) Upon ER stress, depletion of Ca2+ from the ER leads to dissociation of MANF from GRP78 and its 
secretion to the extracellular space, possibly due to increased competition in KDELR-mediated retention. GRP78 dissociates from ATF6, IRE1 and PERK and 
binds to accumulating misfolded proteins in the ER. This activates UPR related cytosolic signaling cascades. ATF6 is translocated to the Golgi, where it gets 
cleaved and activated. Active ATF6 moves into the nucleus, where it functions as a transcription factor for genes involved in protein folding, ER-associated 
protein degradation (ERAD) and lipid synthesis. It also upregulates the expression of GRP78, MANF, pro-apoptotic transcription factor C/EBP homologous 
protein (CHOP) and Xbp1 mRNA. Dissociation of GRP78 allows IRE1 to be dimerized and autophosphorylated. Endoribonuclease activity of the cytoplasmic 
domain of IRE1 removes an intron from Xbp1 mRNA. Spliced Xbp1s mRNA is then translated to XBP1s transcription factor, which upregulates genes for 
chaperons, ERAD, lipid synthesis and MANF. In addition, IRE1 can reduce translational workload by degrading ER associated mRNAs. Chronic activation of IRE1 
can recruit TRAF2 and ASK1, which phosphorylates c-Jun N-terminal kinase (JNK) and leads to the nuclear translocation of NFκB. NFκB upregulates genes of 
inflammatory response, autophagy regulation and apoptosis. Dimerization and autophosphorylation of PERK followed by phosphorylation of translation 
initiation factor eIF2a leads to general inhibition of protein synthesis and increase in the translation of transcription factor ATF4. ATF4 induces genes related 
to protein folding, amino acid metabolism and restoring oxidative balance, as well as CHOP. PM – plasma membrane; SERCA2 – sarco/endoplasmic reticulum 
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Regulation of inflammation by MANF and CDNF 
Inflammation and ER stress are closely linked with each other. In many pathologies, such as 
neurodegenerative diseases, all three ER stress-induced UPR sensor proteins (i.e. IRE1, PERK and 
ATF6) participate in mediating inflammatory processes as reviewed by (Zhang and Kaufman 2008; 
Cao et al. 2016; Sprenkle et al. 2017). ER stress and immune cell activation share many common 
regulators, e.g. NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), JNK and 
p38, forming a vicious cycle of the two signaling pathways that may exacerbate their pro-apoptotic 
effects. As a consequence, the neuroprotective and regenerative properties of CDNF and MANF 
may ultimately be due to regulation of inflammatory responses in the CNS (Zhao et al. 2014; Chen 
et al. 2015; Neves et al. 2016). Immune cell activation occurs at early stages of tissue reparation 
and its regulation is crucial to regenerative success (Sousa-Victor et al. 2018). The precise 
mechanisms through which CDNF and MANF can affect neuroinflammation still remain 
undetermined, but the studies published to date support the notion that they can reduce the 
secretion of pro-inflammatory cytokines and promote the pro-regenerative activation of immune 
cells. 
MANF has been shown to exert immune modulatory functions that bias immune cells toward an 
anti-inflammatory phenotype. Results from Chen and colleagues  suggest that MANF acts as a 
negative regulator of inflammation by suppressing NF-κB pathway activation (Chen et al. 2015). 
They showed that under the condition of inflammation or ER stress MANF was upregulated and 
translocated into the nucleus where its C-terminal domain interfered with the binding of p65, a 
subunit of NF-κB, to the target gene promoters. Consequently, MANF suppressed the expression 
of NF-κB-dependent cytokines and inflammatory cell proliferation. In an in vitro model of 
ischemia, pretreatment of rat primary astrocytes with MANF alleviated oxygen-glucose 
deprivation induced cell damage, suppressed ER stress and decreased the secretion of pro-
inflammatory cytokines IL-1b, IL-6, and TNF-a (Zhao et al. 2013). Anti-inflammatory effects of 
MANF were also reported in lipopolysaccharide (LPS) -exposed neural stem cells where MANF 
inhibited inflammatory signaling (IL-1b, TNF-a and IFN-g) by regulating NF-kB and p38-MAPK 
pathways (Zhu et al. 2016). 
CDNF was shown to be upregulated in rat primary microglia in response to LPS-induced 
inflammation (Zhao et al. 2014). Cultured microglial cells were exposed to LPS which induced 
distinct cytotoxicity and secretion of pro-inflammatory cytokines PGE2 and IL-1b. Pretreatment 
with CDNF was able to attenuate these reactions, possibly due to suppressed activation of JNK 
pathway. In agreement with this, overexpression of CDNF in primary astrocytes was sufficient to 
alleviate ER stress induced cell damage and production of pro-inflammatory cytokines IL-1b, IL-6 
and TNF-a (Cheng et al. 2013). The ability of CDNF to limit neuroinflammation has also been 
observed in vivo. In a rat model of spinal cord injury, the transplantation of mesenchymal stem 
cells overexpressing CDNF was able to decrease the production of PGE2, IL-1b and TNF-a, promote 
nerve regeneration and improve the overall motor function of the injured rats (Zhao et al. 2016). 
Importantly, in a 6-hydroxydopamine (6-OHDA) model of PD in rats, CDNF transfection into the SN 
reduced glial activation and IL-6 levels in the midbrain (Nadella et al. 2014). Finally, it should be 
noted that CDNF and MANF may also exert their actions through different mechanisms leading to 




synergistic effects as proposed by Cordero-Llana and colleagues based on their observation that 
combined overexpression of both CDNF and MANF in the SNpc led to more efficacious 
dopaminergic neuroprotection in 6-OHDA-lesioned rats as compared to the overexpression of 
either one of the NTFs alone (Cordero-Llana et al. 2015). 
2.1.5 Retrograde signaling of neurotrophic factors 
In order to regulate neuronal development, plasticity and survival, target-derived NTFs have to be 
transported retrogradely from the synapses to the cell bodies where they can modulate gene 
transcription. Because the morphology of neurons is highly polarized, NTF-receptor complexes 
internalized at the nerve terminals may need to travel long distances along the axons to reach 
downstream signaling effectors localized in the cell body. 
An early study from 1974 showed distal uptake and axonal transport of exogenous radiolabeled 
NGF and suggested that the retrograde transport of NTFs to neuronal cell bodies plays an 
important role in their survival promoting effects (Hendry et al. 1974). Later, endogenous 
unlabeled NGF was also confirmed to be retrogradely transported in vivo (Palmatier et al. 1984; 
Mufson et al. 1999). Upon NGF binding to TrkA receptor, the activated receptor-ligand complex is 
internalized by clathrin-dependent endocytosis (Ehlers et al. 1995; Grimes et al. 1996; Riccio et al. 
1997; Howe et al. 2001; Ye et al. 2003). The endocytic vesicle containing the activated components 
of MAPK, PLCg and PI3K/Akt pathways is then retrogradely transported along the axon to the soma 
by a microtubule-associated protein complex called dynein (Vallee et al. 1989; Bhattacharyya et 
al. 2002; Vallee et al. 2004). This phenomenon is collectively called “signaling endosome” 
hypothesis. 
Like neurotrophins, GFLs can also provide long-distance trophic support to neurons. For example, 
in the nigrostriatal pathway GFLs are taken up by axon terminals of dopamine neurons and 
transported to the cell bodies: receptor-mediated uptake and retrograde transport of GDNF have 
been demonstrated by injecting biologically active 125I-labeled GDNF into the adult rat striatum 
and using autoradiography to detect accumulated radioactivity in the ipsilateral SNpc 24h later 
(Tomac et al. 1995b; Voutilainen et al. 2009, 2011). This suggests that in the adult nigrostriatal 
system GDNF acts as an endogenous target-derived NTF for dopamine neurons. Similarly, GDNF 
was shown to be internalized and retrogradely transported by spinal motor neurons in neonatal 
rats (Yan et al. 1995). In compartmentalized cultures of sympathetic neurons, addition of GDNF to 
distal axons induced neuronal survival and neurite outgrowth in the cell bodies (Coulpier and 
Ibáñez 2004). The trophic effects were associated with retrograde transport of GDNF and GFRa1, 
as well as activation of RET and Akt in the cell bodies suggesting a saturable, receptor-mediated 
mechanism for the retrograde signaling. A competition study investigating the retrograde 
transport of 125I-labelled GFLs demonstrated that the transport is mediated selectively by 
corresponding GFRa co-receptors and only limited cross-binding occurs (Leitner et al. 1999). 
Proteasomal degradation of RET in distal axons has been suggested to regulate the trophic 
signaling by modulating the amount of active GFL-GFRa-RET complexes that can be transported 
to cell bodies (Tsui and Pierchala 2010).  
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The molecular mechanisms of the retrograde GFL-GFRa-RET signaling are more poorly understood 
than the mechanism of retrograde NGF-TrkA signaling (Ito and Enomoto 2016). In response to 
receptor activation, GFL-GFRa-RET complex can be internalized from the plasma membrane via 
clathrin-mediated endocytosis (Richardson et al. 2006; Richardson et al. 2012; Crupi et al. 2015). 
The resulting early endosome contains phosphorylated RET and signaling effectors that can 
activate downstream trophic pathways. It might also anchor to the microtubule network and be 
transported to the soma by dynein motors in accordance with the “signaling endosome” 
hypothesis. 
Intrastriatally injected CDNF was shown to be internalized by different cortical and striatal 
neurons, possibly via the endocytic pathway, and undergo retrograde transport to the SNpc along 
nigrostriatal dopamine neurons (Voutilainen et al. 2011; Mätlik et al. 2017). 125I-labeled CDNF also 
seemed to spread to the frontal cortex and hippocampus but active transportation to these areas 
could not be confirmed because the spread was not markedly affected by an excess of unlabeled 
CDNF (Voutilainen et al. 2011). Intrastriatally injected 125I-MANF, instead, was retrogradely 
transported, possibly via glutamatergic projection neurons, to the frontal cortex but not to the SN 
(Voutilainen et al. 2009). 
In addition to retrograde transport, there is some evidence of anterograde transport of NTF 
signaling. In retinal ganglion cells, neurotrophins are anterogradely transported in vesicles along 
axonal microtubules to the midbrain superior colliculus using conventional kinesin-I motors 
(Butowt and von Bartheld 2007, 2001). However, the detailed molecular mechanisms and 
physiological significance of anterograde transport of NTFs remain largely elusive. Interestingly, in 
many neurodegenerative diseases there are alterations in axonal transport suggesting that 
defective retro- or anterograde NTF signaling may contribute to neurodegenerative processes 
(Bronfman et al. 2007; Ito and Enomoto 2016). 
2.1.6 Neurotrophic factor mimetics, inducers and variants  
Peripherally administered NTFs do not cross the BBB and have short half-lives. An alternative 
strategy to activate NTF signaling is to use small molecules that bind to and activate NTF receptors 
or enhance NTF expression. The elucidation of the 3D structures of NTFs and their receptors makes 
it possible to use rational drug discovery methods in the design and development of such 
compounds. NTF mimetics potentially afford an opportunity to attain better drug-like properties 
as compared to recombinant NTFs: Ability to penetrate the BBB would make them suitable for 
peripheral administration, thus overcoming the high risks associated with the intracranial delivery 
of NTF proteins or viral vectors. Better diffusion in the brain parenchyma would ensure sufficient 
dose in the target area, selective binding profile and possibility for intermittent delivery would 
contribute to a better safety profile. In addition, small molecules would evade the potential risk 
of immunogenicity related to recombinant protein therapies and would be easier to manufacture 
in large quantities. 




2.1.6.1 GFL mimetics 
Considering the potent neurotrophic effects GFLs on midbrain dopamine neurons, targeting GFL-
GFRa-RET signaling with GFL mimetics is of therapeutic interest in relation to PD (Lin et al. 1993). 
The proposed mechanisms of action for a GFL mimetic activating GFRa-RET receptor complex are 
shown in Figure 2.5. Tokugawa and colleagues described the first small molecule compound, 
XIB4035, mimicking the biological functions of GDNF (Tokugawa et al. 2003). XIB4035 binds to 
GFRa1 and activates the GFRa1-RET complex inducing RET phosphorylation and neurite 
outgrowth in a mouse neuroblastoma cell line. Later, this GDNF mimetic was shown to improve 
sensory function in animals with advanced neuropathy and to act as a positive modulator of GFRa-
mediated signaling instead of being a direct GFRa1 agonist (Hedstrom et al. 2014). 
 
Figure 2.5. Putative mechanisms of action of GDNF family ligand (GFL) mimetics. There are three 
proposed mechanisms for the activation of GFRa-RET receptor complex by an agonist (i.e. endogenous 
GFL dimer or GFL mimetic). (A) The agonist first binds to one GDNF family receptor α (GFRa) co-
receptor, which then engages a second GFRa. Subsequently, the agonist-(GFRa)2 complex recruits two 
receptor tyrosine kinase RET molecules leading to autophosphorylation of intracellular tyrosine 
residues of RET, and activation of intracellular signaling pathways like PI3K/Akt and Ras/MAPK. (B) The 
agonist binds to a preformed GFRa-RET heterodimer, and thereby recruit another GFRa-RET pair and 
activate downstream signaling cascades. (C) The receptor complex exists as a preformed (GFRa)2-
(RET)2 heterotetramer which acquires a conformational change in response to the binding of the 
agonist, enabling the phosphorylation of the tyrosine residues of RET. PM - plasma membrane; MAPK 
- mitogen activated protein kinase; PI3K - phosphatidylinositol 3-kinase. Figure drawn by the author. 
A novel family of small molecule GFL mimetics, termed BT13, BT18 and BT44, can selectively 
activate RET and its downstream signaling pathways (Bespalov et al. 2016; Mahato et al. 2020; 
Sidorova et al. 2017; Sidorova and Saarma 2020; Viisanen et al. 2020). These compounds have 
been shown to promote neurite outgrowth from cultured dorsal root ganglia sensory neurons and 
attenuate hyperalgesia in rat models of neuropathic pain. BT13 also supports the survival of 
cultured dopamine neurons, protects them from 6-OHDA and 1-methyl-4-phenylpyridinium 
(MPP+) induced cell death in a RET-dependent manner, and is able to stimulate dopamine release 
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in the mouse striatum (Mahato et al. 2020). The preferred binding sites of BT13 in the GFRα1-RET 
complex were investigated using molecular docking simulations and identified to be the allosteric 
modulation site of GFRa1 and the GFRa1-interacting site of RET (Ivanova et al. 2018). The latter, 
more likely binding site, enables BT13 to act as a direct RET agonist. 
2.1.6.2 NTF inducers 
A large number of compounds, both pharmacological and natural agents, has been suggested to 
stimulate endogenous NTF synthesis, which potentially has disease-modifying relevance in PD 
management. These compounds are extensively reviewed by Saavedra et al. (2008) and include, 
but are not limited to, dopamine agonists, monoamine oxidase (MAO) inhibitors, catecholamine 
reuptake inhibitors, anti-depressants, anti-psychotics, vitamin D3, estrogen and various medicinal 
herb extracts. Rasagiline, a clinically used MAO-B inhibitor, is one of such compounds that has 
attracted attention. It seems to upregulate BDNF and GDNF levels in vitro and in vivo (Bar-Am et 
al. 2005; Maruyama et al. 2004; Weinreb et al. 2009). In a rat 6-OHDA model of PD, rasagiline 
protected nigrostriatal dopamine neurons and alleviated motor decline (Blandini et al. 2004). 
Likewise, in a mouse lactacystin model of PD, rasagiline showed neuroprotective and 
neurorestorative effects and induced motor recovery (Zhu et al. 2008). Rasagiline has also been 
tested in early-stage PD patients in two phase II trials with delayed-start design (Parkinson Study 
Group 2004; Olanow et al. 2009; Hauser et al. 2009). It showed some disease-modifying effects, 
but further evidence is needed for decisive conclusions. 
Dopaminergic neurotransmission itself is proposed to regulate the expression of GDNF and BDNF 
in the nigrostriatal system (Saavedra et al. 2008). For example, D1 and D2 receptor agonists 
increase the synthesis of GDNF in midbrain and striatal primary cultures (McNaught and Jenner 
2000; Ohta et al. 2000; Guo et al. 2002; Ohta et al. 2004). Consequently, striatal dopamine 
depletion may lead to downregulation of GDNF which can contribute to the disease progression 
in PD patients. Clinically used D2-like dopamine receptor agonists pramipexole and ropinirole have 
been speculated to have neurotrophic properties. In rodent models of PD, they protected 
nigrostriatal dopamine neurons against 6-OHDA- and 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) -induced toxicity (Iida et al. 1999; Zou et al. 2000; Anderson et al. 2001; 
Ramirez et al. 2003). It should be noted, however, that the neuronal uptake of 6-OHDA and MPTP 
via DAT is a prerequisite for their toxic effects and that the neuroprotection seen in these models 
could be attributed to the regulation of DAT function by presynaptic D2 autoreceptor activation 
(Joyce et al. 2004). Neuroimaging evidence from clinical studies also suggests that pramipexole 
and ropinirole can affect the disease progression (Clarke and Guttman 2002; Parkinson Study 
Group 2002; Whone et al. 2003). The clinical relevance of these observations, however, has 
remained insignificant. 
2.1.6.3 NTF variants 
Structurally modified or truncated NTF variants have been engineered in search of improved 
pharmacokinetic properties of NTFs (Piltonen et al. 2009; Runeberg-Roos et al. 2016). Insufficient 
distribution in the brain parenchyma has been proposed as one major factor contributing to the 




lack of efficacy in the phase II clinical trials with GDNF and NRTN. As mentioned earlier, the 
diffusion of GDNF and NRTN in the brain tissue is hindered by their high affinity binding to heparan 
sulfates in the extracellular matrix. Thus, the promising neuroprotective effects of these GFLs in 
relatively small rat brain may not necessarily translate to much larger human brain where the GFLs 
have to diffuse long distances from the site of application.  
To improve the diffusion properties of GFLs, biologically active variants with reduced heparin 
binding affinity have been investigated (Piltonen et al. 2009; Smith et al. 2015; Runeberg-Roos et 
al. 2016; Grondin et al. 2019). N-terminally truncated, non-heparin-binding Δ38N-GDNF was more 
widely distributed in the rat striatum than wild-type GDNF, stable in a brain extract stability assay 
and protective against amphetamine-induced turning behavior in a 6-OHDA model of PD (Piltonen 
et al. 2009). Nevertheless, the Δ38N-GDNF was unable to significantly promote the survival of 
dopaminergic cell bodies in the SNpc. Overall, widespread striatal diffusion of Δ38N-GDNF did not 
improve its efficacy as compared to wild-type GDNF. These data suggest that although heparan 
sulfate binding of GDNF restricts its distribution in the brain, it may be needed for the optimal 
neuroprotective effects.  
Another GDNF variant (GDNFv) was engineered from wild-type GDNF by removing 31 amino acids 
from the N-terminal domain to reduce heparin binding and substituting two conservative amino 
acids (N38Q and D95E) to improve chemical stability (Smith et al. 2015). These modifications 
resulted in significantly improved distribution in the rat brain as well as in the larger rhesus 
macaque brain after intrastriatal administration, better chemical stability and lower predicted 
immunogenicity as compared to wild-type GDNF. In vitro, GDNFv was equivalent to wild-type 
GDNF in GFRα1 receptor binding, RET phosphorylation and neurite outgrowth assays. In a 6-OHDA 
model of PD in rats, its ability to protect dopamine neurons was comparable to wild-type GDNF, 
and in naïve rhesus macaques GDNFv enhanced dopamine turnover (Grondin et al. 2019). 
Structural modifications of NRTN were shown to increase its diffusion properties in the rat and 
monkey brain as compared to wild-type NRTN (Runeberg-Roos et al. 2016). This NRTN variant was 
also able to restore dopamine fibers in the striatum and alleviate motor impairment in 6-OHDA-
lesioned rats more potently than GDNF showing promise for further development of NTF variants 
into disease-modifying therapies for PD. 
2.2 Basal ganglia circuitry and dopaminergic system 
Basal ganglia are comprised of a highly conserved chain of subcortical nuclei in the forebrain that 
orchestrate action selection, motor coordination, habit formation, learning and motivation 
(Gerfen and Surmeier 2011; Macpherson and Hikida 2019). They are in a central position to 
facilitate voluntary movements and to inhibit interfering or competing movements. Hence, the 
functions mediated by the basal ganglia cover behaviors that are vital for animal survival. The 
largest nucleus of the basal ganglia is the striatum. Based on the distinct functions and 
connections, the striatum is subdivided into the dorsal striatum consisting of the caudate nucleus 
and putamen, and the ventral striatum including the nucleus accumbens (NAcc) and olfactory 
tubercle. The other basal ganglia nuclei include the pallidal nuclei, that are comprised of the 
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external and internal segment of the globus pallidus (GPe and GPi, respectively) and the ventral 
pallidum, subthalamic nucleus (STN), substantia nigra pars compacta and pars reticulata (SNpc and 
SNr, respectively) and ventral tegmental area (VTA). Perturbations in basal ganglia functions 
underlie debilitating movement disorders that are characterized by impaired voluntary 
movements, the presence of involuntary movements or both, such as in PD and Huntington’s 
disease (Macpherson and Hikida 2019). Dysfunctions of the basal ganglia also give rise to a 
spectrum of psychiatric conditions including schizophrenia, depression, anxiety, obsessive-
compulsive disorder and addiction. 
2.2.1 Organization of the basal ganglia circuits 
Basal ganglia circuitry receives its information from the cortex, modulates it under the control of 
midbrain dopaminergic innervation, and sends it back to the cortex through the thalamus (Gerfen 
and Surmeier 2011; Macpherson and Hikida 2019). The primary input nucleus of the basal ganglia 
is the striatum. It is anatomically connected to the cerebral cortex, thalamus and limbic system, 
and receives direct glutamatergic inputs from all main cortical areas (motor, sensory and 
associational areas) as well as thalamic nuclei. Midbrain dopamine neurons located in the SNpc 
and VTA send wide and dense dopaminergic innervation to the striatum where it merges with and 
modulates the cortical and thalamic glutamatergic input (Hooks et al. 2018; Klaus et al. 2019). The 
axonal arborization of a single dopamine neuron is shown to cover up to 6% of total striatal volume 
in rats (Matsuda et al. 2009). The basic organization of the basal ganglia circuitry is illustrated in 
Figure 2.6. 
The striatum hosts two groups of GABAergic medium spiny neurons (MSNs; also called spiny 
projection neurons, SPNs) which give rise to two parallel projection pathways that convey 
information from the striatum to the output nuclei of the basal ganglia, i.e. the GPi and SNr (Gerfen 
and Surmeier 2011; Macpherson and Hikida 2019). The GPi and SNr are the final information-
processing nuclei before output signals are sent to the ventral lateral nucleus and ventral anterior 
nucleus of the thalamus, superior colliculus and pedunculopontine nucleus (PPN) via GABAergic 
projections. The GPi and SNr are often considered as one somatotopic structure (the GPi/SNr), 
where the GPi is responsible for axial and limb movements and the SNr for head and eye 
movements. 
The excitatory corticostriatal glutamatergic input arises from the cortex layer 5 pyramidal neurons 
and is directed to the dendritic spines of the MSNs. Similarly, thalamostriatal glutamatergic 
projections arise from the intralaminar thalamic nuclei and form synapses on the dendritic shafts 
and spine heads of the MSNs. These inputs are modulated by dopaminergic input from the 
nigrostriatal pathway which is directed to the spine necks of MSNs (Figure 2.8). Approximately half 
of the striatal MSNs express excitatory dopamine D1 receptors, substance P and dynorphin (D1-
MSNs), and form the “direct” striatonigral pathway that projects monosynaptically to the GPi/SNr 
(Gerfen and Surmeier 2011; Macpherson and Hikida 2019). The other half expresses inhibitory 
dopamine D2 receptors and enkephalin (D2-MSNs) and project polysynaptically to the GPi/SNr 
forming the “indirect” striatopallidal pathway (Figure 2.6). D2-MSNs first extend axonal 




projections to the GABAergic neurons of the GPe, which in turn provide inhibitory innervation to 
the STN. Thereafter, glutamatergic neurons of the STN send excitatory projections to the GPi/SNr. 
 
Figure 2.6. Simplified diagram of the basal ganglia-thalamocortical circuitry. The striatum functions 
as an integrator of the basal ganglia input signals. It receives excitatory glutamatergic input from the 
cortex and thalamus (wide green arrows). In addition, dopaminergic input from the substantia nigra 
pars compacta (SNpc) arrives to the striatum (not shown) and modulates the glutamatergic input. The 
inhibitory GABAergic outputs of the basal ganglia project from the internal segment of the globus 
pallidus (GPi) and substantia nigra pars reticulata (SNr) to thalamus, superior colliculus and 
pedunculopontine nucleus (PPN) (wide red arrows). The direct pathway arises from GABAergic D1 
receptor expressing medium spiny neurons (MSNs) and projects directly to the output nuclei GPi and 
SNr (thin red arrows). The indirect pathway originates from GABAergic D2 receptor expressing MSNs 
that project only to the external segment of the globus pallidus (GPe) (thin blue arrows). The GPe 
further sends GABAergic afferents to the subthalamic nucleus (STN), which connects the signal to the 
output nuclei via glutamatergic projections (thin green arrows). Also, hyperdirect pathway providing 
glutamatergic input from the cortex to the STN (wide green arrow), direct pathway axon collaterals 
from the striatum to the GPe (thin red arrow), and collaterals from the GPe to the output nuclei (thin 
blue arrow) are shown in the diagram. Reproduced with the permission of Annual Reviews, from 
Gerfen and Surmeier (2011), Annual Review of Neuroscience, © Annual Reviews 2011. 
Evidence from optogenetical and electrophysiological measurements has shown, that direct 
pathway D1-MSNs also extend axon collaterals from the dorsal striatum and NAcc to the GPe and 
ventral pallidum, respectively, indicating that the canonical “direct/indirect” architecture of the 
striatal output pathways is more complex than originally though (Gerfen and Surmeier 2011; 
Kupchik et al. 2015). Moreover, the GPe sends some GABAergic projections directly to the GPi/SNr, 
as well as back to the striatum, where they are able to inhibit striatal movement representations 
(see below chapter 2.2.4) (Bevan et al. 1998; Gerfen and Surmeier 2011; Mallet et al. 2016, 2012). 
The STN also receives glutamatergic input in addition to GABAergic input from the GPe. These 
glutamatergic projections originate from the cortex forming the “hyperdirect” pathway that 
bypasses the striatum (Nambu et al. 2002). The hyperdirect pathway has been proposed to be 
critical for suppressing thalamocortical output, and thereby inhibiting erroneous or competing 
motor programs (Nambu et al. 2002; Aron and Poldrack 2006). Dopamine neurons of the ventral 
tier of the SNpc also send dendrites through the SNr where they are able to release dopamine 
(Zhou et al. 2009). This dopaminergic connection between the SNpc and SNr is termed the “ultra-
short pathway”. The dendritic dopamine release can activate presynaptic D1 receptors on the 
striatonigral MSN terminals which enhances GABA release in the SNr, and thus further suppresses 
the activity of nigral output projections to the thalamus (Robertson 1992). 
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2.2.2 Functions of the basal ganglia circuits 
The dorsal striatum is mainly responsible for cognition involving motor and executive functions, 
while the ventral striatum (especially the NAcc) primarily controls motivation, reward, positive 
reinforcement and Pavlovian-instrumental conditioning (Macpherson and Hikida 2019). The 
dorsal striatum is traditionally further divided into dorsomedial region (DMS) and dorsolateral 
region (DLS) based on anatomical and functional characteristics (McGeorge and Faull 1989). DMS 
receives input from the frontal- and parietal-associative cortices and plays an important role in 
skill acquisition and goal-oriented behavior (Gerfen and Surmeier 2011). DLS, on the other hand, 
receives the main input from the sensorimotor cortex, and this loop is responsible for automated 
action programs, habit formation and locomotion. Additionally, the basolateral amygdala sends 
excitatory afferents to the dorsal striatum which, according to  experiments in non-human 
primates (NHPs), seem to modulate striatal activity based on the emotional context and internally 
generated goals (Kelley et al. 1982; Pan et al. 2010; Hernádi et al. 2015; Maeda et al. 2018). The 
NAcc receives projections from the limbic structures such as prefrontal and anterior cingulate 
cortices, amygdala and hippocampus. Recent developments in chemogenetic and optogenetic 
tools, viral tracers and electrophysiological techniques have enabled further division of the 
striatum into smaller functional subregions beyond the simplified ventral-dorsal and medial-
lateral divisions (Chuhma et al. 2019). 
Besides the anatomical and functional organization, the dorsal and ventral striatum can be 
neurochemically divided into two main compartments known as striosomes and matrix 
(Brimblecombe and Cragg 2017; Crittenden and Graybiel 2016; Graybiel and Ragsdale 1978). 
Striosomes occupy on average 10−15% of the striatal volume and form small labyrinth-like zones 
that are surrounded by larger matrix compartment. Striosomes are defined histochemically based 
on high expression of e.g. μ-opioid receptors, substance P, D1 receptors and calretinin. Matrix, by 
contrast, is enriched with acetylcholinesterase, choline acetyltransferase, calbindin, somatostatin 
and D2 receptors. Both compartments contain direct and indirect pathway MSNs. The most 
prominent difference in the neuronal connectivity of the two compartments is the direct D1-MSN 
projection from striosomes to dopamine neurons of the ventral tier of the SNpc forming striato-
nigro-striatal loop. Striosomes also receive more innervation from the ventral tier, and matrix from 
the dorsal tier of the SNpc. Interestigly, studies in rats suggest that dopamine levels and TH-
immunoreactivity are higher in matrix but the density of dopaminergic axons is greater in 
striosomes. In addition to the dopaminergic innervation, striosomes receive abundant input from 
the limbic areas of the prefrontal cortex, whereas matrix receives cortical inputs primarily from 
the sensorimotor and associative cortices. The inputs from the thalamus and amygdala are also 
dissimilar between the two compartments. Studies of functional differences between striosomes 
and matrix are still at an early stage. Striosome-related circuits are proposed to regulate 
motivation, behavioral flexibility and choice under stressed conditions (Crittenden and Graybiel 
2016). The two compartments are also suggested to be differentially involved in pathological 
processes in a range of psychomotor disturbances including PD, Huntington’s disease, attention 
deficit and hyperactivity disorder (ADHD). 




As described above, the striatum receives dense and convergent excitatory inputs from multiple 
cortical areas and thalamic nuclei. Thus, it serves as an integrator of this sensorimotor, cognitive 
and motivational information, selects the most appropriate behaviors and translates them into 
specific changes in the basal ganglia outputs. Cortico-basal ganglia neurocircuits can be divided 
into three functional loops, the sensorimotor, associative/cognitive and limbic loops, which play 
different roles in context-dependent action planning, selection and initiation (Gerfen and 
Surmeier 2011; Macpherson and Hikida 2019). 
According to the classical model of action selection the basal ganglia tonically inhibit downstream 
motor centers (i.e. the motor cortex, superior colliculus and PPN) via GABAergic output 
projections, thus preventing the occurrence of unwanted or wrongly timed movements (Albin et 
al. 1989; Gerfen and Surmeier 2011; Klaus et al. 2019). Cortical and thalamic inputs give rise to the 
activation of the direct and indirect pathways which exert opposing effects on output nuclei. The 
activation of the direct pathway causes pauses in the tonic inhibition of the output projections 
enabling the desired movements, whereas the indirect pathway further suppresses the competing 
actions. Nigrostriatal dopamine release dichotomously modulates the direct and indirect 
projections facilitating the movement initiation. 
Traditionally, rapid phasic activity of the midbrain dopamine neurons is suggested to drive reward, 
learning and transitions between movement states (Jin and Costa 2010; Matsumoto and Hikosaka 
2009; Schultz 2007). Brief increase in the firing rate of the SNpc neurons and subsequent transient 
fluctuation in the striatal dopamine level occur immediately before or around self-paced 
movement initiation (Howe and Dombeck 2016; da Silva et al. 2018). It was recently shown that 
the transient increase in dopaminergic activity immediately preceding movement initiation 
correlates with the vigor of the initiated movement (da Silva et al. 2018). Brief optogenetic 
activation of the SNpc dopamine neurons before movement initiation, but not during an ongoing 
movement, increased the probability and vigor of future movements, while optogenetic inhibition 
resulted in less probable and less vigorous movements.  
The classical model is challenged by accumulating evidence suggesting that both direct and 
indirect projection pathways are coactivated during movement and inhibited during immobility 
(Klaus et al. 2019). The new model proposes that both direct and indirect pathways might work in 
concert to facilitate the desired motor actions and suppress the unwanted movements by 
concurrently activating different basal ganglia output neurons. The cortex represents alternative 
motor plans to specific striatal MSN ensembles. Action specificity arises from the pattern of 
cortical inputs, while dopaminergic inputs nonspecifically modulate the excitability of the MSNs. 
Only with adequate phasic dopamine activity specific MSN ensembles become active depending 
on the strength of their cortical inputs. Too low dopaminergic input results in subthreshold striatal 
output despite the presence of strong cortical signals. In this model, the relative timing and activity 
levels of specific MSN ensembles are thought to have a critical impact on the final basal ganglia 
output signal. However, new cell type -specific recordings with single-cell resolution have 
demonstrated that the spatiotemporal dynamics of MSN subtypes during natural behavior is 
action-specific and rather complex (Klaus et al. 2017; Markowitz et al. 2018; Parker et al. 2018). 
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The abovementioned models of the basal ganglia functions are based on the current 
understanding of the circuitry and provide an oversimplified picture of their true physiology. The 
descriptions provided here, for example, completely ignore the fact that the GPe, GPi, STN and 
SNr neurons can also serve as autonomous pacemakers generating action potentials without 
synaptic input, consequently adding another dimension to the modulation of the basal ganglia 
circuitry (Gerfen and Surmeier 2011). There are still a great many questions to be answered before 
we can fully understand the role of the basal ganglia in action selection and motor control. 
2.2.3 Striatal interneurons 
The distribution of the neuron populations is fairly uniform throughout the striatum: MSNs 
comprise 90-95% of the striatal neurons, and the remaining 5-10% are interneurons (Gerfen and 
Surmeier 2011; Chuhma et al. 2019). Despite the relatively small population, striatal interneurons 
have an important role in regulating the striatal output. Their behavioral relevance, however, 
remains poorly understood thus far. 
Striatal interneurons can be divided into large cholinergic interneurons and  three types of smaller 
GABAergic interneurons: (a) fast spiking (FS) PV-positive, (b) low-threshold spiking (LTS) 
somatostatin-, neuropeptide Y- and nitric oxide synthase-positive, and (c) calretinin-positive 
interneurons (Kawaguchi et al. 1995; Tepper et al. 2008; Kreitzer 2009). FS interneurons are most 
abundant in the rat striatum and their electrophysiological properties are dominated by short-
duration action potentials, abrupt high-frequency firing and hyperpolarized resting potential. FS 
interneurons receive excitatory synapses from the cortex and thalamus and inhibitory inputs from 
other interneurons and a subpopulation of GPe neurons. In addition, dopamine and acetylcholine 
can increase their activity via D5 and nicotinic acetylcholine receptors (nAChRs), respectively. Gap 
junctions between the dendrites contribute to electrotonic coupling that can lead to synchronous 
firing among local FS interneuron populations. 
LTS interneurons are physiologically distinguished from the FS cells by less negative resting 
potential, long-duration action potentials and higher input resistance (Kawaguchi et al. 1995; 
Kreitzer 2009). Like FS interneurons, LTS interneurons are also innervated by glutamatergic 
afferents from the cortex and thalamus and form synapses with MSNs. Dopamine can modulate 
the activation of LTS neurons via D5 receptors, and acetylcholine can exert either activating or 
inhibiting modulation via muscarinic M1 or M2 receptors, respectively. Due to the wide variety of 
transmitters, LTS interneurons can affect the activity of MSNs not only through the release of 
GABA but also nitric oxide, somatostatin and neuropeptide Y.  
Cholinergic interneurons constitute only approximately 1–2% of striatal cells, but their effects are 
much more significant (Kreitzer 2009). They show tonic spontaneous firing on average at 2-10 Hz, 
long-lasting afterhyperpolarizations, depolarized resting potential and relatively high input 
resistance. Cholinergic interneurons receive excitatory innervation primarily from the intralaminar 
thalamic nuclei and, to a lesser extent, from the cortex as well as inhibitory synapses from MSNs. 
Their widespread axonal arborization connects mainly with D1- and D2-MSNs, but also with FS 
interneurons, through perisomatic synapses forming the feedforward thalamostriatal circuit 




(Gerfen and Surmeier 2011). Nigrostriatal dopamine release modulates the activity of cholinergic 
interneurons through D2 and D5 receptors. D2, together with M2 and M4 receptor signaling, 
reduces their excitability (Calabresi et al. 1998; Chuhma et al. 2014; Maurice et al. 2004), whereas 
D5 receptor activation stimulates them (Aosaki et al. 1998). M2 also functions as a presynaptic 
autoreceptor regulating acetylcholine release (Hersch et al. 1994). Cholinergic interneurons can 
modulate direct-pathway MSNs through their M1 and M4 receptors and indirect-pathway MSNs 
through M1 receptors (Bernard et al. 1992; Yan and Surmeier 1996), as well as dopaminergic 
transmission through nAChRs on dopaminergic axon terminals (Wonnacott et al. 2000; Jones et 
al. 2001; Zhou et al. 2001; Cachope et al. 2012; Threlfell et al. 2012; Mamaligas et al. 2016). Thus, 
dopamine and acetylcholine together exert complex modulation of neuronal activity in the 
striatum that strongly influences basal ganglia output. On top of that, other neuromodulators such 
as adenosine, endocannabinoids, nitric oxide and various neuropeptides play important roles in 
shaping the final output signals. 
2.2.4 Striatal microcircuits regulating the direct and indirect pathways 
There are three distinct inhibitory microcircuits in the striatum that counterbalance the 
glutamatergic excitation of the MSNs (Gerfen and Surmeier 2011). They are thought to contribute 
to action selection by suppressing unwanted activities. Firstly, the feedforward inhibitory circuit 
originates from corticostriatal inputs that enhance the activity of FS interneurons (Mallet et al. 
2005). The interneurons then form perisomatic GABAergic synapses on both D1- and D2-MSNs 
and effectively reduce their spiking. Secondly, FS interneurons receive GABAergic innervation from 
the GPe neurons forming the inhibitory pallidostriatal feedback circuit (Gerfen and Surmeier 
2011). On this feedback circuit, dopamine exerts dual excitatory actions by directly depolarizing 
the interneurons through D5 receptors and reducing their synaptic inhibition through presynaptic 
D2 receptors on pallidostriatal nerve terminals (Bracci et al. 2002; Centonze et al. 2002, 2003; 
Wiltschko et al. 2010). Thirdly, the striatal feedback circuit involves local axon collaterals of D1- 
and D2-MSNs that make synaptic connections with the dendrites of other MSNs providing lateral 
inhibition (Gerfen and Surmeier 2011). The release of GABA on these collateral synapses is 
regulated by dopamine; D2 receptor activation decreases and D1 activation increases the release 
of GABA.	Taken together, we can appreciate the complex role of striatal interneurons in regulating 
the activity of direct- and indirect-pathway MSNs. Their exact effects on the basal ganglia circuitry 
are yet to be resolved. 
2.2.5 Dopamine cell groups and projection pathways 
Arvid Carlsson, Eric Kandel and Paul Greengard were awarded the Nobel Prize in medicine and 
physiology in 2000 for their seminal work in the field of catecholaminergic neurotransmission in 
the late 1950s that lead to recognition of dopamine as an independent neurotransmitter in the 
brain (Carlsson 2001, 1959; Carlsson et al. 1958; Sano et al. 1959). Soon after that, in 1964, 
Dahlström and Fuxe mapped for the first time the locations of monoamine-containing cell bodies 
and nerve terminals in the rat brain (Dahlström and Fuxe 1964). Later, the development of 
sensitive immunohistochemical and tract-tracing techniques has provided a more detailed picture 
of the dopamine system making it one of the most completely mapped neurotransmitter systems 
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in the brain. The current understanding of the nine different dopamine-containing neuronal 
groups (groups A8–A16) in the mammalian brain is reviewed in (Björklund and Dunnett 2007) and 
depicted in Figure 2.7. 
 
Figure 2.7. Dopamine neuronal groups and dopaminergic pathways in the rat brain. Dopamine 
neuron cell bodies are localized in nine distinctive groups (A8-A16), distributed from the midbrain to 
olfactory bulb (OB). The nigrostriatal pathway connecting dopamine neurons located in the substantia 
nigra pars compacta (A9) to the dorsal striatum is highlighted with wide red arrows and a circle. The 
mesolimbic and mesocortical pathways from the ventral midbrain dopamine neuron groups are 
illustrated by wide green arrows. The tuberoinfundibular pathway from the A12 and A14 groups and 
the diencephalospinal pathway from the A11 group are shown by thin green arrows. The cell groups 
are defined based on tyrosine hydroxylase immunoreactivity. HPC – Hippocampus. Adapted with 
permission from Elsevier: TRENDS in Neurosciences, Björklund and Dunnett (2007), © Elsevier 2007. 
Ventral midbrain dopamine neurons are arranged in three different groups: the retrorubral field 
(A8 group), the SNpc (A9 group) and the VTA (A10 group) (Björklund and Dunnett 2007). These 
neuron populations project to defined areas of the forebrain and modulate specific functions 
according to their target areas. The dopaminergic projections are traditionally divided into three 
major pathways: Dopamine neurons located in the SNpc mainly innervate the dorsal striatum, 
forming the nigrostriatal pathway (Fallon and Moore 1978; Björklund and Dunnett 2007; Howe 
and Dombeck 2016). The nigrostriatal pathway is predominantly responsible for the regulation of 
motor functions and is implicated in the pathophysiology of PD (see chapter 2.3.2). Dopamine 
neurons located in the VTA primarily project to the ventral striatum (NAcc and olfactory tubercle) 
and cortical areas (prefrontal cortex and cingulate cortex) forming the mesolimbic and 
mesocortical pathways, respectively. These pathways regulate emotional behavior, motivation, 
reward, learning and cognitive functions, and are afflicted in an array of psychiatric disorders 
(Hornykiewicz 1978; Parker et al. 2016; Macpherson and Hikida 2019). The retrorubral field is a 
dorso-caudal extension of the SNpc and projects to both striatal, limbic and cortical areas 
(Björklund and Dunnett 2007).  
The reality of the anatomical organization and projection patterns of the dopamine neurons in the 
midbrain cell groups is more complex than the original division described above (Loughlin and 
Fallon 1984; Swanson 1982). The cell groups can be further divided into different 
subcompartments (such as the dorsal and ventral tier of the SNpc and VTA) that differ in their 











tier of the SNpc also contains neurons that send afferents to limbic and cortical areas (François et 
al. 1999). Using sophisticated tissue clarification, optogenetic and fiber photometry tools Lerner 
and colleagues identified two parallel dopamine neuron subpopulations within the SNpc with 
divergent biophysical properties and distinct output projections to the DMS and DLS (Lerner et al. 
2015). The intermixing of the cell bodies of the nigrostriatal, mesolimbic and mesocortical 
pathways is more prominent in NHPs than in rodents (Williams and Goldman-Rakic 1998; François 
et al. 1999). Midbrain dopamine neurons also send sparse collateral innervation to several other 
basal ganglia structures including the GPe, GPi and STN enabling dopaminergic modulation of the 
basal ganglia circuitry at pallidal and subthalamic levels (Lindvall and Björklund 1979; Lavoie et al. 
1989; Smith et al. 1989; Hassani et al. 1997; Gauthier et al. 1999; Prensa and Parent 2001). 
The total number of TH-ir cells in the ventral midbrain (in A8, A9 and A10 groups together, 
bilaterally) is approximately 20 000–30 000 in mice and 40 000–45 000 in rats (Björklund and 
Dunnett 2007). About half of those cells are located in the SNpc. In humans, the same numbers 
are approximately 400 000–600 000, with >70% of the neurons located in the SNpc. The larger 
number of the midbrain dopamine neurons in humans is accompanied, for example, with much 
more extensive mesocortical innervation as compared to rodents. 
Dopamine neurons in the diencephalon are divided into four groups: A14 (the rostral 
hypothalamic periventricular group), A13 (the dorsal hypothalamic group of the medial zona 
incerta), A12 (the infundibular group of the arcuate nucleus), and A11 (the posterior and dorsal 
hypothalamic group and the periventricular grey matter of the caudal thalamus) (Björklund and 
Nobin 1973). The best known projection pathway arising from these cell groups is the 
tuberoinfundibular pathway which originates from the A12 and A14 dopamine neurons and 
innervates the median eminence and the neural lobe of the pituitary gland (Goldsmith et al. 1990; 
Grattan 2015). Dopamine released from the tuberoinfundibular projections suppresses the 
secretion of prolactin from anterior pituitary gland by binding to D2 receptors.  
The A11 group gives rise to diencephalospinal dopamine system. The A11 neurons project to all 
levels of the spinal cord providing the only source of inhibitory dopaminergic innervation for the 
spinal cord (Barraud et al. 2010; Puopolo 2019; Qu et al. 2006; Skagerberg and Lindvall 1985). 
Descending fibers innervate both the dorsal and ventral horn of the spinal cord and have an 
important role in sensorimotor integration and pain control. Dysfunction of the A11 dopamine 
system is suggested to have implications in the pathophysiology of pain (Fleetwood-Walker et al. 
1988; Puopolo 2019), migraine (Charbit et al. 2009; Charbit et al. 2010) and restless legs syndrome 
(Clemens et al. 2006; Lanza et al. 2017).  
The functions of the A13 group dopamine neurons and their so called incertohypothalamic 
projections are less well established (Fougère et al. 2019). They have been suggested to provide 
local hypothalamic innervation and send projections to locomotor centers of the brainstem. They 
may be associated with visceral and sensorimotor activities. The A15 group in the rostral 
hypothalamus contain TH-ir neurons but not detectable levels of dopamine or noradrenaline 
(Björklund and Dunnett 2007). The A15 neurons give rise to local diencephalic innervation but 
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their functional role has remained rather obscure. There is some evidence of their role in hormonal 
regulation (Clarkson and Herbison 2011; Liu and Herbison 2013; Brown et al. 2015).  
Finally, the A16 group located in the olfactory bulb hosts the most numerous population of 
dopamine neurons in the brain (Pignatelli and Belluzzi 2017). Dopamine neurons form the most 
external (glomerular) layer of the olfactory bulb and function as interneurons co-releasing 
dopamine and GABA from separate vesicle pools. They modulate the activity of the olfactory nerve 
terminals and play a key role in odor processing. Interestingly, the A16 cells are regenerated 
throughout the lifetime; the RMS originating from the SVZ provides a constant source of new 
dopamine neurons to be integrated to the neuronal network of the olfactory bulb. 
2.2.6 Dopamine receptors and modulatory effects 
2.2.6.1 Five dopamine receptors 
Reflecting the dense dopaminergic innervation from the ventral midbrain, the striatum has a 
prominent expression of dopamine receptors. The dopamine receptors are metabotropic G 
protein-coupled receptors and can be divided into two classes on the basis of the G-protein to 
which they couple: D1-like receptors (D1 and D5) are stimulatory and couple to Gs and Golf 
proteins, whereas D2-like receptors (D2, D3 and D4) are inhibitory and couple to Gi and Go proteins 
(Neve et al. 2004). Gs and Golf proteins stimulate adenylate cyclase enzyme which elevates 
intracellular levels of cyclic adenosine monophosphate (cAMP). cAMP further activates protein 
kinase A (PKA) which has a broad range of cellular targets, including receptors, enzymes, ion 
channels and transcription factors.	D1 receptor may also activate phospholipase C (PLC) in a cAMP-
independent manner by interacting with Gq. PLC catalyzes the hydrolysis of a membrane lipid 
phosphatidylinositol 4,5-bisphosphate (PIP2) to two secondary messengers, diacyl glycerol (DAG) 
and inositol 1,4,5-trisphosphate (IP3).  
Gi and Go target many effectors such as ion channels, phospholipases and receptor tyrosine 
kinases through a membrane-delimited mechanism involving the liberation of Gβγ subunits (Neve 
et al. 2004).  For example, D2 receptor stimulation in striatal MSNs activates PLC via Gβγ subunits 
leading to mobilization of intracellular Ca2+ storages. As a result, transmembrane Ca2+ currents 
through L-type Ca2+ -channels are suppressed and neuronal excitability reduced (Hernández-López 
et al. 2000). Gi/o is also negatively coupled to adenylate cyclase leading to decreased levels of cAMP 
and activate protein phosphatases that directly counter the effects of PKA (Neve et al. 2004). Thus, 
the activation of D1-like and D2-like receptors leads to opposing cellular responses. 
All five dopamine receptors (D1-D5) are expressed in the striatum, but D1 and D2 are by far the 
most abundant (Gerfen and Surmeier 2011). Their expression in direct- and indirect-pathway 
MSNs is dichotomous: direct-pathway MSNs express excitatory D1 receptors and indirect-pathway 
MSNs inhibitory D2 receptors. D1 and D2 receptors have different binding affinities (Macpherson 
and Hikida 2019). The high-affinity D2 receptors are occupied at lower dopamine concentrations 
(~10 nM) and respond more readily to tonic basal dopamine levels (~10-30 nM) inhibiting D2-
MSNs. The low-affinity D1 receptors, instead, are primarily activated by increased phasic 




dopamine release (at ~1 µM) transiently enhancing the responsiveness of D1-MSNs (Surmeier et 
al. 2007). Hence, phasic dopamine release has an opposite effect on the activity of MSNs. D2 
receptor signaling decreases the responsiveness of indirect-pathway MSNs to uncoordinated 
cortical activity, whereas transient D1 receptor signaling increases the excitability of the direct-
pathway MSNs contributing to properly coordinated action initiation. 
D2 receptors expressed at presynaptic axon terminals function as autoreceptors regulating 
synaptic neurotransmission. D2 autoreceptor activation inhibits the opening of voltage-gated Ca2+ 
channels resulting in decreased axonal dopamine release (Cardozo and Bean 1995). Additionally, 
D2 autoreceptor activation decreases dopamine release by other mechanisms that include 
inhibiting dopamine synthesis, enhancing dopamine reuptake via DAT and regulating vesicular 
monoamine transporter (VMAT) expression (Schmitz et al. 2003). 
2.2.6.2 Dopaminergic modulation of synaptic plasticity 
In addition to modulating the short-term activity of the corticostriatal circuits, dopamine has an 
important part to play in regulating the long-term weakening and strengthening of synaptic 
transmission, i.e. LTD and LTP, respectively (Gerfen and Surmeier 2011). These synaptic plasticity 
events are believed to be the underlying mechanisms leading to learning and habit formation. 
Transient elevation in striatal dopamine release decreases the excitability of D2-MSNs and 
promotes the induction of LTD at corticostriatal synapses. LTD is also regulated by cholinergic 
interneurons and postsynaptic release of endocannabinoids which activate presynaptic CB1 
cannabinoid receptors causing a decrease in glutamate release (Gerdeman et al. 2002; Tozzi et al. 
2011).  
In contrast, at the glutamatergic synapses of D1-MSNs, activation of D1 receptors increases the 
excitability and promotes the induction of LTP (Gerfen and Surmeier 2011). LTP seems to depend 
on the coactivation of D1 and NMDA receptors, as well as BDNF-TrkB signaling (Kerr and Wickens 
2001; Calabresi et al. 2007; Jia et al. 2010). D1 receptor activation reinforces the function of AMPA 
and NMDA receptors and enhances their surface trafficking which is likely to contribute to the 
induction of LTP (Snyder et al. 2000; Sun et al. 2005; Hallett et al. 2006). Hence, the plastic changes 
caused by transient elevation in striatal dopamine release promotes the ability of cortical input to 
activate direct-pathway MSNs (LTP) and reduces its ability to turn on indirect-pathway MSNs 
(LTD). Ultimately, both changes facilitate movement initiation. 
2.2.7 Dopamine lifecycle 
2.2.7.1 Dopamine biosynthesis and its regulation 
Although dopamine is an important neurotransmitter in the brain, almost half of dopamine in the 
body is synthesized in the gastrointestinal tract (Eisenhofer et al. 1997). Here, the focus is on 
dopamine lifecycle in the CNS which is summarized in Figure 2.8. The biosynthesis of dopamine 
takes place in the cytosol of catecholaminergic neurons in a two-step reaction (Meiser et al. 2013). 
In the first step, TH catalyzes the hydroxylation of L-tyrosine at the phenol ring to L-3,4-
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dihydroxyphenylalanine (L-DOPA). For this, TH requires a cofactor tetrahydrobiopterin (BH4), O2 
and Fe2+. In the second step, L-DOPA is decarboxylated to dopamine by aromatic amino acid 
decarboxylase (AADC, also known as DOPA decarboxylase) in a reaction that uses pyridoxal 
phosphate (vitamin B6) as a cofactor. The biosynthesis of dopamine and other catecholamines 
(noradrenaline and adrenaline) is under strong regulatory control. The activity of AADC, for 
example, is under feedback regulation by the reaction product. 
 
Figure 2.8. Nigrostriatal dopaminergic axon terminal and dopamine lifecycle. Dopamine (DA) 
synthesis takes place in the cytosol. Tyrosine hydroxylase (TH) hydroxylates L-tyrosine to L-3,4-
dihydroxyphenylalanine (L-DOPA) using tetrahydrobiopterin (BH4) as a cofactor. L-DOPA is 
decarboxylated to DA by aromatic amino acid decarboxylase (AADC). DA is sequestered into synaptic 
vesicles via vesicular monoamine transporter 2 (VMAT2). Upon depolarization of the axon terminal, 
synaptic vesicles are fused into the presynaptic membrane in a Ca2+-dependent manner resulting in 
quantal release of DA into the extracellular space. Dopaminergic axons form synaptic contacts on the 
dendritic spines necks of medium spiny neurons (MSN). Released DA diffuses into perisynaptic sites 
and activates postsynaptic D1- and D2-like receptors located along the dendritic membrane of MSNs. 
Presynaptic D2 receptors function as autoreceptors providing feedback inhibition of DA synthesis and 
release. Dopamine transporter (DAT) is responsible for the neuronal high-affinity reuptake of DA and 
termination of the signaling, after which DA is recycled back into the synaptic vesicles via VMAT2. DAT 
is distributed outside of the synaptic membrane. Polyspecific organic cation transporter 3 (OCT3) 
mediates non-neuronal uptake of DA into surrounding glial cells. In the glia, DA undergoes degradation, 
where DA is first metabolized to 3,4-dihydroxyphenylacetaldehyde (DOPAL) via monoamine oxidase 
(MAO). DOPAL is rabidly further converted to 3,4-dihydroxyphenylacetic acid (DOPAC) via aldehyde 
dehydrogenase (ALDH). Catechol-O-methyl transferase (COMT) methylates DOPAC to the main 
metabolite homovanilic acid (HVA). Alternatively, DA is first metabolized to 3-methoxytyramine (3-MT) 



















































TH is the rate-limiting enzyme in the biosynthesis of catecholamines (Kumer and Vrana 1996). The 
regulation of TH expression and activity is strong and versatile. TH mRNA levels are under 
transcriptional and RNA stability regulation. TH protein undergoes translational control and 
allosteric modulations (Daubner et al. 2011). Dopamine competes with the cofactor BH4 to bind 
to the catalytic site of TH (Kumer and Vrana 1996). Thus, high dopamine levels exert feedback 
inhibition on the enzyme activity. In addition, various kinases can phosphorylate four different 
serine residues in the N-terminal regulatory domain of TH which results in substantially increased 
enzyme activity (Dunkley et al. 2004). Reversely, phosphatases can dephosphorylate TH, and 
therefore function as TH deactivators. Interaction with other proteins, such as DJ-1, alpha-
synuclein (α-syn), VMAT2, AADC and BH4 synthesizing guanosine triphosphate cyclohydrolase 
(GTPCH), controls the stability and activity of TH (Daubner et al. 2011). TH can also undergo 
ubiquitylation and subsequent proteasomal degradation (Døskeland and Flatmark 2002). 
TH-immunolabelling is commonly used to identify dopamine neurons in the ventral midbrain. 
However, due to the strong regulation of TH expression in response to aging, neuronal insults or 
altered functional demands, TH-immunoreactivity is not always a reliable marker for identifying 
viable dopamine neurons (Björklund and Dunnett 2007). Thus, in the absence of TH-
immunoreactivity, additional markers such as neuromelanin, DAT, AADC or VMAT2 may be 
needed to identify cells as functional dopamine neurons. 
Interestingly, Nurr1, a transcription factor belonging to the orphan nuclear receptor superfamily, 
is predominantly expressed in dopamine neurons and essential in the development and 
maintenance of the midbrain dopaminergic system (Jankovic et al. 2005). Nurr1 regulates the 
expression of TH, DAT, VMAT2, AADC, GDNF and RET, in other words, all the proteins that are 
crucial for the normal function of dopamine neurons. Studies in Nurr1 knockout mice have shown 
that Nurr1 deficiency results in impaired function and increased vulnerability of midbrain 
dopamine neurons. Nurr1 expression is also decreased in the midbrain samples of PD patients. 
Thus, it may have a role in the pathogenesis of PD. 
Besides the classical TH-dependent pathway, the biosynthesis of dopamine can also follow a 
cytochrome P450-mediated pathway where decarboxylation of tyrosine to tyramine by AADC 
precedes the hydroxylation step, in which CYP2D6 converts tyramine to dopamine (Hiroi et al. 
1998; Bromek et al. 2011). However, the contribution of this pathway to the total dopamine 
synthesis seems to be minimal. 
After synthesis, dopamine is readily sequestered into synaptic vesicles by VMAT2 (Chaudhry et al. 
2008). Vesicular dopamine transport depends on the electrochemical H+ gradient generated by 
the vacuolar H+-ATPase. Inside the vesicles, oxidation-prone dopamine is stabilized by acidic pH 
which prevents the generation of toxic derivatives in the cytosol (Vergo et al. 2007). In 
noradrenergic neurons, dopamine is further hydroxylated to noradrenaline by dopamine-b-
hydroxylase inside the vesicles (Daubner et al. 2011). Amphetamine and similar psychostimulants 
deplete dopamine from the synaptic vesicles by collapsing the electrochemical H+ gradient that 
drives the VMAT2-mediated dopamine transport (Sulzer and Rayport 1990; Chaudhry et al. 2008). 
Amphetamines can also inhibit VMAT2 directly. 
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2.2.7.2 Dopamine release and reuptake 
Nigrostriatal dopamine neurons are autonomous pacemakers. They typically exhibit two main 
activity patterns: Under basal conditions, most dopamine neurons show tonic activity with 
regularly spaced spikes at 2-5 Hz which results in tonic dopamine release in the striatum (Grace 
and Bunney 1984; Hyland et al. 2002). Rewarding events or other stimuli can trigger brief higher-
frequency bursts of approximately two to six action potentials at 15-30 Hz which evoke transient 
dopamine overflow from the synaptic vesicles. Aversive events, on the other hand, transiently 
decrease nigrostriatal dopaminergic activity. These transient changes in striatal dopamine release 
regulate motivation and movement initiation (Klaus et al. 2019). 
In response to action potentials arriving to an axon terminal, depolarization opens voltage-gated 
Ca2+ channels allowing rapid influx of Ca2+. Inside the axon terminal, Ca2+ induces conformational 
changes in synaptic soluble N-ethylmaleimide–sensitive factor attachment protein receptor 
(SNARE)–complex proteins which eventually lead to exocytotic release of synaptic vesicles filled 
with dopamine (Sulzer et al. 2016). Using electrochemical cytometry, it has been estimated that 
the average number of dopamine molecules per vesicle is 33 000 in striatal axon terminals of 
healthy mice, i.e. the quantal size of dopamine release is 33 000 molecules (Omiatek et al. 2013). 
Under basal conditions, the extracellular dopamine concentration resulting from tonic neuronal 
activity is in the range of 10-30 nM (Gonon and Buda 1985; Venton et al. 2003). It is high enough 
to tonically activate the high-affinity pre- and postsynaptic D2 receptors. 
Some of the midbrain dopamine neurons, that express the vesicular glutamate transporter 2 
(VGLUT2), can co-release glutamate in addition to dopamine (Chuhma et al. 2014; Hnasko et al. 
2010; Stuber et al. 2010; Tecuapetla et al. 2010). Dopamine neuron -evoked AMPA and NMDA 
receptor activation have been reported in MSNs and cholinergic interneurons of the NAcc. 
Recently, SNpc dopamine neuron inputs were shown to drive pauses in the firing of DMS and 
bursts in the firing DLS cholinergic interneurons (Cai and Ford 2018). The pauses were mediated 
by D2 receptors while the bursts were driven by glutamate co-release and activation of excitatory 
metabotropic glutamate receptors (mGluRs). Also, rapidly after dopaminergic activation, firing in 
both direct- and indirect MSNs is inhibited by co-release of GABA from a subset of dopaminergic 
axon terminals (Tritsch et al. 2012; 2014; Chuhma et al. 2014). The co-release of GABA seems to 
require its cellular uptake by membrane GABA transporters (mGAT1 and mGAT4) and loading into 
dopaminergic vesicles by VMAT2. 
α-Syn is a 140-amino acid long presynaptic protein that interacts with negatively charged 
phospholipid membranes through its N-terminus, is ubiquitously expressed throughout the 
nervous system and is prone for aggregation in PD (Burré et al. 2013). Although the precise 
function of α-syn is not known, it seems to be an essential negative regulator of synaptic 
neurotransmission and activity-dependent dopamine release (Abeliovich et al. 2000; Larsen et al. 
2006; Nemani et al. 2010). A growing body of evidence suggests a role for α-syn in the 
maintenance of synaptic vesicle pools and/or as an auxiliary chaperone required for normal 
SNARE-complex assembly (Burré et al. 2010; Cabin et al. 2002; Chandra et al. 2005; Murphy et al. 
2000; Snead and Eliezer 2014). Transgenic mice overexpressing human wild-type α-syn show 




selective alteration in the distribution of dopaminergic synaptic vesicles and deficits in dopamine 
release from the nigrostriatal axon terminals (Janezic et al. 2013). This early-onset phenotype is 
followed by age-dependent loss of dopamine neurons, reduced neuronal firing rate and motor 
impairments. 
Other neurotransmitters can also regulate axonal dopamine release. In the dorsal striatum, 
glutamate spillover from its synapses can reduce dopamine release by acting on presynaptic 
mGluR1 on dopaminergic axon terminals (Zhang and Sulzer 2003). GABA has been shown to 
decrease dopamine release via presynaptic GABAB receptors (Charara et al. 1999; Smolders et al. 
1995). In the NAcc, kappa and delta opioid receptors seem to be able to decrease dopamine 
release via a presynaptic mechanism (Schlösser et al. 1995; Svingos et al. 1999; 2001). 
Dopamine released into the extracellular space can interact with postsynaptic dopamine receptors 
and presynaptic autoreceptors (Figure 2.8). The postsynaptic receptors are mostly located at 
distant extrasynaptic sites, often with a higher density in the perisynaptic zone of the dendritic 
spines of striatal MSNs (Hersch et al. 1995; Yung et al. 1995; Caillé et al. 1996). Therefore, 
dopamine has to spillover from the release sites and diffuse rather long distances to reach its 
receptors (Pickel et al. 1996). This kind of “volume transmission” is characteristic for monoamine 
transmitters and can modulate not only neuronal activity in larger brain areas, but also neuron-
glia interactions (Fuxe et al. 2015; Taber and Hurley 2014). Diffusion-based dilution is also the main 
factor eventually terminating the dopamine signaling in most brain areas (Cragg and Rice 2004; 
Rice and Cragg 2008). 
Another important factor contributing to the termination of the dopamine signaling and 
maintaining dopamine homeostasis is its effective reuptake from the extracellular space primarily 
via DAT (Meiser et al. 2013). DAT is rarely expressed on the active zone of a synapse. Instead, the 
dopamine reuptake sites are distributed along the membrane of dopaminergic fibers where they 
effectively restrict the extracellular diffusion of larger dopamine transients (Nirenberg et al. 1996; 
Pickel et al. 1996; Hersch et al. 1997). After release, dopamine can either be recycled back into 
dopaminergic axon terminals by DAT, or it can be degraded after non-neuronal uptake into 
surrounding glial cells by organic cation transporter 3 (OCT3) (so called uptake 2). OCT3 is a low-
affinity and high-capacity transporter for monoamines widely expressed in neurons, astrocytes, 
microglia and oligodendrocytes (Eisenhofer 2001; Gasser 2019). It contributes to the clearance of 
monoamines after synaptic release and restricts their spread. In the striatum, DAT-mediated 
neuronal uptake is primarily responsible for the clearance of extracellular dopamine. Substrate-
induced and PKC-dependent trafficking of DAT away from the cell surface is the predominant 
mechanism to regulate DAT function (Gulley and Zahniser 2003). For example, amphetamine 
typically induces DAT internalization. In addition, presynaptic D2 receptors mediate the 
upregulation of DAT activity. Neuronal uptake of dopamine is followed by its sequestration back 
into the synaptic vesicles via VMAT2. 
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2.2.7.3 Dopamine degradation 
Following the uptake 2 by glial cells, dopamine is readily degraded by MAO and catechol-O-methyl 
transferase (COMT) (Meiser et al. 2013). There are two separate genes coding two isoforms of 
MAO, MAO-A and MAO-B, which are both found in the CNS. MAO is localized in the outer 
membrane of mitochondria and expressed in neurons, astrocytes and microglia. MAO catalyzes 
oxidative deamination of dopamine to a reactive intermediate product 3,4-
dihydroxyphenylacetaldehyde (DOPAL) generating hydrogen peroxide as a side product 
(Eisenhofer et al. 2004). DOPAL is further metabolized predominately by aldehyde dehydrogenase 
to form 3,4-dihydroxyphenylacetic acid (DOPAC), or by aldehyde reductase to form 3,4-
dihydroxyphenylethanol (DOPET), both of which are more stable metabolites. In neurons, 
dopamine that is leaking from the synaptic vesicles into the cytosol, is degraded by MAO and 
aldehyde dehydrogenase (Meiser et al. 2013). Notably, there are species specific differences in 
the affinities of MAO-A and MAO-B: in human, dopamine is mostly oxidized by MAO-B, but in rats 
by MAO-A. 
COMT has two splicing isoforms encoded by one gene, soluble S-COMT and membrane-bound 
MB-COMT. Their role is to transfer a methyl group from S-adenosylmethionine to one of the two 
catechol hydroxyl groups (Guldberg and Marsden 1975; Männistö and Kaakkola 1999). This 3-O-
methylation of DOPAC is Mg2+ -dependent and leads to the formation of homovanilic acid (HVA) 
which is the main degradation product of dopamine and ultimately secreted into urine. In an 
alternative degradation pathway, dopamine is first methylated to 3-methoxytyramine (3-MT) by 
COMT, which is then oxidized to HVA by MAO and aldehyde dehydrogenase (Meiser et al. 2013). 
There is no significant COMT activity in presynaptic axon terminals but some activity in 
postsynaptic dendrites. The main COMT-activity seems to reside in astrocytes and microglial cells 
(Myöhänen et al. 2010). 
Dopamine and its metabolites can also undergo phase II conjugation reactions before excretion, 
although the conjugation reactions seem to play only a minor role in dopamine metabolism in the 
CNS (Uutela et al. 2009). O-Sulfatation of dopamine or its metabolites is catalyzed by phenol 
sulfotransferases (Buu et al. 1981; Swahn and Wiesel 1976), and O-glucuronidation by uridine 
diphosphoglucuronosyl-transferases (Wang et al. 1983; Uutela et al. 2009). 
The metabolism of dopamine inflicts constant oxidative stress on dopaminergic neurons that 
might be one predisposing factor for the specific neuronal vulnerability in PD (Meiser et al. 2013). 
High dopamine content exposes to vesicular leakage of dopamine into the cytosol. The 
degradation of cytosolic dopamine generates reactive oxygen species (ROS). As described above, 
oxidative deamination by MAO generates hydrogen peroxide that is a major source of oxidative 
stress in dopaminergic neurons. Besides this, the electron-rich catechol moiety of dopamine is also 
prone to oxidation if exposed to the neutral pH of the cytosol. Dopamine and L-DOPA can also be 
enzymatically oxidized to form highly reactive ortho-quinones dopamine-o-quinone and 
dopaquinone, respectively (Sulzer and Zecca 1999). Both, quinones and ROS, are apt to react 
unspecifically with cellular components and perturb their functionality.	 Oxidative stress and 




changes in cellular functions can trigger neuroinflammation which is a characteristic feature in PD 
and can contribute to the degeneration of dopamine neurons. 
2.3 Parkinson’s disease 
The first coherent descriptions of a clinical syndrome resembling PD can be found from ancient 
Indian medical literature dating back to 300 BC (later known as Kampavata) (Ovallath and Deepa 
2013). In Western medicine, a British physician James Parkinson provided the first sound picture 
of PD with all the characteristic motor symptoms in his famous monograph An Essay on the 
Shaking Palsy published in 1817 (Parkinson 2002). Almost 150 years later, striatal dopamine 
depletion was associated with PD (Ehringer and Hornykiewicz 1960), and the effectiveness of L-
DOPA in alleviating PD symptoms was demonstrated and brought into clinical practice (Birkmayer 
and Hornykiewicz 1961; Cotzias et al. 1969). 
Although the emerge of motor symptoms is typically diagnostic, PD is not solely a movement 
disorder but associated with numerous debilitating non-motor symptoms (Kalia and Lang 2015). 
Until today, the most urgent unmet medical need in PD is a disease-modifying therapy that could 
halt or slow the progression of the disease and restore the neuronal circuits that have already 
been degenerated by the time of the diagnosis. Accumulating preclinical evidence for the 
neurorestorative properties of several NTFs seems convincing (Paul and Sullivan 2018). However, 
to date, none of them has translated into clinical use, although several clinical trials have been 
conducted and some are currently underway. This calls for new approaches to harness the 
regenerative potential of neuroplasticity in the brain. 
Apart from the lack of a cure and incomplete understanding of the pathogenesis, a particular 
clinical challenge of PD management is that there are no biomarkers which would allow definitive 
diagnosis at early stages of the disease. Better diagnostic tools would also facilitate better 
distinction between different subtypes of PD enabling more effective personalized therapies. 
2.3.1 Epidemiology and risk factors 
PD is the second most common neurodegenerative disease after AD, and the most common 
movement disorder (Hebert et al. 2013; Marras et al. 2018). It is estimated to affect more than 6 
million people worldwide causing over 200 000 deaths per year (Dorsey et al. 2018). The incidence 
of PD sharply increases with age which is the biggest risk factor for the disease (Driver et al. 2009; 
Pringsheim et al. 2014). On average 1% of people aged over 60 years lives with the disease, and 
the prevalence increases to about 2-4% in individuals over the age of 80 (de Lau and Breteler 2006; 
Pringsheim et al. 2014). With the overall aging of the population, PD is expected to impose an 
increasing socio-economic burden on societies. Men are approximately 1.5 times more likely to 
be afflicted than women (de Lau and Breteler 2006). The risk of developing sporadic PD is 
multifactorial involving a complex interplay between normal process of aging, genetic 
susceptibility, epigenetic mechanisms and environmental risk factors (Pang et al. 2019). The 
fundamental cause of the disease remains unknown in the large majority of the cases. 
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2.3.1.1 Environmental risk factors 
Several comprehensive meta-analyses have identified pesticide, herbicide and solvent exposure, 
traumatic head injury, consumption of dairy products, rural living, beta-blocker use, agricultural 
occupation and well-water drinking as environmental risk factors that significantly increase the 
risk of PD (Noyce et al. 2012; Pezzoli and Cereda 2013; Ascherio and Schwarzschild 2016; Yang et 
al. 2017b; Pang et al. 2019). Environmental factors found to have a significant negative association 
with PD are tobacco use (cigarette smoking or smokeless tobacco) and caffeine consumption. 
Importantly, physical activity has been reported to reduce the risk of PD, and this potential 
protective effect has been related to the ability of exercise to stimulate antioxidant defense, 
angiogenesis and NTF expression (Cohen et al. 2003; Zigmond and Smeyne 2014; Bellou et al. 
2016).  
2.3.1.2 Genetic susceptibility 
Only 5-10% of PD patients suffer from a familial form of the disease (Kalinderi et al. 2016). To date, 
more than 20 causal genes and 90 independent genetic risk variants for PD have been identified 
(Blauwendraat et al. 2020). The gene encoding α-syn, SNCA, was the first one found to cause 
monogenic PD (Polymeropoulos et al. 1997). SNCA missense mutations and multiplications of the 
gene locus cause autosomal dominant form of the disease by increasing the tendency of α-syn to 
misfold and form aggregates (Deng et al. 2018). The most frequent cause for late-onset and 
autosomal dominant PD are missense gain-of-function mutations in LRRK2-gene (Paisán-Ruıź et 
al. 2004; Zimprich et al. 2004; West et al. 2005; Deng et al. 2018; Pang et al. 2019). LRRK2 
mutations and elevated kinase activity can also be found in some sporadic cases (Di Maio et al. 
2018; Simón-Sánchez et al. 2009). LRRK2 encodes a large multidomain protein called leucine-rich 
repeat kinase 2 which is involved in multiple cellular processes, e.g. neurite outgrowth, 
synaptogenesis, vesicular trafficking, autophagy and protein synthesis (Dzamko and Halliday 2012; 
Martin et al. 2014).  
Loss-of-function mutations in PRKN, PINK1 and DJ-1 are the most common examples of genes 
accounting for autosomal recessive forms of PD (Pang et al. 2019). Recessively inherited mutations 
in these genes are often associated with early-onset PD (Schrag and Schott 2006). Parkin (encoded 
by PRKN), PINK1 and DJ-1 are implicated in mitochondrial function, dynamics and quality control 
(McCoy and Cookson 2012). Mutations in GBA, which encodes a lysosomal enzyme b-
glucocerebrosidase, form another major risk factor for early-onset PD and cause a more severe 
phenotype of PD with increased risk for dementia and reduced survival (Cilia et al. 2016; Lwin et 
al. 2004; Sidransky and Lopez 2012). Apart from the abovementioned typical examples, advances 
in human genetics and bioinformatics have identified various other PD-causing genes and risk loci 
as reviewed in (Deng et al. 2018) and (Blauwendraat et al. 2020). 




2.3.2 Pathology of Parkinson’s disease 
2.3.2.1 Neurodegeneration 
PD is a complex neurodegenerative disorder. The main pathological feature is progressive loss of 
dopamine neurons within the SNpc (Kalia and Lang 2015). The neuronal loss and the 
accompanying denervation of the nigrostriatal pathway leads to decreased dopamine release in 
the dorsal striatum (Figure 2.9.A and C). Striatal dopamine depletion disrupts the equilibrium 
between striatonigral and striatopallidal pathway MSNs resulting in increased activation of the 
GABAergic output nuclei of the basal ganglia (Mallet et al. 2006; McGregor and Nelson 2019). The 
outcome of these pathological changes is reduced activation of the motor cortex, and ultimately, 
the appearance of the cardinal parkinsonian motor symptoms (see below chapter 2.3.3). 
When PD is diagnosed, a substantial proportion of dopamine neurons in the SNpc has already 
died. It has been estimated that at the onset of the motor symptom there is approximately 30% 
loss of dopaminergic cell bodies in the SNpc and 50-70% loss of striatal dopaminergic terminals in 
comparison to age-matched controls (Burke and O’Malley 2013). Thus, the molecular and cellular 
neuropathology is likely to start years or decades before the diagnosis. Over the course of the 
disease, the neurodegeneration continues progressing and results in 60-80% loss of nigral 
dopamine neurons and almost complete loss of striatal fibers at the time of death (Burke and 
O’Malley 2013; Kordower et al. 2013). The greater loss of striatal fibers as compared to the loss of 
neuronal bodies in the SNpc suggests that in PD the neurodegeneration occurs in a “dying-back” 
fashion with the distal axons deteriorating first and the cell bodies dying only months or years 
later. In addition, the substantial neurodegeneration observed at the time of the diagnosis 
suggests a prolonged preclinical stage. These two characteristics offer a clear therapeutic window 
for disease-modifying interventions. 
Axonal degeneration of the nigrostriatal dopamine neurons is proposed to be an early pathological 
process and mediated by different mechanisms than those responsible for the degeneration of 
the cell bodies (Cheng et al. 2010; Tagliaferro and Burke 2016; O’Keeffe and Sullivan 2018). 
Axonopathy is accompanied with disturbances in axonal transport which is another important 
feature in the early-stage PD pathology (Chu et al. 2012; De Vos et al. 2008). The lack of proper 
axonal transport can interfere with many neuronal functions crucial, for example, for synaptic 
communication. Accumulation of α-syn inclusions in the axons in the early stages of the disease 
has been shown to hamper the retrograde transport of signaling endosomes from axon terminals 
to the cell bodies (Volpicelli-Daley et al. 2014). Importantly, this may have implications for 
neuroprotective actions of striatally secreted NTFs and reduce the effectiveness of interventional 
neurotrophic therapeutics administered into the striatum (Bartus et al. 2011). 




Figure 2.9. Neuropathology of Parkinson’s disease (PD). (A) Left panel: The cell bodies of dopamine 
neurons are located in the substantia nigra pars compacta (SNpc). In intact nigrostriatal pathway, 
neuromelanin in dopamine neurons produces the dark pigmentation of the SNpc as shown in the 
photograph of the brainstem transverse section (black arrows). Dopamine neurons project to the 
dorsal striatum (i.e. putamen and caudate nucleus) as illustrated with thick solid red lines. Righ panel: 
Degeneration of the nigrostriatal pathway is the pathological hallmark of PD. The loss of neuromelanin-
containing dopamine neurons causes depigmentation of the SNpc (black arrows). The loss of 
dopaminergic projections to the putamen (dashed red line; prominent loss) and the caudate nucleus 
(thin solid red line; less prominent loss) results in dopamine depletion in the dorsal striatum. 
Reproduced with permission from Elsevier: Neuron, Dauer and Przedborski (2003), © Cell Press 2003 
(B) Intracellular Lewy pathology in SNpc specimens from a PD patient. Upper panel: Nerve cell body 
with three Lewy body inclusions that are double-stained for alpha-synuclein and ubiquitin. Lower 
panel: Lewy neurites in neuronal processes double-stained for alpha-synuclein and ubiquitin. Images 
adopted from Spillantini et al. (1998), © 1998 by The National Academy of Sciences (C) Classical 
(simplified) “Box and Arrow model” of cortico-basal ganglia-thalamocortical circuitry depicting the 
essential neuronal pathways in the healthy brain (left panel) and PD affected brain (right panel). In PD, 
the excitability of the direct and indirect pathways shifts in opposite directions following the dopamine 
depletion in the dorsal striatum; the excitability of D1 receptor expressing medium spiny neurons (D1-
MSN) reduces whereas the excitability of D2-MSN increases. These changes contribute to the 
increased firing of the output nuclei internal globus pallidus (GPi) and substantia nigra pars reticulata 
(SNr). The resultant suppression of the motor thalamus leads to the decreased activation of the motor 
cortex. VL - ventral lateral nucleus of the thalamus; VA - ventral anterior nucleus of the thalamus; IL - 
intralaminar thalamic nuclei; STN - subthalamic nucleus; GPe - external globus pallidus. Figure drawn 












































The neuropathological processes are not confined exclusively to dopaminergic neurons but affect 
several non-dopaminergic neurotransmitter systems too. Histopathological, biochemical and 
imaging findings in PD patients have demonstrated the concomitant degeneration of 
serotonin, noradrenaline, acetylcholine and various neuropeptides containing neurons (Halliday 
et al. 1990; Gesi et al. 2000; Hirsch et al. 2003; Kish et al. 2008). Widespread neuronal loss can be 
found in several non-dopaminergic nuclei including the locus coereleus, the nucleus basalis of 
Meynert, the dorsal motor nucleus of the vagus, the pedunculopontine nucleus, the raphe nuclei, 
amygdala and hypothalamus (Dickson 2012; Giguère et al. 2018). Dysfunctions in these systems 
are likely to contribute to the manifestation of non-motor symptoms of PD such as sleep disorders, 
depression and cognitive impairment (see chapter 2.3.3). 
2.3.2.2 Pathological protein accumulation 
The other pathological hallmark of PD is the presence of cytoplasmic fibrillar protein inclusions 
called Lewy bodies (within cell bodies) and Lewy neurites (mostly in dystrophic neuronal 
processes) (Goedert et al. 2013) (Figure 2.9.B). Lewy inclusions are composed of numerous cellular 
proteins, the most abundant being misfolded α-syn, together with membranous material 
originating from vesicles and fragmented organelles (Shahmoradian et al. 2019; Spillantini et al. 
1998, 1997; Wakabayashi et al. 2013; Xia et al. 2008). Misfolded α-syn has the propensity to 
acquire a β-sheet-rich structure and form insoluble amyloid fibrils. Several post-translational 
modifications, including phosphorylation at serine 129, nitration and C-terminal truncation, have 
been proposed to be responsible for the conformational changes that contribute to the 
fibrillization of α-syn (Barrett and Greenamyre 2015). A recent study by Mahul-Mellier et al. (2020) 
suggests that Lewy body formation involves a complex interplay between α-syn fibrillization, post-
translational modifications and interactions between α-syn aggregates and membranous 
organelles. They argued that different stages of Lewy body formation, rather than simply α-syn 
fibril formation, lead to molecular events that contribute to neuronal dysfunction and 
degeneration. Until today, however, the causal role of the Lewy pathology in the neuronal loss has 
not been confirmed (Kalia and Lang 2015). Clinical PD can also occur in the absence of Lewy 
pathology, particularly in certain monogenic forms of the disease such as most of the PRKN 
mutation -related cases and a proportion of patients with LRRK2 mutations (Poulopoulos et al. 
2012; Doherty et al. 2013; Kalia et al. 2015). 
As intermediates of the aggregation process α-syn forms soluble oligomers and protofibrils that 
are proposed to be the most neurotoxic species potentially damaging cell membranes (Kalia et al. 
2013; Karpinar et al. 2009; Winner et al. 2011). Some types of α-syn oligomers may increase 
membrane permeability via a pore-forming mechanism which leads to Ca2+ influx and disruption 
cellular ion homeostasis (Angelova et al. 2016; Danzer et al. 2007). Notably, misfolded α-syn loses 
its physiological functionality in nerve terminals which leads to synaptic dysfunction characterized 
by compromised neurotransmitter release and enlarged synaptic vesicles (Scott et al. 2010). 
A number of cellular mechanisms are implicated in PD pathogenesis, including mitochondrial 
dysfunction, oxidative stress, ER stress, defective protein degradation systems, impaired 
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intracellular Ca2+ homeostasis and neuroinflammation, as described in the following chapters. 
However, their mechanistic details and interrelations have yet to be elucidated. 
2.3.2.3 Braak staging system and Lewy pathology spreading 
Lewy pathology spreads and afflicts multiple neuroanatomical areas in the brain. In 2003, Braak 
and colleagues introduced a staging system of Lewy pathology propagation based on 
semiquantitative assessment of Lewy body inclusions in postmortem autopsy samples of 
incidental and symptomatic sporadic PD cases (Braak et al. 2003). This hypothesis proposes that 
Lewy pathology spreads in an ascending direction throughout the brain in a sequence of six stages 
from medullary and olfactory nuclei towards the cortical areas as described in Figure 2.10.A. 
Generally, the staging system seems to apply to the majority of PD cases studied postmortem 
making it widely accepted (Dickson et al. 2010; Postuma et al. 2012). However, some studies have 
shown that not all cases fit to the hypothesis questioning its predictive validity and underpinning 
the heterogenous nature of PD (Kalaitzakis et al. 2008; Parkkinen et al. 2008; Jellinger 2009; 
Halliday and McCann 2010). 
The Braak hypothesis was later revised to postulate that the initial event in sporadic PD is the 
access of α-syn pathology to the brain through nasal and intestinal mucosal sites (Braak et al. 
2003b; Braak et al. 2006; Hawkes et al. 2007; Hawkes et al. 2009). According to this “dual-hit 
hypothesis” α-syn pathology enters the brain from the olfactory bulb via anterograde progression 
into the temporal lobe, as well as from the enteric plexuses via transsynaptic transmission and 
retrograde transport along the vagus nerve into the medulla and pons. Indeed, Lewy pathology is 
not restricted to the brain in PD; α-syn immunoreactive inclusions have a widespread distribution 
throughout the spinal cord and PNS as well as multiple peripheral organs including skin, heart, 
submandibular gland and gastrointestinal system (Beach et al. 2010; Bloch et al. 2006; 
Wakabayashi and Takahashi 1997). This lends support to the hypothesis that the disease originates 
from the periphery. Interestingly, an epidemiological study showed that a full truncal vagotomy 
was associated with a decreased risk of subsequent PD supporting the role of the vagus as a 
gateway to the brain (Perez-Pardo et al. 2017; Svensson et al. 2015). The dual-hit hypothesis goes 
well together with hyposmia and constipation being prevalent prodromal symptoms in PD (see 
chapter 2.3.3). 
The Braak hypothesis gained support from the observations that α-syn aggregates can transfer 
between neurons. Findings of Lewy bodies in fetal dopamine neurons grafted into the striatum of 
PD patients showed that Lewy pathology can spread from host to grafted cells, and triggered the 
idea that the propagation of Lewy pathology is mediated by a prion-like transmission of α-syn 
between neurons (Chu and Kordower 2010; Kordower et al. 2008; Li et al. 2008; Visanji et al. 2013). 
These findings have been confirmed in several in vivo experiments where intracerebral inoculation 
of synthetic recombinant α-syn fibrils or Lewy body extracts from PD brains induced spreading of 
α-syn pathology to anatomically interconnected brain areas and subsequent neurodegeneration 
(Luk et al. 2012; Recasens et al. 2014; Chu et al. 2019; Henderson et al. 2019). Indeed, mounting 
evidence has demonstrated the cell-to-cell transmission of small α-syn aggregates, their ability to 
seed further aggregation via recruitment of endogenous host α-syn in the recipient cells and their 




bidirectional axonal transport (reviewed in Brundin et al. 2016; Killinger and Kordower 2019). The 
molecular mechanisms of α-syn release to the extracellular space and uptake by neighboring cells 
are not fully elucidated and they may vary between different α-syn species and conditions (Tyson 
et al. 2016). Data from cell culture models suggest that oligomeric and fibrillar α-syn can be 
released via exocytosis in a process that is enhanced by cellular stress, or through uncontrolled 
leakage upon cell death. The uptake of α-syn is believed to be mediated by receptor mediated 
endocytosis (Karpowicz et al. 2019). 
Lewy pathology can also coexist with other proteinaceous inclusions, such as cytoplasmic tau-
containing neurofibrillary tangles and extracellular β-amyloid (Aβ) plaques, suggesting 
interactions between pathogenic mechanisms of different proteinopathies (Jellinger 2012). Tau 
and Aβ inclusions have been detected postmortem in the cortex of up to half of cognitively 
impaired or demented PD patients (Compta et al. 2011; Irwin et al. 2013). Thus, comorbidity with 
AD-type pathologies seems to be associated with the cognitive decline in PD. 
2.3.2.4 Dysfunctional protein degradation systems 
Abnormal proteins are removed from cells via two main protein clearance systems: ubiquitin-
proteasome system (UPS) and autophagy-lysosome pathway (ALP) (Rubinsztein 2006). Both UPS 
and ALP are responsible for the clearance of intracellular α-syn (Rocha et al. 2018). Hence, 
dysfunction in either of these proteolytic machineries is a potential pathogenic mechanism in PD 
(Olanow and McNaught 2006; Pan et al. 2008; Ebrahimi-Fakhari et al. 2012; Xilouri et al. 2013; 
Lehtonen et al. 2019). Upon impaired degradation, misfolded α-syn and other defective proteins 
accumulate in the cytoplasm contributing to their aggregation, perturbed cellular functions and 
cytotoxicity. Reciprocally, accumulating aberrant α-syn species may further aggravate the 
dysfunction of UPS and ALP forming a vicious feedback loop that leads to neuronal death. The 
activity of both UPS and ALP declines with aging which may play a role in the neurodegenerative 
process (Xilouri et al. 2013). 
The first evidence of the UPS abnormalities in PD was provided by postmortem studies of the SNpc 
where the proteasomal catalytic activity was found the be significantly reduced when compared 
to healthy brains (McNaught and Jenner 2001). Apart from the diminished activity, lower 
expression of different components involved in the normal function of UPS was also identified in 
the SNpc of PD brains (McNaught et al. 2002, 2003). Additional evidence is provided by genetic 
studies. Two genes linked to monogenic forms of PD are involved in UPS function: PRKN encodes 
parkin, an E3 ubiquitin ligase, which ubiquitinates substrate proteins and is needed for normal 
proteasome activation. PD-linked mutations in PRKN abolish this function which is thought to lead 
to the manifestation of the disease (Kitada et al. 1998; Um et al. 2010). A missense mutation in 
the gene encoding ubiquitin C-terminal hydrolase L1 (UCH-L1; a neuron-specific ubiquitin recycling 
enzyme) causes partial loss of the enzymatic activity and has been linked to increased risk of 
familial PD due to impaired de-ubiquitination and negative regulation of UPS (Leroy et al. 1998; 
Nishikawa et al. 2003). 
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Animal models of PD also provide support to the notion that impaired UPS is an important 
etiopathogenic factor in PD. In wild-type rats, selective proteasome inhibition with an intranigral 
lactacystin injection caused motor impairment, dose-dependent degeneration of nigrostriatal 
dopamine neurons and cytoplasmic accumulation of α-syn immunoreactive protein inclusions 
(McNaught et al. 2002b). In transgenic mice, depletion of 26S proteasomes using a conditional 
knockout approach led to extensive neurodegeneration of the nigrostriatal pathway and forebrain 
regions and appearance of intraneuronal Lewy body -like inclusions (Bedford et al. 2008). 
Similar to the findings in UPS system, various ALP-related components are differently expressed 
or dysfunctional in PD. For example, in postmortem examinations of the SNpc, chaperone-
mediated autophagy-related proteins, such as lysosomal membrane receptors LAMP1 and 
LAMP2A and heat-shock proteins 70 and 73, were found to be decreased in PD brains as compared 
to age-matched controls (Alvarez-Erviti et al. 2010; Chu et al. 2009). Several genes linked to ALP 
have also been associated with PD (Gan-Or et al. 2015). For example, mutant LRRK2 interferes 
with ALP leading to retardation of α-syn degradation and, as a consequence, its accumulation (Yue 
and Yang 2013). Additionally, loss-of-function mutations in the GBA gene, which encodes the 
lysosomal enzyme glucocerebrosidase, are strong genetic risk factors for PD suggesting a role for 
dysfunctional ALP in the pathogenesis of PD (Sidransky and Lopez 2012).  
2.3.2.5 Neuroinflammation 
Neuroinflammation, with reactive astrocytosis and microgliosis, is strongly implicated in the 
pathogenesis of PD. Upon immune response, the morphology of microglia changes from a resting 
state ramified shape to an amoeboid profile (Kim and Joh 2006; Brück et al. 2016). This 
morphological change is accompanied with alterations in the expression of cell surface receptors 
and increased release of nitric oxide, ROS and cytokines. Some of the secreted factors are 
neuroprotective, such as GDNF and BDNF, but the majority are proinflammatory such as TNFα and 
IL-1β. Thus, reactive microglia amplify neuroinflammatory response and trigger oxidative damage 
and cytokine-receptor-mediated apoptosis in surrounding cells. This might contribute to the 
neurodegeneration in PD. On the other hand, reactive microglia can phagocyte cell debris and 
pathological protein aggregates, thus promoting neuroprotection. 
Increased microglia and complement activation, T-cell infiltration and proinflammatory cytokine 
levels have been detected postmortem in the SNpc and striatum specimens from PD patients as 
compared to age-matched healthy subjects (McGeer et al. 1988; Hunot et al. 1999; Loeffler et al. 
2006; Hirsch and Hunot 2009). Neuroimaging studies using positron emission tomography (PET) 
with a radiotracer for reactive microglia (11C-PK11195) has demonstrated increased and stable 
microglial activation in the brainstem, basal ganglia and several cortical regions in patients with 
early-stage PD (Edison et al. 2013; Gerhard et al. 2006; Ouchi et al. 2005). Genetic studies have 
also identified a single-nucleotide polymorphism within the human leucocyte antigen (HLA) class 
II region that is associated with increased risk of developing PD, suggesting an immune system-
related susceptibility to PD (Hamza et al. 2010; Nalls et al. 2014; Saiki et al. 2010). 




Intriguingly, serum immune marker profile seems to be predictive of disease progression in PD 
patients. Elevated proinflammatory and lower anti-inflammatory marker levels were associated 
with faster progression of motor symptom and worse cognitive performance (Williams-Gray et al. 
2016). In line with this, epidemiological studies have found a potential protective effect of regular 
non-steroidal anti-inflammatory drug use on the risk of PD (Gagne and Power 2010; Gao et al. 
2011). 
Although one can consider neuroinflammation to be a secondary phenomenon, accumulating 
evidence suggests that inflammatory processes per se have a contributing role in the pathogenesis 
of PD. For example, it has been demonstrated in 6-OHDA and MPTP mouse models of PD, that 
microglial-induced inflammatory events play a role in the neurotoxic effects on nigrostriatal 
dopamine neurons (He et al. 2001; Wu et al. 2002). In these studies, inhibition of microglia 
activation with minocycline mitigated dopaminergic cell death in the SNpc and reduced the level 
of IL-1β. Regardless of whether neuroinflammation has a causal role in neurodegeneration or it is 
a consequence of neuronal damage, it is clear that the engagement of immune system can 
exacerbate neuronal dysfunction in PD. 
A strong body of evidence suggests that α-syn can directly activate microglia in the CNS and initiate 
inflammatory response (Rocha et al. 2018). For example, overexpression of human wild-type α-
syn resulted in early microglial activation in the SNpc of transgenic mice (Su et al. 2008). In primary 
culture models, extracellular α-syn triggered microglial activation and increased the expression of 
proinflammatory cytokines presumably in a receptor mediated manner (Zhang et al. 2005; Klegeris 
et al. 2008; Su et al. 2008). α-Syn has also been shown to interact with astrocytes via Toll-like 
receptor 4 inducing nuclear translocation of NF-κB and subsequent astrocyte activation with 
increased expression of proinflammatory cytokines (Rannikko et al. 2015; Chavarría et al. 2018). 
2.3.2.6 Mitochondrial dysfunction, oxidative stress and ER stress 
Mitochondrial dysfunction is closely related to sporadic and familial forms of PD (Moon and Paek 
2015; Ryan et al. 2015). It can contribute to dopaminergic cell death due to cellular energy 
depletion, impaired calcium homeostasis, production of free radicals and increased oxidative 
stress. Early evidence arose from a group of young drug addicts in California who developed severe 
parkinsonian symptoms after self-administering a synthetic heroin (pethidine analogue) which 
was contaminated with a synthesis by-product MPTP (Langston et al. 1999, 1983). Later, 
postmortem examination of these individuals revealed that MPTP had selectively destroyed 
dopamine neurons in the SNpc.	MPTP, when oxidized to MPP+, is taken up by dopamine neurons 
and leads to the inhibition of mitochondrial complex I which is a vital component in the electron 
transport chain (Nicklas et al. 1985). Other toxins and pesticides that interfere with mitochondrial 
complex I, like rotenone and paraquat, are also linked to the increased risk of PD (Tanner et al. 
2011). Furthermore, in idiopathic PD cases, postmortem studies of the SNpc showed deficiency in 
mitochondrial complex I providing another direct indication of the mitochondrial dysfunction in 
PD (Schapira et al. 1989). 
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Importantly, several genes associated with monogenic forms of PD play a role in mitochondrial 
homeostasis. For example, PINK1 and parkin are the key regulators of mitophagy that is a process 
to dispose damaged mitochondria (Pickrell and Youle 2015; Ryan et al. 2015). The function of DJ-
1 is less well characterized, but it seems to protect mitochondria from oxidative stress and be 
involved in maintaining mitochondrial homeostasis. Interestingly, α-syn itself is known to interfere 
with mitochondrial bioenergetics. In the striatum and SNpc autopsy samples from PD subjects, α-
syn was shown to accumulate in the mitochondria of dopamine neurons where it interacted with 
the inner membrane, interfered with complex I activity and increased the production of ROS (Devi 
et al. 2008; Luth et al. 2014). Oligomeric and post-translationally modified species of α-syn have 
also been shown to inhibit mitochondrial protein import leading to reduced mitochondrial 
respiration and enhanced production of ROS (Di Maio et al. 2016). 
Accumulation of misfolded proteins can trigger ER stress which leads to UPR activation. ER stress 
and UPR are also common features of the PD pathogenesis and closely associated with aggregated 
α-syn (Mercado et al. 2013). Neuropathological analysis of postmortem brain tissue derived from 
PD patients revealed increased immunoreactivity of the UPR markers phosphorylated PERK, IRE1α 
and eukaryotic initiation factor 2α (eIF2α) in dopamine neurons of the SNpc (Heman-Ackah et al. 
2017; Hoozemans et al. 2007; Mercado et al. 2018).  Phosphorylated PERK and IRE1α also 
colocalized with α-syn inclusions. In line, genetic and neurotoxin rodent models of PD as well as 
induced pluripotent stem cell -derived neurons overexpressing α-syn have shown similar ER stress 
phenotype and activated UPR. Of note, ER-resident CDNF and MANF serve as potential therapeutic 
agents to mitigate ER stress in PD. 
2.3.2.7 Selective vulnerability of the SNpc dopamine neurons 
The particular susceptibility of the dopamine neurons in the SNpc to the neuronal damage is not 
fully understood. As described earlier, nigral dopamine neurons are autonomous pacemakers 
spiking at low frequencies (2-5 Hz) and exhibiting broad action potentials (>2 ms). Unlike most of 
the other pacemaking neurons that rely on Na+ channels, the SNpc dopamine neurons have a 
strong reliance on L-type voltage-dependent Ca2+ channels with a Cav1.3 subunit leading to 
increased Ca2+ entry into the cells (Surmeier and Schumacker 2013). In addition, the SNpc 
dopamine neurons have low intrinsic Ca2+ -buffering capacity. In comparison, the dopamine 
neurons in the VTA, which are also slow pacemakers but less prone to degeneration in PD, have 
much lower L-type Cav1.3 Ca2+ channel density, do not manifest significant intracellular Ca2+ 
oscillations and express high levels of the Ca2+ -buffering protein calbindin. The maintenance of 
Ca2+ gradient across the plasma membrane is energetically expensive. Because of the high energy 
demand, nigral dopamine neurons are strongly dependent on the mitochondrial ATP production. 
Increased mitochondrial oxidative phosphorylation gives rise to high levels of ROS generation and 
oxidative stress in the neurons. High metabolic demands also increase the risk of bioenergetic 
crisis in case of an episodic disruption in the mitochondrial function. Reduced Ca2+ influx might 
explain the potentially reduced risk of PD associated with the use of calcium channel blockers 
(Noyce et al. 2012).  




The SNpc dopamine neurons have a massively arborized axonal tree with a very high number of 
axon terminals which causes a great bioenergetic burden on these cells (Giguère et al. 2018). 
Elevated energetic requirements can deplete cellular antioxidant storages and subject neurons to 
chronic oxidative stress. It is estimated that up to half of the energy consumed by the SNpc 
dopamine neurons is used to action potential firing and neurotransmitter release. Thus, stressed 
neurons may try to adapt to excessive metabolic needs by dysregulating axon terminals as seen in 
the early phases of PD. 
 
Figure 2.10. (A) Braak staging system of Lewy pathology spreading. In stage 1, Lewy inclusions start 
to appear in the dorsal motor nucleus of the vagus nerve in the medulla oblongata and olfactory 
system. In stage 2, locus coeruleus and caudal raphe nuclei in the pontine tegmentum become 
affected. In stage 3, the pathology ascends to the midbrain including substantia nigra, amygdala and 
the cholinergic nuclei of the basal forebrain. In stage 4, the pathology reaches thalamus, hippocampus 
and temporal mesocortex. In stages 5 and 6, several cortical areas, including prefrontal, primary 
sensory and motor cortices, and finally, the entire neocortex become involved. Growing severity of the 
Lewy pathology is shown by increasing shading (red, violet, black). Reproduced with permission from 
Springer Nature: Journal of Neural Transmission, Braak et al. (2003b), © Springer Nature 2003 (B) Time 
course of Parkinson’s disease progression. Accumulating clinical symptoms (red line) are associated 
with the loss of nigral dopamine neurons (dashed black line) and Braak stages of Lewy pathology 
spreading (in violet). Up to two decades long pre-motor/prodromal phase (stages 1 and 2) 
characterized by specific, mainly autonomic, olfactory and sleep-related non-motor symptoms can 
precede the diagnosis (time 0 years). During stage 3, the characteristic motor features start to 
manifest, leading to the diagnosis between stages 3 and 4. Additional non-motor symptoms develop 
with the disease progression, causing significant disability. Stages 5 and 6 are associated with advanced 
disease with debilitating axial motor symptoms. Complications of dopaminergic therapy contribute to 
clinical disability. EDS - excessive daytime sleepiness; MCI - mild cognitive impairment; RBD - REM sleep 
behavior disorder. Adapted with permission from Elsevier: The Lancet, Kalia and Lang (2015), © 
Elsevier 2015. 
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Another hypothesis linking increased oxidative stress to the vulnerability of the SNpc neurons is 
that oxidation of cytosolic dopamine and its metabolites leads to the excessive production of 
cytotoxic free radicals, dopamine-quinones, which may disrupt the function of e.g. mitochondrial 
protein complexes or DAT (Greenamyre and Hastings 2004; Giguère et al. 2018). This may well be 
a contributing factor in the pathogenesis of PD but probably not the principal culprit. Dysfunctional 
iron homeostasis causing overload of free iron in the SNpc has also been proposed to trigger 
oxidative stress in PD. However, this hypothesis has remained controversial thus far (Sian-
Hülsmann et al. 2011). 
2.3.3 Symptoms and diagnosis of Parkinson’s disease 
The characteristic motor manifestations of PD include bradykinesia, rigidity, resting tremor, 
postural instability and gait disturbances (Kalia and Lang 2015). Bradykinesia is the precondition 
for the clinical diagnosis of PD [UK Parkinson's Disease Society Brain Bank clinical diagnostic 
criteria (Hughes et al. 1992); revised by Movement Disorder Society Clinical Diagnostic Criteria for 
Parkinson's disease (Postuma et al. 2015)]. In addition, at least one other motor feature is required 
for the diagnosis: muscular rigidity, 4-6 Hz resting tremor, and/or postural instability. The 
diagnosis is confirmed by excluding possible alternative disorders and with the presence of at least 
three supportive criteria such as unilateral onset, progressive symptoms, marked responsiveness 
to L-DOPA treatment, L-DOPA-induced dyskinesias and clinical course of 10 years or more. The 
diagnosis is based on clinical neurological examination but neuroimaging techniques such as 
single-photon emission computed tomography (SPECT), magnetic resonance imaging (MRI) and 
PET can be used in differential diagnosis and tracking the progression of the disease (see below 
chapter 2.3.4) (Politis 2014). Neuropathological overlap and heterogeneity in clinical 
manifestations complicate the differential diagnosis between early-stage PD and atypical 
parkinsonian syndromes such as multiple system atrophy (MSA), progressive supranuclear palsy 
(PSP) and corticobasal degeneration (CBD). Despite advanced diagnostic tools, full certainty of the 
diagnosis cannot be achieved pre mortem; 75-95% of the diagnoses are confirmed by histological 
identification of Lewy pathology upon autopsy (Postuma et al. 2015). 
Apart from the motor impairment, PD patients suffer from heterogenous non-motor symptoms 
such as olfactory deficits, cognitive impairment, psychiatric symptoms, sleep disturbances, 
autonomic dysfunctions, pain and fatigue (Khoo et al. 2013; Kalia and Lang 2015) (Figure 2.10.B).	
Some of these symptoms are of dopaminergic origin while the others are non-dopaminergic, 
reflecting the multisystem nature of PD (Fox et al. 2008; Chaudhuri and Schapira 2009). 
Oftentimes, it is the non-motor symptoms, rather than the motor symptoms, that dominate the 
decline of patients’ health-related quality of life (Barone et al. 2009; Martinez-Martin et al. 2011; 
Duncan et al. 2014). Cognitive decline is one of the most prevalent and debilitating non-motor 
feature of PD (Aarsland et al. 2009; O’Callaghan and Lewis 2017). Mild cognitive impairment (MCI) 
is considered as an intermediate state that typically progresses to PD dementia. In some patients, 
MCI is recognized already at the earliest stages of the disease. The likelihood of manifesting MCI 
or dementia considerably grows as the disease progresses. On the whole, the burden of non-
motor symptoms increases over time. Psychiatric symptoms such as anxiety, depression and 




psychosis, and autonomic dysfunctions including constipation, dysphagia, urinary incontinence 
and postural hypotension are common features in the later stages of PD and resistant to L-DOPA 
treatment. These late-stage symptoms are predictive for institutionalization and, eventually, 
mortality. 
Certain non-motor symptoms can precede the onset of the motor impairment and clinical 
diagnosis by more than a decade (Postuma et al. 2012) (Figure 2.10.B). These prodromal, or pre-
motor, symptoms typically include impaired olfaction (hyposmia), constipation, orthostatic 
hypotension, rapid eye movement (REM) sleep behavior disorder (RBD), depression and excessive 
daytime sleepiness. Efforts have been made to identify prodromal symptoms that could be used 
as diagnostic markers to screen for PD before the motor manifestations. Depression, constipation 
and idiopathic RBD are currently the strongest candidates that, together with family history of PD, 
could support the diagnosis but the specificity and predictive value of these markers are still 
insufficient (Howell and Schenck 2015; Noyce et al. 2012). 
2.3.4 Biomarkers of Parkinson’s disease 
Biomarkers can be used to assist in early and differential diagnosis and predict the course of a 
disease. They can also help to assess response to a therapeutic intervention. An optimal biomarker 
is easily accessible, inexpensive, sensitive and reproducible (Yilmaz et al. 2019). Currently, there 
are several biomarker candidates available for PD but none of them is specific or reliable enough 
to be used alone to diagnose or follow the progression of the disease (Kalia 2018; Parnetti et al. 
2019). This shortage mainly arises from the heterogeneity of PD on genetical, pathophysiological 
and clinical level. The potential approaches to identify new biomarkers include biomolecular, 
histological and “omics” based analyses of biofluids and peripheral tissue samples (biochemical 
biomarkers), brain imaging modalities (imaging biomarkers), electrophysiological and digital 
biomarkers (other biomarker modalities). In general, the diagnostic utility of these approaches 
remains to be validated in large trials with standardized study protocols before their introduction 
to clinical practice. The use of a combination of biomarkers could detect multiple pathological 
aspects and result in improved diagnostic accuracy. 
2.3.4.1 Biochemical biomarkers 
Identifying biomarkers from body fluids that are easily accessible (e.g. blood, saliva or urine) would 
be desirable, but due to the peripheral nature of these matrixes, the sensitivity and specificity 
issues might limit their utility (Chahine and Stern 2017). Accumulating evidence suggests 
diagnostic value for cerebrospinal fluid (CSF) and blood biomarkers reflecting the pathophysiology 
of PD such as α-syn species, lysosomal enzymes, neurofilaments and markers of Aβ and tau 
pathology (Parnetti et al. 2019). Especially various forms of α-syn, total monomeric, 
phosphorylated, oligomeric and aggregated species, have been investigated intensively (Atik et al. 
2016; Visanji et al. 2017). The close contact of the CSF to the brain makes it a potential source for 
diagnostic markers reflecting the ongoing pathological processes and metabolic changes in the 
CNS (Constantinescu and Mondello 2013; Eusebi et al. 2017; Parnetti et al. 2019). It is not, 
however, an ideal matrix for longitudinal monitoring because of the need for repeated lumbar 
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punctures and risk for blood contamination which may disturb some analyses. Nevertheless, the 
CSF levels of α-syn species have provided encouraging results as biomarker candidates for PD. The 
total concentration of α-syn in the CSF seems to be lower, whereas the levels of α-syn oligomers 
and phosphorylated α-syn are elevated in PD patients as compared to healthy controls. 
Efforts have also been made to quantify plasma levels of α-syn species, neurofilaments and 
inflammatory cytokines as potential biomarkers for PD. Plasma sampling would provide a 
convenient route for early diagnosis and longitudinal disease monitoring. However, the 
measurement of total α-syn from plasma has provided inconsistent outcomes, partly because 
plasma samples are easily contaminated with α-syn containing  erythrocytes (Constantinescu and 
Mondello 2013; Parnetti et al. 2019). Quantification of α-syn oligomers and phosphorylated α-syn 
from plasma provides an alternative approach which has shown more concordant results with 
increased levels in PD patients. 
Untargeted “omics” techniques in combination with bioinformatic tools provide a powerful 
approach to detect large amounts of analytes in various biosamples and then compare these 
analytical “fingerprints” between patients with healthy controls. Metabolomics has been utilized 
to detect PD-related alterations for example in plasma and CSF levels of amino acids, fatty acids 
and sugars (LeWitt et al. 2013; Trupp et al. 2014; Willkommen et al. 2018). Also, attempts to use 
proteomics and transcriptomics data collected from the body fluid samples have been made 
(Scherzer et al. 2007; Halbgebauer et al. 2016; Santiago et al. 2018). These “omics” based 
biomarkers have the potential to unravel new aspects of PD pathogenesis and aid in the future 
diagnostics of the disease. 
In consistence with the evidence suggesting that α-syn pathology appears in the PNS before 
propagating to the brain, attention has been paid to histological examination of phosphorylated 
α-syn deposits in various peripheral tissue biopsies from PD patients (Cersosimo and Benarroch 
2012; Lee et al. 2017). For example, submandibular gland biopsy and subsequent detection of 
phosphorylated α-syn aggregates in the autonomic nerve fibers have shown promise as an early 
histological biomarker (Adler et al. 2016; Vilas et al. 2016). Histological analysis of phosphorylated 
α-syn in dermal nerve fibers in skin biopsies is also a sensitive candidate for early diagnosis 
(Doppler et al. 2016). 
2.3.4.2 Imaging biomarkers 
Brain imaging techniques are widely studied tools that can provide support for early, differential 
and prognostic diagnosis. Multimodal imaging allows the visualization of structural and functional 
changes in the brain and can reveal pathophysiological mechanisms underlying the disease 
processes (Saeed et al. 2017). As imaging modalities are non-invasive, they are well suited for 
longitudinal tracking of disease progression and therapeutic responses. 
Structural MRI is used to assess regional tissue atrophy and serves as a potential aid for PD 
diagnosis (De Marzi et la. 2016; Frosini et al. 2017; Pyatigorskaya et al. 2017). Neuromelanin-
sensitive MRI imaging of the SNpc and locus coeruleus has shown promising diagnostic accuracy 




in differentiating PD patients from healthy controls (Castellanos et al. 2015). Functional MRI (fMRI) 
can be used to detect changes in brain network activities by measuring cerebral oxygen-rich blood 
flow. Significantly reduced functional connectivity in resting-state fMRI have been reported within 
the basal ganglia of patients with early-stage PD (Rolinski et al. 2015; Szewczyk-Krolikowski et al. 
2014). Indeed, resting-state fMRI of basal ganglia connectivity is a promising diagnostic tool that 
may help to identify patients at risk of developing PD (Rolinski et al. 2016). 
SPECT is a useful technique to assess the integrity of the nigrostriatal dopamine pathway (Saeed 
et al. 2017). Gamma-emitting cocaine analogues, such as 123I-FP-CIT and 123I-β-CIT, bind selectively 
to presynaptic DAT and can be used to measure the density of nigrostriatal fibers. Reduced striatal 
uptake in DAT-SPECT is a characteristic readout in PD patients when compared to healthy controls. 
A meta-analysis suggests that DAT-SPECT is useful in the diagnosis of early PD and in differentiating 
PD from essential tremor and vascular parkinsonism (Vlaar et al. 2007). DAT-SPECT can also be 
utilized to follow disease progression because striatal binding seems to correlate to disease 
severity stages (Benamer et al. 2000; Brücke et al. 1997). 
PET is another imaging modality taking advantage of radioactive ligands. It can be utilized to gauge 
the integrity of dopaminergic system, cerebral glucose metabolism, pathological Aβ and tau 
protein accumulation and neuroinflammation (Saeed et al. 2017). 6-18F-fluoro-L-dopa (18F-DOPA) 
is a PET tracer that is converted to 18F-dopamine by AADC. Thus, 18F-DOPA measures the activity 
of AADC and provides an indirect estimation of the presynaptic dopamine storage pools. In PD, 
striatal 18F-DOPA uptake is decreased and associated with the progression of the disease. PET 
imaging of presynaptic DAT, using for example 18F-FP-CIT or 11C-methylphenidate, shows reduced 
striatal uptake in PD patients, in line with DAT-SPECT findings. However, compensatory 
mechanisms, such as upregulation of AADC activity and downregulation of DAT, in response to 
neurodegeneration may inflict biases in AADC-PET, DAT-PET or DAT-SPECT -based estimates of the 
nigrostriatal injury (Lee et al. 2000). VMAT2 imaging, instead, for example with 11C-
dihydrotetrabenazine (11C-DTBZ) PET, seems to be less prone to the compensatory changes, thus 
producing more reliable readouts of the nigrostriatal degeneration in PD. Despite considerable 
efforts to develop an α-syn-specific radiotracer, a direct method for α-syn imaging in vivo is still 
lacking (Eberling et al. 2013). Such a tracer would allow for tracking α-syn pathology spreading 
over time and monitoring the efficacy of α-syn targeting therapies. 
2.3.4.3 Other biomarker modalities 
Electrophysiological techniques, such as electroencephalography (EEG), can be used to identify 
candidate biomarkers for PD. For example, lower background rhythm frequency and increased 
relative power of delta and theta oscillations in resting-state EEG show promise as predictive 
biomarkers for cognitive deterioration in PD (Caviness et al. 2015; Klassen et al. 2011). In a 
prospective EEG study, slower background frequency during REM sleep together with increased 
delta and theta band powers predicted the later development of PD dementia (Latreille et al. 
2016). 
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With recent technological advancements, digital biomarkers form a rapidly emerging field of 
research to improve the longitudinal tracking of neurodegenerative diseases (Espay et al. 2016; 
Hansen et al. 2018; Baker et al. 2019; Kourtis et al. 2019; Mahadevan et al. 2020). Digital 
biomarkers refer to the use of inbuilt sensors in portable (e.g. smartphone), wearable (e.g. smart 
watch) or implantable devices allowing for continuous active and/or passive data collection of 
biological (e.g. blood glucose), physiological (e.g. heart rate or blood pressure) or functional (e.g. 
motor activities, speech or facial expression) parameters (Dorsey et al. 2017). 
2.3.5 Current treatments for Parkinson’s disease 
Today, there is no cure available for PD patients. The current therapies ameliorate the disease 
associated motor symptoms by replenishing striatal dopamine deficiency with the BBB-
penetrating dopamine precursor L-DOPA or boosting dopaminergic transmission with dopamine 
receptor agonists or drugs that prevent the degradation of dopamine (Armstrong and Okun 2020; 
Fox et al. 2018). The efficacy of these dopamine-based therapies, however, gradually diminishes 
as the disease progresses and they are unable to delay or reverse the neurodegenerative 
processes underlying the disease. Thus, there is an unmet medical need for a disease-modifying 
therapy for PD. The currently used treatments for motor and non-motor symptoms of PD are 
presented in Table 2.2. 
L-DOPA has been the cornerstone of PD treatment since the seminal experiments in 1961 by 
Walther Birkmayer and Oleh Hornykiewicz who showed the striking effect of the first intravenous 
injections of L-DOPA on akinetic PD patients (Birkmayer and Hornykiewicz 1961; Hornykiewicz 
2002). L-DOPA, given in combination with a peripheral AADC inhibitor, has remained the “the gold 
standard” of PD treatment until today due to its efficacy, tolerability and low cost (Lewitt 2015). 
Although L-DOPA has remarkable therapeutic efficacy in the early-stage PD, the progressive loss 
dopamine neurons results in narrowing therapeutic window (Armstrong and Okun 2020; Chou et 
al. 2018; Connolly and Lang 2014). The required dose escalations, the short half-life of L-DOPA and 
its intermittent availability after oral administration cause fluctuations in drug levels in the brain. 
Eventually, the effect of a L-DOPA dose starts to wear off faster causing the re-emerge of 
parkinsonian motor and non-motor symptoms (“off” state) while the highest L-DOPA 
concentrations cause troublesome dyskinesias, i.e. involuntary, nonrhythmic chorea-type 
movements. 
The motor fluctuations between the “off” state and the “on” state, when the symptoms are 
controlled but often associated with peak-dose dyskinesias, are proposed to result from the 
reduced capacity of the degenerating synaptic terminals to store extra dopamine and alterations 
in the striatal postsynaptic signaling cascades (Chou et al. 2018; Marsden and Parkes 1976). The 
pathogenic mechanisms of dyskinesias remain to be fully elucidated but appear to include 
pulsatile stimulation of dopamine receptors, conversion of L-DOPA to dopamine in serotonin 
neurons and subsequent unphysiological release of dopamine from the striatal serotonergic 
terminals as a “false neurotransmitter”, corticostriatal glutamatergic overdrive, stimulation of 




nAChRs on dopaminergic terminals and aberrant activation of direct-pathway MSNs (Chase and 
Oh 2000; Espay et al. 2018). 
Over time, the motor fluctuations become increasingly difficult to manage and their prevalence 
increases (Armstrong and Okun 2020; Chou et al. 2018; Connolly and Lang 2014). A common 
strategy to reduce them is to divide L-DOPA dosage into smaller but more frequent doses. Various 
combinations of medications are also commonly used together with L-DOPA to increase 
therapeutic benefit while limiting the high dose-related side-effects. The most common adjunct 
medications are dopamine receptor agonists and MAO-B and COMT inhibitors (Fox et al. 2018). 
Subcutaneous apomorphine (D1 and D2 agonist) injections, self-administered via an injection pen, 
can be used to achieve faster medication response for those who suffer from severe “off” periods. 
The abovementioned strategies are effective to a certain extent, but as the disease advances, 
some patients become irresponsive to conventional medication adjustments. In these cases, 
device-aided interventions such as intracranial deep brain stimulation (DBS), small dose infusion 
of L-DOPA-carbidopa gel into jejunum or continuous subcutaneous apomorphine infusion may be 
considered to treat difficult motor fluctuations and dyskinesias (Armstrong and Okun 2020; Fox et 
al. 2018; Martinez-Martin et al. 2015; Volkmann et al. 2013). The selection between these 
advanced therapy options is made based on case-by-case evaluation. 
In addition to the pharmacological interventions, physical exercise regimens, physiotherapy and 
occupational therapy may be useful in improving motor performance or delaying the disease 
progression (Armstrong and Okun 2020; Fox et al. 2018; Mak et al. 2017). Strength and aerobic 
endurance training programs appear to produce long-lasting positive effects on the physical 
functioning of PD patients. Balance, gait, Tai chi and dance exercises have also been shown to 
reduce falls and improve mobility and walking capacity. The physical exercise interventions should 
be sustained, intensive, multimodal and start at an early stage of the disease in order to produce 
maximal benefits. Additionally, speech therapy seems to be a useful strategy for managing 
hypophonia and dysphagia that are common symptoms in PD. 
The non-motor symptoms substantially increase the clinical and financial burden of PD but remain 
largely refractory to the existing dopaminergic drugs (Armstrong and Okun 2020; Connolly and 
Lang 2014; Seppi et al. 2019). The management of non-motor symptoms is symptomatic and 
extrapolated from the general treatment guidelines for these symptoms in non-PD individuals 




Table 2.2. Currently used treatments for motor and non-motor symptoms of Parkinson’s disease. References provided in the main text 



















p.o. immediate release 
L-DOPA:  
Precursor of DA, crosses the BBB à AADC converts to DA in the CNS 
à increases DA content in the remaining DA neurons 
 
Carbidopa/ benserazide:  
peripheral AADC inhibitor à prevents the conversion of L-DOPA to DA 
outside the brain à increases L-DOPA concentration in the CNS and 
reduces peripheral side-effects of DA 
Early symptomatic monotherapy, 
motor fluctuations 
Nausea, vomiting, diarrhea, loss of appetite, orthostatic hypotension, 
dizziness, cardiac arrhythmia, dyspnea, sleepiness, insomnia, 
restlessness, depression, confusion, hallucinations, strange dreams, 
motor fluctuations, peak-dose dyskinesias 
L-DOPA-carbidopa/ 
benserazide, 
p.o. extended release 
L-DOPA-carbidopa  
intestinal gel infusion 
See above, reduces fluctuations in the plasma concentration of L-
DOPA 
Advanced motor fluctuations and 
dyskinesias that are irresponsive 
to conventional medication 
adjustments 
See above 
+ weight loss, constipation, falls, anxiety, neuropathy 
+ complications of surgical device insertion, abdominal pain, irritation 




Activates postsynaptic D2-like DA receptors 
Early symptomatic monotherapy, 
L-DOPA adjunct, motor 
fluctuations, depression 
Nausea, vomiting, constipation, sleepiness, orthostatic hypotension, 
dizziness, edema, hallucinations, impulsive-compulsive disorders* Ropinirole 
Like Pramipexole 





Activates postsynaptic D2- and D1-like DA receptors 
Motor fluctuations 
The same as other non-ergot DA agonists. In addition, yawning, 
runny nose, heart palpitation, dyskinesias, priapism, injection/ 
infusion site reactions and nodules Apomorphine, 
continuous s.c. infusion 
Advanced motor fluctuations that 




Blocks the degradation of DA to DOPAL in the CNS à increases DA 
concentration in the CNS 
Early symptomatic monotherapy, 
L-DOPA adjunct,  
motor fluctuations 
Headache, exacerbation of L-DOPA adverse effects 
Safinamide 
Rasagiline Headache, arthralgia, dyspepsia, constipation, flu-like syndrome, exacerbation of L-DOPA adverse effects 
COMT inhibitors 
Entacapone 
Blocks the degradation of L-DOPA to 3-OMD in periphery à increases  
L-DOPA concentration in the CNS 
Motor fluctuations 
Dark-colored urine, GI complications, dry mouth, increased sweating, 
angina pectoris, exacerbation of L-DOPA adverse effects 
Opicapone 
Like Entacapone 
+ muscle spasms 
+ increased plasma levels of creatine kinase 
Tolcapone 
Blocks the degradation of L-DOPA to 3-OMD in periphery as well as  
L-DOPA and DA degradation to 3-OMD and 3-MT in the CNS, 




Biperiden Centrally active muscarinic receptor (especially M1) antagonist à 
reduces  
the relative cholinergic overactivity in basal ganglia 
Early symptomatic monotherapy, 
L-DOPA adjunct, tremor-
prominent symptoms, drooling, 
neurogenic bladder dysfunction 





Not completely understood. Blocks NMDA and nAChRs à decreases 
corticostriatal glutamatergic activity; increases DA and NA release and 




Orthostatic hypotension, nausea, dry mouth, blurred vision 
constipation, urinary retention, edema, insomnia, confusion, 
hallucinations, livedo reticularis 
Atypical 
antipsychotic Clozapine 
5-HT2 receptor favoring antagonist with lower affinity for D1 and D2 
receptors Dyskinesias 
Sleepiness, dizziness, sedation, tachycardia, constipation, orthostatic 
hypotension, drooling, risk of agranulocytosis à regular monitoring of 






Bilateral STN DBSa 
 Not completely understood. High frequency electric stimulation via 
implanted electrodes causes global inhibition of the target nucleus à 
mitigates abnormal oscillations in basal ganglia 
Advanced motor fluctuations and 
dyskinesias that are irresponsive 
to conventional medication 
adjustments 
Dysarthria, impaired working memory, falls, surgery related 
complications, infections, device related problems, depression 
Bilateral GPi DBSa Like Bilateral STN DBS - depression 
Unilateral VIM DBSa or 
thalamotomy Mitigates abnormal oscillations in the thalamus 
Medication-refractory tremor as 




















Decrease the hydrolysis of ACh à increases ACh concentration at  
cholinergic synapses in the brain Dementia 
GI complications, weight loss, bradycardia, vivid dreams, risk for 




citalopram, sertraline SSRI 
Depression 
Nausea, anorexia, drowsiness, sexual dysfunction, akathisia 




Tricyclic antidepressants Anticholinergic side-effects**, orthostatic hypotension, ventricular arrhythmias, heart block, sleepiness, sexual dysfunction, weight gain 
Atypical 
antipsychotics 
Clozapine 5-HT2 receptor favoring antagonists with lower affinity for D1 and D2 
receptors 
(First, potentially hazardous medications such as anticholinergics, 
amantadine, DA agonists, MAO-B and COMT inhibitors are reduced) 
Psychosis, hallucinations 
See above 
Quetiapine Extrapyramidal symptoms, sedation 
Pimavanserin Nausea, constipation, edema, confusion, weight gain 
Hypnotic Eszopiclone Positive allosteric modulator of GABAA receptor à increases Cl
- influx 
into the neurons Insomnia  Headache, dry mouth, nausea, and dizziness 
Hormone Melatonin Melatonin receptor agonist à regulates physiological sleep-wake cycle Insomnia, RBD Not common, rarely daytime sleepiness, dizziness, headache 
Tranquilizer Clonazepama Positive allosteric modulator of GABAA receptor à increases Cl
- influx 
into the neurons  RBD Sedation, drowsiness confusion 
Mineralocorticoid Fludrocortisone Increases the reabsorption of Na
+ and water in the kidney à increases 
blood volume and blood pressure 
Orthostatic hypotension 
Hypertension, metabolic abnormalities, GI complications, myopathy 
Sympathomimetics 
Midodrine Activates adrenergic α1-receptors in the vasculature à increases vascular tone and blood pressure Hypertension, nausea, weakness, heartburn, headache, chills 
Droxidopa Precursor of NA, AADC converts to NA in the PNS à maintains blood pressure and blood flow Hypertension, tachycardia, nausea, vomiting, headache 
Osmotic laxative Macrogol Inert substance that osmotically retains water in the bowel à softens and increases the volume of the stool 
Constipation 




Probiotics and  
prebiotic fiber 
Stimulate the growth and activity of beneficial micro-organisms in the 
gut à aid digestion Bloating, increased bowel gas, diarrhea 
Prostaglandin E1 
derivative Lubiprostone 
Activates Cl--channels on the apical surface of GI epithelial cells à 
increases fluid secretion, softens the stool and promotes bowel motility Nausea, diarrhea, headache, bloating, abdominal pain, flatulence 
Antidiuretic 
hormone analog Desmopressin 
Increases the presence of aquaporin channels in the distal nephron by 
binding to V2 receptors à increases water reabsorption from urine à 
decreases the total amount of urine 
Neurogenic bladder dysfunction Hyponatremia, hypertension, edema, urinary tract complications, headache, dizziness, GI complications, sleepiness 
Neurotoxin Botulinum toxin injection  into salivary glands 
Prevents the release of ACh from the postganglionic parasympathetic 
axon terminals à reduction of saliva production Drooling Dysphagia, dry mouth, injection-related discomfort 
3-OMD, 3-O-methyldopa; ACh, acetylcholine; DA, dopamine; GI, gastrointestinal; NA, noradrenaline; nAChR, nicotinic acetylcholine receptor; p.o., peroral; s.c., subcutaneous; SNRI, serotonin and 
noradrenaline reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; VIM, ventralis intermedius nucleus of the thalamus; see text for other abbreviations. 
* Impulsive-compulsive disorders include pathological gambling, hypersexuality, binge eating, compulsive shopping and overuse of dopaminergic medications. 
** Anticholinergic side-effects include cognitive impairment, confusion, tachycardia, vertigo, impaired accommodation, increased intraocular pressure, dry mouth, urinary retention and constipation. 
a For cognitively intact patients; b Not commonly used anymore
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2.4 Animal models of Parkinson’s disease 
In spite of fast developments in in vitro disease models, organoids and computer-aided drug 
development tools, none of these techniques have been able to completely replace the pre-clinical 
studies in animal models. In vivo experiments still form a crucial step where the efficacy and safety 
of a novel therapy can be tested in a complex, whole-organism setting before entering into the 
first human trials. Furthermore, animal models provide a powerful means to gain deeper 
understanding of pathogenic mechanisms which, in turn, contribute to establishing novel targets 
for disease-modifying therapies. The 3R principles lay the groundwork for performing responsible 
and humane animal research: they aim at replacing, reducing and refining animal testing 
whenever possible. 
Reflecting the complex nature of the disease, a wide array of strategies and organisms has been 
used to produce in vivo models of PD (Dauer and Przedborski 2003; Gubellini and Kachidian 2015). 
They all model certain aspects of the disease, but none of the current models can fully recapitulate 
the neuropathology and symptoms of PD. Although non-mammals provide simple and powerful 
systems to model the pathobiology of PD, the focus here is on the most widely used rodent and 
NHP models. They can be classified into four main categories: pharmacological, neurotoxin-based, 
genetic and α-syn pathology spreading models. The main features of these models are 
summarized in Figure 2.11. 
2.4.1 Pharmacological models 
Reserpine and alpha-methyl-p-tyrosine (AMPT) are pharmacological agents that have been used 
to induce parkinsonism in rodents and NHPs (Carlsson et al. 1957; Windle and Cammermeyer 
1958; Bezard and Przedborski 2011). They deplete brain dopamine and other catecholamines by 
inhibiting VMAT2 (reserpine) or TH (AMPT) while leaving dopamine neurons intact. Striatal 
dopamine depletion leads to PD-like motor deficits. 
2.4.2 Neurotoxin-based models 
Neurotoxins produce a prominent and rapid degeneration of the nigrostriatal dopamine system 
resulting in a clear motor impairment in experimental animals. 6-OHDA is a widely used 
catecholaminergic neurotoxin (Simola et al. 2007). 6-OHDA is a hydrophilic structural analogue of 
catecholamines that is unable to cross the BBB. Thus, it needs to be directly injected into the target 
brain structure in a stereotaxic surgery. Prophylactic peripheral administration of a noradrenaline 
transporter blocker, such as desipramine, is common to prevent the uptake of 6-OHDA into 
noradrenergic nerve terminals. 
 
 
Figure 2.11. Animal models of Parkinson’s disease. The main characteristics of pharmacological, neurotoxin-based, genetic and alpha-synuclein pathology 
spreading models of PD. AMPT - Alpha-methyl-p-tyrosine; a-syn+/- - alpha-synuclein positive/negative; BAC - bacterial artificial chromosome; BBB - blood-
brain barrier; DA - dopamine; DAT - dopamine transporter; ER - endoplasmic reticulum; LB - Lewy body-like; MAO-B - monoamine oxidase B; MFB - medial 
forebrain bundle; NHP - non-human primate; PFF - a-syn preformed fibrils; ROS - reactive oxygen species; SN - substantia nigra; TFAM - mitochondrial 
transcription factor A; Tg - transgenic, TH - tyrosine hydroxylase; VMAT2 - vesicular monoamine transporter 2. References are provided in the text. Figure 
drawn by the author and Fanni-Sofia Renko.
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Urban Ungerstedt developed a widely used unilateral 6-OHDA lesion model of PD (Ungerstedt 
1968; Ungerstedt and Arbuthnott 1970; Ungerstedt 1971). Unilateral injection of 6-OHDA into the 
SNpc, medial forebrain bundle (MFB) or dorsal striatum induces degeneration of nigrostriatal 
dopamine neurons on the injected side accompanied with contralateral motor impairment 
(Perese et al. 1989; Sauer and Oertel 1994; Kirik et al.1998; Deumens et al. 2002). In severe lesion 
models (SNpc and MFB lesions), marked dopamine depletion in the striatum leads to 
supersensitization of postsynaptic dopamine receptors. Unilateral lesions produce asymmetrical 
motor deficits that can be easily assessed with behavioral tests. For example, amphetamine-
induced dopamine release in the intact striatum elicits ipsilateral rotational behavior, whereas 
activation of supersensitized dopamine receptors in the lesioned striatum by apomorphine 
induces turning to the contralateral direction. Important advantages of unilateral lesion model 
include increased survival of the experimental animals as compared to bilateral lesions and the 
possibility to use contralateral hemisphere as an internal control in the analyses. 
MPTP is another dopaminergic neurotoxin most commonly used to model PD in mice and NHPs, 
but not in rats which were found to be resistant to the toxin (Bezard and Przedborski 2011; Dauer 
and Przedborski 2003). Lipophilic MPTP readily crosses the BBB, and thus is suitable for systemic 
administration. In the brain, MAO-B converts MPTP to the toxic metabolite MPP+. Utilizing 
mitochondrial transmembrane potential MPP+ concentrates into the mitochondria where it 
inhibits the complex I of the electron transport chain (Chiba et al. 1984; Nicklas et al. 1985). MPTP 
intoxication also causes ER stress, neuroinflammation and upregulation of pro-apoptotic Bax and 
downregulation of anti-apoptotic Bcl-2 in dopamine neurons (Vila et al. 2001; Mercado et al. 2013; 
Lee et al. 2019). In mice, strain, gender, age and body weight affect the sensitivity to MPTP 
(Jackson-Lewis and Przedborski 2007). Prolonged subcutaneous or intraperitoneal administration 
of low or moderate doses of MPTP to C57/Bl6 mice produces a robust PD-like phenotype with 
defined apoptosis of the SNpc dopamine neurons and impaired motor functions. A more recent 
model was characterized by Prediger and colleagues who administered MPTP to rodents via an 
intranasal infusion (Prediger et al. 2011, 2010, 2006). Intranasal MPTP delivery resulted in 
olfactory, cognitive, emotional and motor defects, loss of TH-ir cells in the olfactory bulb and SNpc, 
decreased fiber density in the striatum as well as dopamine depletion in the olfactory bulb, 
striatum and prefrontal cortex. These features appear analogous to many of those observed 
during the prodromal and early stages of PD making the model a valuable tool for testing novel 
therapeutic strategies to restore sensory and cognitive deficits of early PD. The MPTP monkey 
model, however, remains the gold standard model in the preclinical assessment of novel 
treatment strategies as a final step before proceeding to clinical trials (Burns et al. 1983; Emborg 
2007; Porras et al. 2012).  
Rotenone is a natural cytotoxic compound used as an insect and fish poison. Systemically 
administered rotenone reproduces many features of PD but can cause high mortality in 
experimental animals (Heikkila et al. 1985b; Betarbet et al. 2000; Gubellini and Kachidian 2015). 
The dopaminergic damage caused by rotenone can be variable or difficult to reproduce. Paraquat 
(N,Nʹ-dimethyl-4-4ʹ-bipiridinium), a structural analog of MPP+, is a potent and widely used 
herbicide that produces progressive, but poorly reproducible, dopaminergic neurodegeneration 
and accumulation of α-syn immunoreactive inclusions after systemic administration (Cochemé 




and Murphy 2008; Manning-Bog et al. 2002; McCormack et al. 2002; Ossowska et al. 2005; 
Rappold et al. 2011; Richardson et al. 2005; Shimizu et al. 2001). 
Lactacystin is a selective proteasome inhibitor. When stereotaxically injected of into the 
nigrostriatal pathway, it disturbs cellular protein homeostasis, causes dose-dependent formation 
of cytoplasmic, α-syn and ubiquitin containing protein inclusions and triggers dopaminergic 
neurodegeneration (McNaught et al. 2002b; Bentea et al. 2017). Other proteasome inhibitors, for 
example systemic administration of PSI (N-carbobenzoxy-L-isoleucyl-L-γ-t-butyl-L-gultamyl-L-
alanyl-L-leucinal), have also been tested to model PD in rodents and NHPs with equivocal results 
(Bentea et al. 2017). 
2.4.3 Genetic models 
A number of the genetic causes of familial PD have been modeled in mice and rats (Dawson et al. 
2010). The most common genetic models are derived from transgenic overexpression of 
autosomal dominant genes (SNCA and LRRK2) or knockout of autosomal recessive genes (PRKN, 
PINK1 and DJ-1). Even though these models represent direct etiological causes of PD, and thus 
should replicated relevant pathogenic mechanisms, they fail to produce robust nigrostriatal 
degeneration, striatal dopamine depletion or motor impairments. Nevertheless, they provide 
valuable tools to dissect the pathophysiological roles of these proteins. 
Duplication or triplication of SNCA gene leads to a rare form of familial early onset PD with a clear 
gene dosage effect on the severity of the disease. This suggests that the level of α-syn dictates its 
toxicity and has spurred the creation of several animal models based on the overexpression of 
human or murine wild-type α-syn (Dawson et al. 2010; Visanji et al. 2016). Other α-syn transgene 
models overexpress PD-related missense mutations of SNCA (e.g. A30P or A53T). Viral vectors, 
such as adeno-associated virus (AAV) or lentivirus, offer another approach to deliver α-syn 
transgene into the brain of wild-type animals which has been shown to recapitulate the essential 
neuropathological features of PD (Kirik et al. 2003, 2002; Lo Bianco et al. 2002). It is worthwhile to 
note, however, that transgenic α-syn models rely on the expression of supraphysiological levels of 
α-syn which might reduce their validity in mimicking sporadic PD pathology. 
Knockout of PRKN, PINK1 or DJ-1 genes seems to be insufficient to perturb the survival or function 
of nigrostriatal dopamine neurons or to induce formation of α-syn positive protein inclusions 
(Dawson et al. 2010; Blesa and Przedborski 2014). Due to the absence of consistent parkinsonian 
phenotype in single knockout mice, a triple knockout model with parkin, DJ-1 and PINK1 deletion 
was created (Kitada et al. 2009). However, even the inactivation of all three recessive PD genes 
was insufficient to induce loss of nigral dopamine neurons within the mouse lifespan. Only 
bacterial artificial chromosome (BAC) -mediated overexpression of truncated human PRKN 
(Q311X) in dopamine neurons has been shown to produce age-dependent degeneration of 
nigrostriatal dopamine system, accumulation of α-syn positive protein inclusions and late-onset 
motor deficits in mice (Lu et al. 2009). 
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MitoPark is an example of a genetic PD model that is not derived from any of the known PD-related 
genetic risk factors. In MitoPark mice, TFAM gene encoding mitochondrial transcription factor A 
(TFAM) is conditionally deleted from dopaminergic neurons (Ekstrand et al. 2007; Galter et al. 
2010; Good et al. 2011). TFAM is required for the transcription of mitochondrial DNA coding for 
essential subunits of the respiratory chain. MitoPark mice show apparent PD-like phenotype both 
on pathological and behavioral level. 
2.4.4 Alpha-synuclein pathology spreading model 
Recombinant α-syn preformed fibrils (PFFs) can be inoculated into various brain regions to induce 
propagating Lewy body-like pathology both in mice with different genetic backgrounds, rats and 
NHPs (Luk et al. 2012; Luk et al. 2012b; Rey et al. 2016; Abdelmotilib et al. 2017; Karampetsou et 
al. 2017; Thakur et al. 2017; Shimozawa et al. 2017; Chu et al. 2019; Henderson et al. 2019). PFF-
induced α-syn pathology triggers reactive microgliosis prior to dopaminergic degeneration in the 
SNpc suggesting that neuroinflammation contributes the vulnerability of dopamine neurons 
(Duffy et al. 2018). One advantage of this model is that the PD-like phenotype develops slower 
than in neurotoxin or AAV-α-syn overexpression models offering a therapeutic window for 
experimental interventions (Okuzumi et al. 2018). 
2.4.5 Behavioral and histological assessment in animal models 
As described in chapter 2.2, the nigrostriatal dopamine system plays a key role in regulating motor 
behavior. Thus, the degree of nigrostriatal degeneration in animal models of PD can be followed 
longitudinally by measuring motor deficits with specific behavioral tests (Asakawa et al. 2016; 
Dunnett and Lelos 2010). The behavioral tests that are commonly used to measure motor 
impairment in rodents include, but are not restricted to, drug-induced rotational behavior 
(rotametry), limb-use asymmetry (cylinder), open field, rotarod, stepping, skilled paw-reaching 
(staircase) and adhesive removal tests. The non-motor symptoms of PD can also be measured with 
various behavioral tests which are not, however, specifically designed for rodent models of PD. 
The brains of NHPs are anatomically and physiologically closest to the human brains making NHPs 
invaluable subjects in PD research (Emborg 2007; Porras et al. 2012). NHPs replicate almost all of 
the human parkinsonian motor symptoms after neurotoxin administration enabling much more 
versatile behavioral assessments as compared to other species, for example the use of various 
rating scales that imitate the clinically used Unified Parkinson’s disease Rating Scale (UPDRS).  
When studying disease-modifying therapies in animal models of PD, the decisive 
neuropathological outcomes (e.g. neuroprotective or restorative effects) can be obtained only 
with cellular and molecular level investigation after tissue collection. Histologically, the integrity 
of the nigrostriatal pathway can be measured by immunolabelling dopaminergic markers such as 
TH, DAT or VMAT2 and quantifying the number of immunoreactive cell bodies in the SNpc and the 
density of immunoreactive fibers in the dorsal striatum. Lewy body-like pathology can be 
visualized for example by immunostaining phosphorylated α-syn. In histological assessments, it is 
important to note that the expression levels of individual molecular markers are under divergent 




regulation. Thus, a combination of markers should be favored in order to draw reliable 
conclusions. 
2.5 Preclinical studies of neurotrophic factors for Parkinson’s 
disease 
Due to the dopaminotrophic properties of GDNF, NRTN, CDNF and MANF, their potential as a 
disease-modifying therapy for PD has been examined extensively both in vitro and in vivo. Here, 
an overview of the key preclinical studies, with the main focus on in vivo experiments in normal 
and lesioned nigrostriatal dopamine system, will be provided. 
2.5.1 Effects of neurotrophic factors on dopaminergic function of intact 
nigrostriatal system 
NTF delivery into the brain of a PD patient would be likely to affect both degenerating and intact 
neurons. Therefore, knowledge on the effects of exogenous recombinant NTFs not only on the 
pathological processes but also on the physiological functions of the brain is pivotal. 
Characterization of the effects of NTFs on normal, non-lesioned basal ganglia circuitry allows for 
improving their therapeutic efficacy and safety profile. 
2.5.1.1 Neurochemical and functional effects of exogenous GDNF 
The exogenous administration of GDNF elicits long-lasting neurochemical and functional changes 
in the intact nigrostriatal system. GDNF augments dopamine, DOPAC and HVA levels in tissue 
samples and induces spontaneous motor activity in young and aged animals (Hudson et al. 1995; 
Hebert et al. 1996; Martin et al. 1996; Hebert and Gerhardt 1997; Kobayashi et al. 1998; Grondin 
et al. 2003; Georgievska et al. 2004; Hadaczek et al. 2010). Dopamine turnover, measured as 
HVA/dopamine ratio, reflects the strength of dopaminergic transmission and is enhanced in GDNF-
treated animals. The abovementioned effects, however, are not specific to the dopaminergic 
system, since nigrostriatal serotonin, 5-hydroxyindoleacetic acid (5-HIAA) and noradrenaline 
levels are also altered. Intracranial GDNF injections are also associated with reduced food intake 
and body weight in experimental animals. Noteworthily, unilateral striatal delivery of GDNF has 
been shown to produce bilateral effects on dopamine neurochemical markers, neuronal activity 
and motor functions in normal animals as well as in PD patients (Grondin et al. 2003; Salvatore et 
al. 2009; Slevin et al. 2005; Stanford et al. 2007). 
GDNF has been shown to modulate the activity of dopaminergic nerve terminals. GDNF application 
increases stimulus-evoked dopamine release in cultured midbrain dopamine neurons as well as in 
striatal synaptosomes and slices (Feng et al. 1999; Gomes et al. 2006). Amperometric recordings 
showed that in primary cultures GDNF exposure increased the quantal size of dopamine-
containing synaptic vesicles (Pothos et al. 1998). With patch clamp technique, GDNF was 
demonstrated to acutely potentiate the excitability and synaptic transmission of dopamine 
neurons in midbrain cultures and slices by inhibiting A-type K+ channels and potentiating high 
voltage-gated Ca2+ channel currents (Bourque and Trudeau 2000; Yang et al. 2001; Wang et al. 
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2003). Similar effects have also been observed in vivo in brain microdialysis measurements. 
Intracranial administration of GDNF augmented stimulus-evoked overflow of striatal dopamine in 
non-lesioned rats (Hebert et al. 1996; Hebert and Gerhardt 1997; Cass et al. 1999; Salvatore et al. 
2004; Cass and Peters 2010) and NHPs (Gash et al. 1995; Grondin et al. 2003). These microdialysis 
studies, however, were conducted under general anesthesia which is known to have profound 
effects on neuronal activity, neurotransmitter synthesis, release, reuptake and metabolism 
(Marinelli and McCutcheon 2014; Müller et al. 2011). In a microdialysis study with freely-moving 
rats, no significant differences in potassium-evoked dopamine output was detected between 
GDNF- and vehicle-injected animals (Xu and Dluzen 2000). 
GDNF-induced enhancements in dopaminergic function are associated with a sustained increase 
in TH phosphorylation and activity. Exogenous GDNF has been shown to downregulate the 
expression of TH but increase its phosphorylation and activity (Beck et al. 1996; Rosenblad et al. 
2003; Georgievska et al. 2004; Kobori et al. 2004; Salvatore et al. 2004, 2009). The downregulation 
of TH may be a compensatory response to its enhanced activity. In line with this, in vivo TH activity 
is also elevated in MEN2B (multiple endocrine neoplasia type 2B) mice with constitutively active 
RET (Mijatovic et al. 2008). 
2.5.1.2 Neurochemical and functional effects of other NTFs 
Data on the molecular and functional effects of other exogenously administered GFLs, CDNF or 
MANF on the intact nigrostriatal system are scarce. Similarly to GDNF, striatal administration of 
NRTN has been shown to provoke some behavioral and neurochemical changes associated with 
functional upregulation of dopamine neurons. In non-lesioned rats, NRTN delivery augmented 
amphetamine-induced locomotor activity and caused a persistent increase in dopamine turnover 
(Horger et al. 1998; Hadaczek et al. 2010). A single nigral injection of NRTN increased stimulus-
evoked dopamine release in the striatum and tissue levels of dopamine in the SN of normal rats 
(Cass and Peters 2010). In naïve monkeys, striatal delivery of an AAV2 vector encoding human 
NRTN (CERE-120, see Table 2.3) increased the number of TH-ir cells in the SNpc and fibers in the 
striatum (Herzog et al. 2008, 2007). PET imaging demonstrated that 18F-dopa uptake was increased 
in the NTRN-transduced striatum as compared to the control side. 
2.5.1.3 Diffusion properties of GDNF, NRTN, CDNF and MANF in the intact brain 
The volume of distribution of exogenous GDNF and NRTN in the brain parenchyma is limited due 
to their high-affinity binding to extracellular matrix-associated heparan sulfates (Hamilton et al. 
2001; Piltonen et al. 2009; Runeberg-Roos et al. 2016). Poor diffusion of GDNF has also been 
demonstrated in the normal rhesus monkey brain (Lapchak et al. 1998; Salvatore et al. 2006). 
Intrastriatally administered MANF, instead, diffuses significantly better than GDNF in the intact rat 
brain distributing throughout the striatum and frontal cortex (Voutilainen et al. 2011, 2009). CDNF 
also diffuses rapidly in the intact rat brain resulting in widespread distribution that extends almost 
over the entire hemisphere at the level of the striatal infusion site (Mätlik et al. 2017). 




2.5.2 Effects of neurotrophic factors in animal models of Parkinson’s 
disease  
According to the initial findings, GDNF selectively promotes the survival and morphological 
differentiation of dopamine neurons in rat embryonic midbrain cultures and enhances their high-
affinity dopamine uptake (Lin et al. 1993). GDNF is also able to support the viability of nigral 
dopamine neurons in postnatally derived primary cultures by inhibiting natural cell death (Burke 
et al. 1998). In in vitro neurotoxin models, GDNF prevents the loss of cultured midbrain dopamine 
neurons in response to MPP+ or 6-OHDA (Eggert et al. 1999) and  promotes the recovery and 
regrowth of damaged dopamine neurons after the removal of the toxin challenge (Hou et al. 1996; 
Kramer et al. 1999). Likewise, NRTN supports the survival of dopamine neurons in embryonic 
midbrain cultures with similar potency and efficacy to that observed for GDNF (Cacalano et al. 
1998; Horger et al. 1998; Runeberg-Roos et al. 2016). MANF was shown to selectively increase the 
survival and sprouting of dopamine neurons in embryonic midbrain cultures (Petrova et al. 2003). 
CDNF protected primary neurons in embryonic midbrain cultures against cytotoxicity induced by 
6-OHDA and α-syn oligomers (Latge et al. 2015). The promising outcomes in in vitro studies have 
encouraged testing the neuroprotective and regenerative effects of GDNF, NRTN, CDNF and MANF 
in various animal models of PD. An overview of these in vivo studies is provided in Table 2.3. 
Notably, according to toxin-induced neurorestoration models, GDNF delivery into the striatum 
seems to provide better protection on TH-ir fibers in the striatum and result in more robust 
functional recovery as compared to nigral delivery. GDNF delivery to its physiological site of 
expression (i.e. the striatum) may be an underlying cause for this discrepancy (Kirik et al. 2004; 
Ibáñez and Andressoo 2017). 
A combined lentiviral vector-mediated transduction of CDNF and MANF into the SNpc led to 
synergistic neuroprotective effects in 6-OHDA-lesioned rats with reduced amphetamine-induced 
turning behavior and robust preservation of dopaminergic fibers in the striatum and cell bodies in 
the SNpc (Cordero-Llana et al. 2015c). Also, when CDNF protein was injected into the striatum of 
6-OHDA-lesioned rats together with GDNF, the co-administration resulted in stronger 
neurorestorative effects than either of the NTFs could produce alone (Voutilainen et al. 2017). The 
additive effects of the NTFs may stem from different mechanisms of action: both proteins 
activated the survival promoting PI3K/Akt signaling pathway and CDNF reduced the expression of 
ER stress-related markers GRP78, ATF6 and phosphorylated eIF2α. 
Continuous NTF infusion may cause ligand-dependent receptor desensitization decreasing the 
responsiveness of the target tissue to the treatment (Lohse 1993). To circumvent this risk, 
intermittent convection-enhanced delivery (CED), which enables target engagement in a pulsatile 
fashion, has been developed and tested in preclinical studies (Bobo et al. 1994; Gash et al. 2005). 
CED significantly enhances tissue distribution of macromolecules by delivering brief bolus 
infusions of a treatment solution in addition to low-rate basal infusion. 
 
 
Table 2.3. Disease-modifying effects of neurotrophic factors (NTFs) in animal models of Parkinson’s disease (PD). 
NTF Species; PD model 
Para-
digma NTF delivery NTF dose 
Neuropathological and  





Unilateral 6-OHDA-lesion in MFB 
Neuro-
restoration 
Single ipsilateral injection 
into SN 100 µg 
Preserved nigral DA and metabolite levels; 
increased survival of TH+ neurons and neurites in SN Reduced APO-induced rotations 
(Hoffer et al. 1994); 
(Bowenkamp et al. 1995) 
Mice;  
Repeated MPTP s.c. injections 
Neuro-
protection Single unilateral injection 
into SN or STR 10 µg 
Preserved nigrostriatal DA and metabolite levels, increased 
survival of TH+ neurons in SN and TH+ fibers in STR Increased locomotor activity (Tomac et al. 1995) Neuro-
restoration 
Partially preserved nigrostriatal DA and metabolite levels, 
increased survival TH+ fibers in STR 
Rats; 
Unilateral 6-OHDA-lesion in STR 
Neuro-
protection 
Single ipsilateral injection 
into SN, STR or LV 
25 µg,  
25 µg or 
50 µg 
Increased survival of TH+ neurons in SN (STR and SN 
delivery), increased survival TH+ fibers in STR (STR delivery) 
Normalized contralateral forelimb akinesia in 
stepping test, reduced APO- and AMPH-
induced rotations (STR delivery) 
(Kirik et al. 2000) 
Rats; 




ipsilateral transduction into 
SN, STR or SN+STR 
4x109 vg (SN),  
9x109 vg (STR) 
Increased survival of TH+ neurons in SN (SN, STR and 
SN+STR delivery), increased survival TH+ fibers in STR  
(STR delivery) 
Reduced AMPH-induced rotations, improved 
spontaneous contralateral paw use in cylinder 
and staircase test (STR delivery)  
(Kirik et al. 2000b) 
Rats; 




ipsilateral transduction into 
STR 
2.6x105 TU Increased survival TH+ fibers in STR Improved spontaneous contralateral paw use  in staircase test (Brizard et al. 2006) 
Rats; 
Unilateral 6-OHDA-lesion in STR 
Neuro-
protection Single ipsilateral injection 
into STR 10 µg 
Increased survival of TH+ neurons in SN and TH+ fibers  
in STR Reduced AMPH-induced rotations (Yue et al. 2014) Neuro-
restoration Increased survival of TH+ neurons in SN 
Rats; 
Unilateral lentiviral vector- 




ipsilateral transduction into 
SN 
? Lack of protective effect on TH+ neurons in SN and TH+ fibers in STR N.D. (Lo Bianco et al. 2004a) 
Rats; 
Unilateral AAV vector-transduction of 
wild-type hα-syn to SN 
Neuro-
protection 
Lentiviral or AAV vector-
mediated ipsilateral 
transduction into SN, STR 
or SN+STR 
3x104 TU (SN), 
4.5x104 TU (STR) 
Lack of protective effect on TH+ neurons in SN and TH+ and 
VMAT2+ fibers in STR, no effect on the number of  
α-syn+ aggregates 
Failed to reduce AMPH-induced rotations (Decressac et al. 2011) 
Monkeys; 




ipsilateral transduction into 
SN and STR 
2.4x109 vg (SN),  
6x109 vg (STR) 
Increased survival of TH+ and VMAT2+ neurons in SN, 
increased size of TH+ neurons in SN 
Improved rating scale scores, reduced AMPH- 
and APO-induced rotations (Eslamboli et al. 2003) 
Monkeys; 
Unilateral MPTP infusion via car. art. 
Neuro-
restoration 
Ipsilateral injection into SN, 
STR or LV 
1x150 µg,  
1x450 µg or 
3x100/450 µg 
Increased cell size and neurite density of TH+ neurons in SN 
(SN and STR delivery), preserved DA levels in ventral 
midbrain (ICV delivery) 
Improved rating scale scores in bradykinesia, 
rigidity, posture and balance (Gash et al. 1996) 
Monkeys; 
Unilateral MPTP infusion via car. art. 
Neuro-
restoration 
Single ipsilateral injection 
into LV  300 µg Preserved nigrostriatal DA and metabolite levels Improved rating scale scores (Gerhardt et al. 1999) 
Monkeys; 




ipsilateral transduction into 
SN+STR 
? Increased survival of TH+ neurons in SN and TH+ fibers  in STR 
Increased uptake in 18F-DOPA-PET, improved 
rating scale scores, reversed motor deficits in  
a hand-reach task 
(Kordower et al. 2000); 
(Emborg et al. 2009) 
Monkeys; 
Unilateral MPTP infusion via car. art. 
Neuro-
restoration 
Chronic infusion to 
ipsilateral LV or bilaterally 
into STR 
5 or 15 µg/24h 
Increased cell size and survival of TH+ neurons in SN, 
increased survival TH+ fibers in STR, preserved DA and 
metabolite levels in STR and GP 
Improved rating scale scores in bradykinesia, 
rigidity, posture and balance (Grondin et al. 2002) 
Monkeys; 
Unilateral MPTP infusion via car. art. 
Neuro-
restoration 
Pulsed, CED infusion into 
ipsilateral SN 
7.5 or 22.5 
µg/24h Increased cell size and survival of TH+ neurons in SN 
Improved rating scale scores, increased 




Unilateral 6-OHDA-lesion in STR 
Neuro-
restoration 
Single or repeated 
ipsilateral injection into SN 
1x1 or 1x10 µg or 
7x5 µg (every 3rd 
day) 
Increased survival of TH+ (single injection) and FG+ neurons 
in SN (single and repeated injections) N.D. (Horger et al. 1998) 
Rats; 




injections into STR or LV 
7x5 or 7x10 µg 
(every 3rd day) 
Increased survival of TH+ and FG+ neurons in SN (STR 





Unilateral 6-OHDA-lesion in STR 
Neuro-
protection Single ipsilateral injection 
into STR 5 µg 
Increased survival of TH+ neurons in SN, preserved striatal  
DA and metabolite levels Reduced MetAMPH-induced rotations, 
increased DA turnover (restoration study) (Oiwa et al. 2002) Neuro-
restoration 
Increased survival TH+ fibers in STR, preserved striatal  
DA and metabolite levels 
Rats; 
Unilateral 6-OHDA-lesion in STR 
Neuro-
protection 
AAV2 vector (CERE-120b) 
-mediated ipsilateral 
transduction into STR 
1.6x108, 8x108 or 
4x109 vg 
Increased survival of TH+ neurons in SN, increased survival  
of VMAT2+ fibers in STR 
Reduced AMPH-induced rotations, no effect on 
spontaneous forepaw use in the cylinder test 
(Gasmi et al. 2007) 
(Gasmi et al. 2007b) 
Monkeys; 
Unilateral MPTP infusion via car. art. 
Neuro-
restoration 
AAV2 vector (CERE-120b) 
-mediated ipsilateral 
transduction into SN+STR 
Total dose 
1.7x1011 TU 
Increased survival of TH+ neurons in SN and TH+ fibers  
in STR Improved rating scale scores (Kordower et al. 2006) 
Monkeys; 
Unilateral MPTP infusion via car. art. 
Neuro-
restoration 
Chronic infusion into 
ipsilateral STR 30 µg/24h Preserved DA metabolite levels in GP 
Improved rating scale scores, increased 





Unilateral 6-OHDA-lesion in STR 
Neuro-
protection Single ipsilateral injection 
into STR 
1-10 µg Increased survival of TH+ neurons in SN and TH+ fibers  in STR (3-10 µg) Reduced AMPH-induced rotations (3-10 µg) (Lindholm et al. 2007) Neuro-
restoration 10 µg Partially (N.S.) increased survival TH+ neurons in SN 
Rats; 
Unilateral 6-OHDA-lesion in STR 
Neuro-
restoration 
Chronic infusion into 
ipsilateral STR 1.5-4.5 µg/24h 
Increased survival of TH+ neurons in SN (3-4.5 µg/24h) and 
TH+ fibers in STR (1.5-4.5 µg/24h) Reduced AMPH-induced rotations (3 µg/24h) (Voutilainen et al. 2011) 
Mice;  
Repeated MPTP i.p. injections 
Neuro-
protection Single bilateral injections 
into STR 10 µg/side 
Increased survival of TH+ neurons in SN and TH+ fibers  
in STR Increased locomotor activity (Airavaara et al. 2012) Neuro-
restoration 
Rats; 




ipsilateral transduction into 
STR 
4x107, 2x108 or 
1x109 vg 
Partially (N.S.) increased survival TH+ neurons in SN (2x108 
and 1x109 vg), partially (N.S.) increased survival TH+ fibers  
in STR (1x109 vg) 
Reduced AMPH-induced rotations  
(2x108 and 1x109 vg) (Back et al. 2013) 
Rats; 




ipsilateral transduction into 
STR 
? 
Increased survival of TH+ neurons in SN and TH+ fibers  
in STR, preserved TH expression in SN, preserved TH and 
DAT expression in STR 
Reduced AMPH-induced rotations, increased 
locomotor activity, increased DAT-PET uptake 
in STR 
(Ren et al. 2013) 
Rats; 




ipsilateral transduction into 
SN or STR 
6x105 TU 
Increased survival of TH+ fibers in STR (SN delivery), lack of 
protective effect on TH+ neurons in SN (SN and STR delivery) 
and TH+ fibers in STR (STR delivery) 
Reduced AMPH-induced rotations (SN 
delivery), no effect on AMPH- or APO induced 
rotations (STR delivery) 
(Cordero-Llana et al. 
2015c) 
Rats; 
Unilateral 6-OHDA-lesion in MFB 
Neuro-
restoration 
Single ipsilateral injection 
into SN 1-100 µg No effect on TH+ neurons in SN and TH+ fibers in STR 
Modestly reduced APO- induced rotations  
(10 µg) (Huotarinen et al. 2018) 
Monkeys; 
Mild unilateral 6-OHDA-lesion in STR 
Neuro-
restoration 
Ipsilateral injection into 
STR (two injection sites) 2x10 µg No effects on TH+ fibers or neurons 
Increased DAT-SPECT uptake in STR 
(proper negative control group and between 
group comparisons are lacking) 






Unilateral 6-OHDA-lesion in STR 
Neuro-
protection Single ipsilateral injection 
into STR 
3-30 µg Increased survival of TH+ neurons in SN (10 µg) 
Reduced AMPH-induced rotations (10 µg) (Voutilainen et al. 2009) Neuro-
restoration 10 µg Partially (N.S.) increased survival TH+ neurons in SN 
Rats; 
Unilateral 6-OHDA-lesion in STR 
Neuro-
restoration 
Chronic infusion into 
ipsilateral STR 1.5-4.5 µg/24h 
Lack of protective effect on TH+ neurons in SN and TH+ fibers 
in STR No effect on AMPH-induced rotations (Voutilainen et al. 2011) 
Rats; 




ipsilateral transduction into 
SN or STR 
1.6x106 TU 
Increased survival of TH+ neurons in SN (SN delivery), lack of 
protective effect on TH+ neurons in SN (STR delivery) and 
TH+ fibers in STR (SN and STR delivery) 
No effect on AMPH- or APO induced rotations (Cordero-Llana et al. 2015c) 
Rats; 




ipsilateral transduction into 
STR 
2x1010 vg Increased survival of TH+ neurons in SN and TH+ fibers  in STR, increased striatal DA and metabolite levels Reduced AMPH-induced rotations (Hao et al. 2017) 
AAV, adeno-associated virus; AMPH, amphetamine; APO, apomorphine; car. art., carotid artery; CED, convection-enhanced delivery; DA, dopamine; DAT, dopamine transporter; FG, fluorogold; GP, glopus pallidus; hα-syn, 
human α-synuclein; i.p., intraperitoneal; LV, lateral ventricle; MFB, medial forebrain bundle; N.D., not determined; N.S., not significant; s.c., subcutaneous; SN, substantia nigra; STR, striatum; TH, tyrosine hydroxylase; TU, 
transducing units (lentiviral titer); vg, viral genomes (AAV titer); VMAT2, vesicular monoamine transporter 2 
a In neuroprotection paradigm, NTF is administered prior to, or at the same time as the lesion. A neuroprotective therapy slows down or prevents neurodegeneration. In neurorestoration paradigm, NTF is applied after the lesion 
when neuronal damage has occurred. Neurorestoration refers to recovery of damaged or impaired neuronal connections, somas, functionality or phenotype. 
b CERE-120 is an AAV2-derived vector encoding a hybrid form of human NRTN cDNA where the NRTN pre-pro domain is replaced with that of human NGF to ensure enhanced secretion (Ramirez et al. 2004; Gasmi et al. 2007)
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2.6 Neurotrophic factors in clinical trials for Parkinson’s 
disease  
The encouraging outcomes in preclinical studies spurred the assessment of intracerebrally 
delivered recombinant NTFs in PD patients. To date, four different trophic factors have entered 
clinical trials in PD: GDNF, NRTN, platelet-derived growth factor (PDGF) and most recently CDNF. 
A summary of these trials is provided in Table 2.4., excluding the placebo-controlled phase I/II 
study by Paul et al. (2015) assessing the safety and tolerability of intracerebroventricularly (ICV) 
infused PDGF-BB, which lies beyond the scope of this thesis. 
2.6.1 Clinical studies with GDNF 
The safety and efficacy of GDNF protein therapy as well as AAV2 vector -mediated gene therapy 
have been evaluated in several clinical trials in patients with advanced PD (Table 2.4.). In two 
separate open-label phase I trials, intraputamenal infusion of GDNF led to significantly improved 
motor function associated with increased 18F-DOPA uptake in the posterior putamen after one 
year of treatment and caused no serious adverse effects (Gill et al. 2003; Patel et al. 2005; Slevin 
et al. 2007, 2005). A case report described that these functional improvements sustained up to 
three years after the cessation of the protein infusion (Patel et al. 2013). Nevertheless, the primary 
endpoints in two double-blind, placebo-controlled phase I/II trials were not met (Nutt et al. 2003; 
Lang et al. 2006). ICV injections of GDNF failed to improve patients' UPDRS scores and caused 
severe side effects like nausea, vomiting, weight loss, anorexia and paresthesias (Nutt et al. 2003). 
The lack of efficacy was possibly due to a suboptimal delivery method; a postmortem histological 
analysis of one GDNF-treated subject from the study suggested the lack of target engagement by 
showing little penetration of GDNF into the brain parenchyma from the lateral ventricle (Kordower 
et al. 1999). Likewise, intraputamenal infusion of GDNF was unable to improve the off-medication 
UPDRS motor score although 18F-DOPA uptake was increased in GDNF-infused patients after six 
months of treatment (Lang et al. 2006). Intraputamenal infusion of GDNF, however, seemed to be 
better tolerated as compared to ICV injections: treatment-related adverse events included mainly 
paraesthesias, headache and upper respiratory tract infections in some subjects. In a few patients, 
neutralizing antibodies against the recombinant GDNF were detected. 
The discrepancies in the outcomes of these first trials could be attributed to insufficient 
bioavailability of GDNF in the target area (Sherer et al. 2006). The continuous low-rate 
intraputamenal infusion protocol utilized in Lang et al. (2006) study resulted in spatially limited 
and heterogenous distribution in the putamen (Salvatore et al. 2006). Intermittent intraputamenal 
CED delivery, instead, allows much wider and homogeneous exposure across the putamen and 
avoids receptor desensitization (Bobo et al. 1994; Lohse 1993). Thus, Whone and colleagues set 
out to evaluate the efficacy and safety of recombinant GDNF administered via intermittent 
intraputamenal CED infusion in a randomized, placebo-controlled phase II study (Whone et al. 
2019; Whone et al. 2019b). Although there was a clinically significant motor improvement in 43% 
of the GDNF-treated patients and overall increase in putamenal 18F-DOPA uptake in the GDNF 




group, the trial failed to meet its primary efficacy endpoint. The treatment administration setup 
used in this trial is illustrated in Figure 2.12. 
Table 2.4. Neurotrophic factors (NTFs) in clinical trials for Parkinson’s disease (PD). 










25, 75, 150, 300 or 
4000 μg for 6-8 
months  
+ 20 months open-









H&Y 3-5 (off) 
No improvement in UPDRS motor 
scores, various SAEs e.g. 
paresthesias, nausea, anorexia, 
weight loss and vomiting 
(Nutt et al. 2003) 
rhGDNF; 
putamen;  






+ 12 months 









57% improvement in UPDRS 
motor score (off) at 24 months, 
increased 18F-DOPA-PET uptake 
in putamen, sprouting of 
dopaminergic fibers, no therapy-
related SAEs 
(Gill et al. 2003) 
(Patel et al. 2005) 






3, 10 and 30 μg/day 
for  
6 months + 12 







H&Y 3-4 (off) 
45% bilateral improvement in 
UPDRS motor score (off) at 12 
months, no therapy-related SAEs, 
anti-GDNF antibodies in some 
patients 
(Slevin et al. 2005) 





















No improvement in UPDRS motor 
score (off), increased 18F-DOPA-
PET uptake in putamen, well 
tolerated, anti-GDNF antibodies in 
some patients 







120 μg/putamen  
for 9 months +  









H&Y 2-3 (off) 
No improvement in UPDRS motor 
score (off), increased 18F-DOPA-
PET uptake in putamen, no 
therapy-related SAEs 
(Whone et al. 2019) 














H&Y 3-4 (off) 
No improvement in UPDRS motor 
scores, increased 18F-DOPA-PET 
uptake in putamen, no therapy-
related SAEs, anti-GDNF and anti-
AAV2 antibodies in some patients 

















H&Y 3-4 (off) 
36% improvement in UPDRS 
motor score (off) at 12 months, no 
increase in 18F-DOPA-PET 
uptake, no therapy-related SAEs 






5.4x1011 vg  
+ double-blind 












No improvement in UPDRS motor 
score (off) at 12 months, no 
increase in 18F-DOPA-PET 
uptake, improved PDQ-39 score 
at 12 months, improved UPDRS 
motor score (off) at 18 months 
(n=30), no therapy-related SAEs 







2x1011 vg/SN + 
2.7x1011 vg/putamen 






H&Y 2-3 (off) 
Well-tolerated, no therapy-related 
SAEs 






2x1011 vg/SN  








H&Y 2-3 (off) 
No improvement in UPDRS motor 
score (off), no therapy-related 
SAEs, anti-AAV2 antibodies in 
some patients 










dose for 6 months + 












related SAEs, potentially improved 
UPDRS motor score in some 
patients at 12 months, increased 
DAT-PET uptake in putamen of 
some patients, ongoing analyses 
of exploratory endpoints 
(Huttunen and Saarma 
2019) 
NCT03295786a 
AAV2, adeno-associated virus serotype 2; CED, convection-enhanced delivery; H&Y, Hoehn and Yahr scale of Parkinson’s disease symptoms; off, 
off medication; PDQ-39, a 39-item Parkinson’s disease Questionnaire to assess health and quality of life; rh, recombinant human; SAE, serious 
adverse event; SN, substantia nigra; UPDRS, Unified Parkinson’s Disease Rating Scale; vg, viral genomes 
a ClinicalTrials.gov identifier; b CERE-120 
Viral vector -mediated gene transfer provides another opportunity for targeted delivery of 
therapeutic proteins into restricted brain regions in a safe and sustained manner. Gene therapy 
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may also enhance the tissue distribution of the expressed protein. An open-label phase I trial 
sought to assess the safety and effectiveness of bilateral intraputamenal AAV2-GDNF gene 
therapy in advanced PD (Heiss et al. 2019). Delivery of AAV2-GDNF using intraoperative MRI-
guided CED infusion was safe and well tolerated. It also increased 18F-DOPA uptake in the putamen 
suggesting a neurotrophic effect on dopaminergic neurons but failed provide any clinically 
significant improvements in the UPDRS scores. 
 
Figure 2.12. Intracranial administration of GDNF to Parkinson’s disease patients in a clinical trial. (A) 
A manikin head demonstrating the drug delivery system used in the study. An application set coming 
from infusion pumps was attached to a skull-mounted transcutaneous port. Intracranially implanted 
catheters were also connected to the skull-mounted port. (B) The skull-mounted port was relatively 
imperceptible. It was the only external component when a patient was not receiving an infusion. (C) 
An axial MRI image at the level of the putamen shows two of catheters entering either side of the brain 
posteriorly and reaching the putamen. Gadolinium test infusate can be seen distributed throughout 
both putamen. (D) A single patient receiving GDNF infusion. (E) Three patients receiving their monthly 
GDNF infusions in a study infusion suite. Image reproduced from (Whone et al. 2019), under the terms 
of the Creative Commons Attribution 4.0 International. 
2.6.2 Clinical studies with NRTN 
Supported by the promising safety and efficacy outcomes in preclinical animal studies, 
intraparenchymal injections of AAV2 vector encoding human NRTN (CERE-120) have been 
evaluated in several clinical trials (Table 2.4.). In an open-label phase I study, AAV2-NRTN injected 
into the putamen showed evidence for safety and produced a 36% increase in the off-medication 
UPDRS motor score as compared to the baseline at 12 months (Marks et al. 2008). However, in a 
12-month double-blind phase II trial, the intraputamenal AAV2-NRTN gene transfer failed to show 
superiority to sham surgery when assessed using the off-medication UPDRS motor score (Marks 
et al. 2010). Interestingly, a subgroup of patients, who were followed in a double-blind manner up 
to 18 months, revealed a small but significant clinical benefit in favor of AAV2-NRTN suggesting a 
possibility for a delayed effect. In addition, the gene therapy was well tolerated and improved 
several secondary outcome measures both at 12 and 18 months. 




In contrast to the findings in MPTP-treated monkeys (Kordower et al. 2006; Herzog et al. 2007), 
brain autopsy data from four PD subjects who died from unrelated causes after intraputamenal 
administration of AAV2-NRTN showed impaired axonal transport of NRTN from the putamen to 
SNpc (Bartus et al. 2011; Bartus et al. 2015). To overcome this axonal transport deficiency, the 
next studies utilized a new dosing paradigm: AAV2-NRTN was injected into the SNpc in 
combination with putamenal delivery to activate repair genes directly in the cell bodies, and 
thereby enhance the potential trophic effects. Nonetheless, after encouraging safety outcomes in 
an open-label phase I study (Bartus et al. 2013), a sham-surgery controlled double-blind phase II 
trial failed to meet the primary endpoint assessed by the off-state UPDRS motor score at 15-month 
time point (Olanow et al. 2015). Postmortem analysis of two patients from these studies 
demonstrated that AAV2-NRTN delivery provided persistent, but spatially restricted, transgene 
expression in the putamen and SN still at 8 and 10 years after the transfection (Chu et al. 2020). 
NRTN expression was associated with focal sprouting and upregulation of TH expression, but not 
with antiparkinsonian effects such as reduced Lewy pathology when compared to untreated PD 
control subjects. 
2.6.3 The first clinical study with CDNF 
The first-in-human, double-blind, placebo-controlled phase I/II study investigating the safety and 
efficacy of intraputamenal CDNF application in 17 patients with moderate PD was recently 
completed (Huttunen and Saarma 2019; ClinicalTrials.gov identifier NCT03295786). The study 
consisted of two parts: the initial 6-month main study in which patients were assigned to receive 
either placebo or two dose levels of CDNF, and the 6-month open-label extension part during 
which all patients received one of the two doses of CDNF. The company announced in a press 
release that the study achieved its primary endpoint of safety and tolerability at 12 months 
(Herantis Pharma Plc, press release 27 August 2020). Two patients had to discontinue the study 
due to adverse events related to the implanted dose delivery system. Treatment-related adverse 
events, however, were transient and mild. The preliminary non-statistical assessment of the 
secondary endpoints suggests an improvement in the UPDRS motor score in some patients at 12 
months supporting the potential efficacy of CDNF therapy. The exploratory endpoints included 
DAT-PET imaging which showed encouraging response in the putamen of some CDNF-treated 
individuals. Noteworthily, the final analyses of the secondary and exploratory outcomes including 
CSF proteomics and α-syn measurements are still underway.  
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3 AIMS OF THE STUDY 
The promising preclinical results of GDNF and NRTN have failed to translate into an effective 
disease-modifying treatment for PD. Therefore, to fulfill this unmet medical need, new approaches 
for neurotrophic therapies have to be explored. The studies were executed to support the 
preclinical characterization of unconventional NTFs, CDNF and MANF, and novel small molecule 
RET agonists. We aimed to uncover the functional effects of intracranially administered CDNF and 
MANF in the normal rat brain and to clarify the neuroprotective potential of RET agonists in a rat 
model of PD. 
 
The specific objectives were to determine: 
 
 
1. the effects of exogenously administered GDNF, CDNF and MANF on dopamine and GABA 




2. the diffusion and transport properties of CDNF after injection to the substantia nigra of 
non-lesioned rats (Study II) 
 
 
3. the neuroprotective and neurorestorative effects of small molecule RET agonists in a 6-
OHDA model of PD in rats (Studies III and IV).  




4 MATERIALS AND METHODS  
The main methods used by the author in studies I-IV are shortly described here. More 
comprehensive descriptions of the materials and methods can be found in the original 
publications and their supplementary materials which are attached to the thesis. 
4.1 Animals 
Adult Wistar male rats (RccHan:WIST, Harlan, the Netherlands) were used for all experiments in 
study I and II, for the neuroprotection experiment in study III and for the neurorestoration 
experiment in study IV. Rats were normally housed in groups of 3-4 per cage under a 12h light/dark 
cycle (lights on 06:00-18:00). All experiments were performed during the light period. Rats had ad 
libitum access to rat chow and tap water at all times. In study I, rats were moved to individual 
microdialysis cages (30 × 30 × 30 cm) after the surgery. In studies III and IV, rats were housed in 
individual cages during the brain infusion of the treatments but regrouped again after removing 
the infusion cannulas and minipumps. The animal experiments were reviewed and approved by 
the National Animal Experiment Board of Finland (ESLH-2009-05234/Ym-23; 
ESAVI/5459/04.10.03/2011; ESAVI/7551/04.10.07/2013; ESAVI/ 198/04.10.07/2014 and 
ESAVI/7812/04.10.07/2015) and carried out in accordance with the European Union directive 
2010/63/EU on the protection of animals used for scientific purposes. 
4.2 Drugs, toxins and neurotrophic therapies 
4.2.1 Neurotrophic factors 
The following NTFs were used: recombinant human (rh) GDNF (ProSpec-Tany TechnoGene Ltd., 
Israel) (study I and unpublished experiment), rhGDNF (PeproTech Inc., USA) (studies III and IV), 
rhCDNF (Biovian Oy, Finland) (studies I, II and unpublished experiment) and rhMANF (Icosagen AS, 
Estonia) (study I and unpublished experiment). NTFs were diluted in sterile phosphate-buffered 
saline, pH 7.4 (PBS) which also served as a vehicle control in studies I, IV and unpublished 
experiment. 
4.2.2 Small molecule RET agonists 
BT13 (N,N-diethyl-3-(4-(4-fluoro-2-(trifluoromethyl)benzoyl)piperazin-1-yl)-4-methoxy-benzene-
sulfonamide), MW 517.54 g/mol (study III), and BT44 ((4-5-((3,4-dihydroisoquinolin-2(1H)-
yl)sulfonyl)-2-methoxy-phenyl)piperazin-1-yl(4-fluoro-2-(trifluoromethyl)phenyl)-methanone), 
MW 577.59 g/mol (study IV), were synthesized by EvoBlocks Ltd. (Hungary). The structure and 
integrity of the compounds were verified by NMR spectrometry, and the purity by liquid 
chromatography–mass spectrometry (BT13, 98.6%) or high-performance liquid chromatography 
(HPLC) (BT44, 97.3%). BT13 and BT44 were dissolved in 100% propylene glycol (PG) for the in vivo 
neuroprotection and -restoration experiments due to limited solubility in aqueous solutions 
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(studies III and IV). Their long-term stability in PG at 37°C was confirmed before the in vivo 
experiments. PG was used as a vehicle control in the studies. 
4.2.3 Neurotoxin 
In studies III and IV, dopaminergic lesions were induced using intracranial injections of 6-OHDA (6-
hydroxydopamine hydrochloride, Sigma-Aldrich GmbH, Germany), dissolved in ice-cold, de-
oxygenated saline with 0.02% ascorbic acid. Desipramine hydrochloride 15 mg/kg, i.p. (calculated 
as free base; Sigma-Aldrich) was administered 30 min before the 6-OHDA injection to prevent the 
uptake of 6-OHDA into noradrenergic nerve terminals. 
4.2.4 Drugs 
Isoflurane (Vetflurane® 1000 mg/g, Virbac SA, France) was administered via inhalation to induce 
and maintain general anesthesia during stereotaxic surgeries. Lidocaine-adrenalin solution 
(Lidocain 10 mg/ml c. adrenalin, Orion Pharma Oyj, Finland) was used for local anesthesia. To 
relieve postoperative pain, rats received tramadol 1 mg/kg, s.c. (Tramal® 50 mg/ml, Orion Pharma) 
at the end of the surgeries (study I), or buprenorphine 0.05 mg/kg, s.c. (Temgesic® 0.3 mg/ml, 
Indivior UK Limited, United Kingdom) before and carprofen 5 mg/kg, s.c. (Rimadyl Vet® 50mg/ml, 
Zoetis Inc., USA) immediately after the surgeries (studies II-IV). Additional doses of the analgesics 
were given one day later. 
D-amphetamine sulfate (Division of Pharmaceutical Chemistry and Technology, University of 
Helsinki, Finland) was used to stimulate dopamine overflow from striatal nerve terminals in study 
I and induce turning behavior in unilaterally 6-OHDA lesioned rats in studies III and IV. In GABA 
microdialysis experiment (unpublished), nipecotic acid (Sigma-Aldrich) served as a universal 
inhibitor of GABA transporters (IC50 ~18 μM). For in vivo TH activity experiment in study I, rats 
were administered with 3-hydroxybenzylhydrazine (NSD1015) (Sigma-Aldrich) to inhibit AADC in 
the brain. Clorgyline (IC50 ~1.2 nM) and pargyline (IC50 ~8.2 nM) (included in the Monoamine 
Oxidase Assay Kit, MAK136, Sigma-Aldrich) were used to irreversibly inhibit MAO-A and MAO-B 
activities, respectively, in MAO activity experiment in study I. Before transcardial perfusions in 
studies II-IV, rats were deeply anesthetized with sodium pentobarbital (Mebunat Vet® 60 mg/ml, 
Orion Pharma). 
4.3 Stereotaxic surgeries 
All stereotaxic surgeries were performed under isoflurane anesthesia (3.5–4.5% during induction 
and 2.0–3.5% during maintenance) using a stereotaxic frame (Stoelting Co., USA). The skull was 
exposed and burr holes were made using a high-speed drill (Foredom Electric Co., USA). NTFs, RET 
agonists, vehicles and 6-OHDA were administered into the target brain regions as described below. 
Brain injections were made using an electronic microinjector (Quintessential stereotactic injector, 
Stoelting) and 10-μl syringes with 26G (Hamilton Co., USA) (studies I-III) or 33G (NanoFil, World 
Precision Instruments, USA) (study IV) blunt tapered needle attached. At the completion of the 
injections, the needle was kept in place for 4-5 min to minimize backflow of the solution. All 




coordinates were determined relative to the bregma, according to the rat brain atlas (Paxinos and 
Watson 1998). After the surgeries, rats were allowed to recover at least one week before 
microdialysis or behavioral experiments. 
4.3.1 Neurotrophic factor injections and guide cannula implantation 
In study I, a unilateral injection of GDNF, CDNF or MANF (10 μg in 5 μl) or PBS (5 μl) was made into 
the left dorsal striatum (A/P +1.0, M/L +2.7, D/V −5.0 mm). The injection rate was 1.0 μl/min. For 
the enzyme activity assays, the incision was sutured after the injection. For the microdialysis 
experiments, a guide cannula (BASi MD-2250, Bioanalytical Systems Inc., USA) was implanted after 
the NTF injection.	The tip of the cannula was placed into the left dorsal striatum (A/P +1.0, M/L 
+2.7, D/V − 4.0 mm) for dopamine release measurements, or into the left GPe (A/P -1.4, M/L +3.5, 
D/V -5.5 mm) for GABA release measurements. Thereafter, the cannula was fixed to the skull with 
three stainless steel screws and polycarboxylate cement (Aqualox, Voco GmbH, Germany). In 
study II, CDNF (3 μg in 4 μl, or 3 μg in 1 μl) was injected into the left SN (A/P −5.4, M/L +2.0, D/V 
−7.2 mm) with the flow rate of 0.5 μl/min. The incision was sutured after the injection. 
4.3.2 6-OHDA injections 
In study III, rats received a single unilateral injection of 6-OHDA (16 μg in 4 μl; calculated as free 
base) into the left dorsal striatum (A/P +1.0, M/L +2.7, D/V -4.0 mm) at the flow rate of 1.0 μl/min. 
In study IV, 6-OHDA injections were made into three different sites in the right dorsal striatum 
(A/P +1.6, M/L -2.8, D/V -6.0 mm; A/P 0.0, M/L -4.1, D/V -5.5 mm; and A/P -1.2, M/L -4.5, D/V -5.5 
mm) with the dose of 3 μg in 1.5 μl per site and flow rate of 0.5 μl/min (Penttinen et al. 2016). The 
needle was kept at a 10° angle to avoid lateral ventricles. Lastly, the scalp incision was closed with 
sutures. 
4.3.3 Infusions of RET agonists and GDNF with osmotic minipumps 
Osmotic infusion pumps (Alzet Osmotic pump model 2002, Durect Co., USA), connected with 
catheter tubing to brain cannulas (Alzet Brain infusion kit no. 2, Durect), were used to deliver RET 
agonists, GDNF and vehicles into the lesioned dorsal striatum in studies III and IV. The pumps were 
aseptically filled with study solutions and allowed to reach the steady-state pumping rate by 
incubating overnight in isotonic saline at 37°C. The pumps and cannulas were implanted in a 
stereotaxic surgery one hour (study III) or two weeks (study IV) after the 6-OHDA injections. The 
pump was placed into a subcutaneous pocket between the scapulae. The tip of the cannula was 
lowered to coordinates A/P +1.0, M/L +2.7, D/V -4.0 mm (study III) or A/P +0.2, M/L -3.0, D/V -5.0 
mm (study IV) after which the cannula was secured to the skull with three stainless steel screws 
and polycarboxylate cement (Aqualox). 
In study III, the pumps constantly delivered BT13 ~3-6 μg/24h (0.25-0.5 μg/μl), GDNF 3 μg/24h 
(0.25 μg/μl) or 100% PG into the dorsal striatum at the flow rate of 0.5 μl/h for seven days. The 
dose for BT13 could not be determined accurately because the solubility of BT13 in 100% PG was 
limited to 0.5 μg/μl in stabile test tube conditions at 37°C. In study IV, the pumps infused BT44 0.1 
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μg/24h (8.3 ng/μl), BT44 0.3 μg/24h (25 ng/μl), GDNF 3 μg/24h (0.25 μg/μl), 100% PG or PBS at 
the flow rate of 0.5 μl/h for 14 days. The doses for BT44 were selected based on the potency of 
the compound in neuronal survival assay in vitro where it showed at least 10 times higher potency 
as compared to BT13. Therefore, 10-20 and 30-60-times lower doses of BT44 were chosen for 
study IV than were used for BT13 in study III. After the treatment infusions, the pumps, cannulas 
and screws were removed, and the incision was cleaned, disinfected and sutured. 
4.4 Microdialysis experiments 
Microdialysis experiments were carried out in freely-moving rats one and three weeks after the 
stereotaxic injection of NTFs and implantation of guide cannulas (study I and unpublished 
experiment). The one-week time point was selected based on an earlier brain microdialysis 
experiment with GDNF in freely-moving rats (Xu and Dluzen 2000). The three-week time point 
served to probe the long-term effects of NTFs on dopamine and GABA transmission. Proper 
function of the microdialysis probes (BASi MD-2200, Bioanalytical Systems, membrane length 2 
mm) was verified with in vitro recovery test at room temperature before the experiments but in 
vivo dialysate concentrations were not corrected for in vitro recoveries. In each experiment, the 
probe was inserted into the guide cannula and perfusion of the microdialysis membrane was 
started with modified Ringer solution (147 mM NaCl, 2.7 mM KCl, 1.2 mM CaCl2, 1.0 mM MgCl2, 
0.04 mM ascorbic acid) at the flow rate of 2.0 μl/min. After a two-hour stabilization period, 
dialysate samples were collected every 15 min for 270 min (study I) or 150 min (unpublished 
experiment) as described below and in Figure 4.1.	To minimize variation between the subjects, 
the results were analyzed as percent changes of the analyte concentrations from the baseline 
levels instead of actual analyte concentrations. In addition, the conventional microdialysis (as 
opposed to no-net-flux microdialysis) used here is not a suitable method to measure exact analyte 
concentrations in the extracellular fluid. After the first microdialysis experiment at week 1, the 
probe was removed from the brain. After the second experiment at week 3, rats were sacrificed 
and the brains were collected to verify the correct placements of the probes. Data only from the 
rats with accurate probe placements were included in the analyses. 
Figure 4.1. Time course of the dopamine and GABA microdialysis experiments. The lag time between 
the administration of a stimulation solution and the corresponding response is due to slow flow rate 
of the perfusion solution (2.0 μl/min) and large dead volume of the long tubes. Figure drawn by the 
author. 
In the dopamine microdialysis experiment (study I), dopamine, DOPAC and HVA concentrations in 
the first four samples were used to calculate the baselines. To depolarize the striatal nerve 
terminals and evoke dopamine release, 100 mM potassium solution (27.5 mM NaCl, 100 mM KCl, 




1.2 mM CaCl2, 1.0 mM MgCl2, 0.04 mM ascorbic acid) was administered for 15 min via reverse 
dialysis starting at 15 min. To stimulate dopamine release for the second time by draining synaptic 
dopamine vesicles and reversing DAT function, 100 μM D-amphetamine (in modified Ringer) was 
administered via reverse dialysis for 15 min starting at 120 min. The analyte concentrations were 
quantified right after collecting the samples using a HPLC system with a C18 reverse-phase column 
(Kinetex C18, Phenomenex Inc., USA) and an electrochemical detector (Coulochem II, ESA 
Biosciences Inc., USA). 
In the GABA microdialysis experiment (unpublished), reuptake of GABA into neurons and glial cells 
was blocked with 100 µM nipecotic acid which was included in the Ringer solution during the 
whole experiment (Vihavainen et al. 2008). The baseline level for GABA was calculated as an 
average in the first three samples. To stimulate GABA release, modified Ringer solution with 50 
mM potassium (100 µM nipecotic acid, 99.7 mM NaCl, 50 mM KCl, 1.2 mM CaCl2, 1.0 mM MgCl2) 
was delivered for 15 min starting at 3 min (reverse dialysis). The samples were stored at -80°C until 
analyzing with a HPLC system equipped with a C18 reverse-phase column (Kinetex C18, 
Phenomenex) and a fluorescence detector (Jasco FP-1520, Jasco Co., United Kingdom) as 
described in detail elsewhere (Julku et al. 2016; Piepponen and Skujins 2001). To enable sensitive 
fluorometric detection of GABA, it was derivatized with a mixed o-phthaldialdehyde (Sigma-
Aldrich) and 2-mercaptoethanol (Sigma-Aldrich) reagent before the samples were injected into 
the column. 
4.5 Enzymes activity measurements 
Seven days after the intrastriatal injections of NTFs or vehicle in study I, tissue samples were 
collected from the dorsal striatum for enzyme activity measurements. Rats were decapitated, and 
the brains were excised rapidly and rinsed in ice-cold saline. Bilateral striatal punches were 
collected from coronal slices with a 3-mm sample corer, snap frozen on dry ice and stored at -
80°C. Later, the samples were weighed, homogenized and centrifuged. 
For in vivo TH activity measurement, rats were administered with a BBB penetrating AADC 
inhibitor	NSD1015 100 mg/kg, i.p., 30 min before tissue collection (Vihavainen et al. 2008). After 
sample preparation, the S1 supernatants filtered with Vivaspin® 500 filter concentrators (10,000 
MWCO PES; Sartorius Stedim Biotech GmbH, Germany) were analyzed with a HPLC system 
equipped with a C18 reverse-phase column (Kinetex XD-C18, Phenomenex) and an 
electrochemical detector (ESA CoulArray Electrode Array, ESA Biosciences) to measure the 
amount of accumulated L-DOPA as ng/g wet weight of the tissue specimen (Valros et al. 2015).	
For COMT, MAO-A and MAO-B activity assays, the total protein concentration was determined 
using bicinchoninic acid method (PierceTM BCA Protein Assay Kit, ThermoFisher Scientific Inc., 
USA). Total COMT activity was measured as described in (Schendzielorz et al. 2012; Smith et al. 
2014). The reaction products, vanillic and isovanillic acid, were analyzed with HPLC using an 
electrochemical detector (Coulochem II, ESA Biosciences). MAO-A and MAO-B activities were 
determined with Monoamine Oxidase Assay Kit (MAK136, Sigma-Aldrich). To differentiate MAO-
A and MAO-B activities, isoform-specific inhibitors (5 μM of clorgyline for MAO-A and 5 μM of 
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pargyline for MAO-B) were used. The fluorescence of the samples was measured with a multi-well 
plate reader (Victor2, 1420 Multilabel Plate Reader, PerkinElmer Inc., USA) using wavelengths 530 
nm and 590 nm for excitation and detection, respectively. 
4.6 Behavioral tests 
In studies III and IV, behavioral tests were conducted at defined timepoints as indicated in Figure 
4.2. which shows the designs of the neuroprotection (A; study III) and neurorestoration (B; study 
IV) experiments. All behavioral assessments were carried out in a blinded manner. 
 
 
Figure 4.2. Experimental design for the neuroprotection and neurorestoration experiments. The 
neuroprotective effect of BT13 (A) and neurorestorative effect of BT44 (B) were investigated in a 
unilateral 6-OHDA model of PD in rats. Amph I-III: amphetamine-induced (2.5 mg/kg, i.p.) rotational 
asymmetry tests, Cylinder I and II: cylinder tests. Figure drawn by the author. 
4.6.1 Amphetamine-induced rotational behavior 
Amphetamine-induced rotational asymmetry test was used to measure motor deficits arising from 
the unilateral 6-OHDA lesion of the nigrostriatal dopamine system. Rotational behavior was 
monitored in automated rotometer bowls (Med Associates Inc., USA) as described previously in 
(Ungerstedt and Arbuthnott 1970; Lindholm et al. 2007). After a 30-min habituation period, rats 
received a single injection of D-amphetamine 2.5mg/kg, i.p. (calculated as free base). The number 
of full (360°) uninterrupted clockwise and counterclockwise turns was recorded for 120 min. Net 
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ipsilateral turns to the lesion side were calculated by subtracting contralateral turns from 
ipsilateral turns. 
4.6.2 Cylinder test 
In study IV, cylinder test was used to evaluate spontaneous limb-use asymmetry. Cylinder tests 
were carried out before the amphetamine-induced rotational asymmetry tests using a protocol 
described by (Schallert et al. 2000; Tillerson et al. 2001). Briefly, rats were placed in a transparent 
plexiglass cylinder (diameter ~20 cm, height ~30 cm) and their exploratory activity was recorded 
for 10 min with a video camera placed under the cylinder. The number of weight-shifting 
movements against the wall was scored individually for the ipsilateral (non-impaired) and 
contralateral (impaired) forepaws. A simultaneous placement of both forepaws on the wall as well 
as lateral exploration along the wall by alternating right and left forepaw placements were scored 
as “both paw contacts”. After a rear, the first weight-receiving contact to the ground was scored 
as a landing contact for the forepaw used for landing, or as a “both paw contact” if both paws 
contacted the ground simultaneously. Percentual limb-use asymmetry score was first calculated 
separately for wall exploration and landing using the following formula (Schallert and Woodlee 
2005): 
!"#!$%&'(%$	*+,&%*&# + 0.5 × 	2+&ℎ	"%4	*+,&%*&#
!"#!$%&'(%$ + *+,&(%$%&'(%$ + 2+&ℎ	"%4	*+,&%*&# × 100% 
Finally, the mean of these scores was used as an averaged asymmetry score. Scores >50% indicate 
greater reliance on the ipsilateral (non-impaired) forelimb and <50% on the contralateral 
(impaired) forelimb. 
4.7 Perfusion and brain sectioning 
After completing the microdialysis (study I) or behavioral experiments (studies III and IV), or 2-24 
h after CDNF injections in the diffusion study (study II), rats were deeply anesthetized with sodium 
pentobarbital 90 mg/kg, i.p., and transcardially perfused with PBS and 4% paraformaldehyde (PFA) 
in PBS. The brains were removed, post-fixed in 4% PFA overnight and stored in 20% sucrose in PBS 
at 4°C until snap freezing in dry ice-cooled isopentane. The frozen brains were cut into 40 µm-
thick coronal sections with a cryostat (Leica CM3050, Leica Biosystems, Germany). The sections 
were collected in a series of six sections and stored in cryoprotective buffer at -20°C. For the 
diffusion study (study II), some brains were embedded in paraffin and cut to 5 μm sagittal sections 
(M/L 1.4-3.4 mm), taking every 10th section. The paraffin sections were collected on microscope 
slides and stored at 4°C.  
4.8 Immunohistochemistry 
Immunohistochemical labelling was performed on free-floating coronal (studies II-IV) or paraffin-
embedded sagittal (study II) sections using standard immunohistochemical procedures as 
described in detail in the original publications. The primary and secondary antibodies used in the 
experiments are listed in Table 4.1.
 
 
Table 4.1. Primary and secondary antibodies used for immunohistochemical labelling. 
Primary antibodies Secondary antibodies 
Studies 
Antibody Cat#,  Supplier Reactivity 
Concentration; 













+4°C o/n  
Goat anti-rabbit Biotin 
BA-1000,  
Vector Laboratories Inc., 
USA 
1:200;  




Horse anti-rabbit Biotin BA-1100,  Vector Laboratories 
1:200;  
RT 1h II 
Goat anti-rabbit AlexaFluor488 A-11034,  ThermoFischer Scientific 
1:200;  












Goat anti-mouse AlexaFluor568 A-11004,  ThermoFischer Scientific 
1:200;  
RT 2h II 











Horse anti-mouse Biotin BA-2001,  Vector Laboratories 
1:200;  




Goat anti-mouse AlexaFluor568 A-11004,  ThermoFischer Scientific 
1:200;  











Rabbit anti-rat Biotin BA-4000,  Vector Laboratories 
1:200;  
RT 1h III 










Protein A (binds to 
IgG:s of rabbit, 
mouse, human, 
guinea pig etc.) 
Biotin 
MP Biomedicals, USA 
(protein A), Sigma-Aldrich 
(N-hydroxysuccinimido-
biotin), conjugated in-house 
1:100;  
RT 1h IV 









Goat anti-rabbit Biotin BA-1000,  Vector Laboratories 
1:500;  
RT 1h IV 
RT, room temperature; o/n, overnight; TH, tyrosine hydroxylase; DAT, dopamine transporter; IgG, immunoglobulin G
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4.9 Histological analyses 
The striatum and midbrain sections were stained for TH and DAT to assess the density of 
dopaminergic fibers in the striatum and the number of dopamine neurons in the SNpc. 
4.9.1 Fiber density in the striatum 
The optical densities of TH-ir and DAT-ir fibers in the dorsal striatum were measured bilaterally 
from three different rostro-caudal levels through the striatum from each rat (studies III and IV). 
The analyses were performed under blinded conditions. First, digital images of the immunostained 
sections were acquired with an automated bright field microscope whole slide scanner 
Pannoramic P250 Flash II (3DHistech Ltd., Hungary). The images were converted to 8-bit gray scale, 
and colors were inverted. The dorsal striata were outlined, and integrated optical densities divided 
by the size of the outlined areas were measured with Fiji ImageJ software (Media Cybernetics Inc., 
USA). All density values were corrected for nonspecific background staining measured from the 
corpus callosum. The data are expressed as percentage of the fiber density on the lesioned 
hemisphere as compared to the intact hemisphere. The total magnitude of striatal denervation 
was estimated as an average reduction in the fiber density at the three levels measured. 
4.9.2 Cell counts in the SNpc 
In studies III and IV, the number TH-ir cells in the SNpc was estimated in a blinded manner with 
the optical fractionator method and dissector principle according to unbiased counting rules (West 
et al. 1991). Olympus BX51 microscope (Olympus Co., Japan) was connected to a computer 
running Stereo Investigator platform (MBF Bioscience Inc., USA), and cell counting was done 
bilaterally under 60x magnification (Olympus PlanApo 60x 1.40 Oil /0.17 objective) from three 
sections per brain at approximately the same rostro-caudal levels as described earlier (Voutilainen 
et al. 2009). The results are presented as percentage of cells in the lesioned SNpc as compared to 
the intact SNpc. 
Additionally, in study IV, TH-ir cells bodies in the SNpc were counted using an automated deep 
convolutional neural networks (CNN) algorithm in a cloud-embedded image processing platform 
(Aiforia Technologies Oy, Finland). This computer-assisted cell counting method, that is based on 
supervised machine learning and automated image recognition, is described in detail and 
validated in (Penttinen et al. 2018). Briefly, digitized images of TH-immunolabelled sections were 
uploaded to AiforiaTM platform. The SNpc was demarcated bilaterally in six sections from each 
brain. CNN algorithm, that was trained to recognize dopaminergic cell bodies from digital images, 
counted the number of TH-ir neurons within the demarcated areas. The number of neurons was 
summed up from the six sections separately for both hemispheres. The performance of the 
algorithm was confirmed against stereological assessment of TH-ir cell counts in 20 randomly 
selected brains in study IV. The results obtained with CNN algorithm and stereological counting 
method had a strong positive correlation (Pearson’s r = 0.83, p < 0.001). 
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4.10 Statistical analyses 
All results are presented as mean ± standard error of the mean (SEM). The statistical analyses were 
conducted with SPSS® Statistics 24 software (IBM SPSS Inc., USA). The group sizes and NTF doses 
were selected on the basis of our earlier experience (Airavaara et al. 2006; Käenmäki et al. 2010; 
Lindholm et al. 2007; Voutilainen et al. 2011, 2009). Paired two-tailed Student’s t-test was used 
for two-sample within-subject comparisons and unpaired two-tailed Student’s t-tests for two-
sample between-subject comparisons. Group-wise analyses were done using one-way analysis of 
variances (ANOVA) in case of between-group comparisons, or repeated measures ANOVA in case 
of within-group comparisons, followed by Ryan-Einot-Gabriel-Welsch F (REGWF; study I) or Tukey 
HSD (studies II-IV) post hoc tests. To assess the strength of a linear association between two 
variables, Pearson correlation test was applied. The results were considered to be statistically 






5.1 Injection of neurotrophic factors into the intact rat brain 
5.1.1 Effects of exogenous neurotrophic factors on dopamine release and 
turnover in the striatum (I) 
In the microdialysis experiment one week after the intrastriatal NTF injections, the baseline levels 
of extracellular dopamine, DOPAC or HVA did not differ between the treatment groups. Both 
potassium and amphetamine-evoked release of dopamine was significantly elevated in MANF-
injected rats as compared to vehicle or GDNF-injected rats (Figure 5.1.A and B). There was also a 
trend for increased stimulus-evoked dopamine release in CDNF-injected rats, but this effect did 
not reach statistical significance when compared to vehicle. At three weeks post injection, there 
were no more significant differences in dopamine release between the treatment groups (Study 
I, supplementary material). 
Reflecting enhanced dopamine metabolism, MANF induced a significant increase in dopamine 
turnover in the striatum as evaluated by calculating DOPAC/dopamine ratio in the microdialysis 
samples at one week, but not anymore at three weeks post injection (Figure 5.1.C). There were 
no significant differences in HVA/dopamine ratio between the treatment groups at one or three 
weeks after the injection. 
 
Figure 5.1. Striatal dopamine release and turnover measured with brain microdialysis one week after 
an intrastriatal injection of neurotrophic factors. (A) Potassium- and amphetamine-evoked (75–135 
min and 180–255 min, respectively) dopamine release was increased in MANF group as compared to 
vehicle and GDNF groups (*p < 0.05; REGWF after repeated measures ANOVA; 75–135 min: F3,36 = 
4.874, p = 0.006; 180–255 min: F3,36 = 3.683, p = 0.021). In addition, the overall (15–270 min) 
extracellular concentration of dopamine was elevated in MANF group as compared to vehicle and 
GDNF groups (*p < 0.05) and in CDNF group as compared to GDNF group (#p < 0.05; REGWF after 
repeated measures ANOVA; 15–270 min: F3,36 = 4.678, p = 0.007). (B) Averaged total potassium- and 
amphetamine-evoked dopamine overflow was augmented in MANF group when compared to vehicle 
and GDNF groups (*p < 0.05; REGWF after one-way ANOVA; K+ response: F3,36 = 4.874, p = 0.006; 
Amphetamine response: F3,36 = 3.683, p = 0.021). (C) DOPAC/dopamine ratio was higher in MANF-
injected rats as compared to vehicle and GDNF-injected rats during the whole experiment and in the 
baseline samples (*p < 0.05; REGWF after repeated measures ANOVA; 15–270 min: F3,36 = 3.065, p = 
0.040; 15–60 min: F3,36 = 3.868, p = 0.017). The dose of each NTF was 10 μg. Results are shown as % of 
the baseline (A and B) or concentration ratio (C); mean ± SEM; n = 10. Figures adapted from (Renko et 
al. 2018), under the terms of the Creative Commons Attribution 4.0 International. 









































































































































































5.1.2 Effects of exogenous neurotrophic factors on dopamine 
neurochemistry (I) 
The amount of L-DOPA, the precursor of dopamine, accumulated into striatal tissue samples after 
AADC inhibition by NSD1015 provides a direct measure for L-DOPA production rate indicating the 
in vivo TH activity of the nigrostriatal pathway (Carlsson et al. 1972). At one week post NTF 
injection, TH activity was increased approximately by 60% in the dorsal striatum of rats 
administered with GDNF as compared with the vehicle-administered controls (Figure 5.2.A). MANF 
also tended to increase TH activity (approximately by 50%), but the effect was not statistically 
significant. 
 
Figure 5.2. Effects of neurotrophic factors on dopamine neurochemistry-regulating enzymes one 
week after an intrastriatal injection. (A) In vivo TH activity was increased in GDNF-injected rats when 
compared with vehicle-injected rats as analyzed by measuring the amount of accumulated L-DOPA in 
the striatal samples after AADC inhibition with NSD1015 (*p < 0.05; REGWF after one-way ANOVA; F3,22 
= 3.780, p = 0.025). (B) DOPAC/HVA ratio was significantly smaller in GDNF group than in the other 
groups during the whole experiment (#p < 0.05; REGWF after repeated measures ANOVA; 15–270 min: 
F3,36 = 7.397, p = 0.001). (C) GDNF injection increased total COMT activity in the striatum when 
compared to the vehicle-injected striatum (**p < 0.001; unpaired two-tailed Student’s t-test t(13) = − 
5.159) as well as compared to the non-injected striatum (#p < 0.001; paired two-tailed Student’s t-test 
t(7) = 6.041). (D) MAO-A activity in the GDNF-injected striatum was reduced as compared to the 
vehicle-injected striatum (*p = 0.011; unpaired two-tailed Student’s t-test t(14) = 2.944). The dose of 
the NTFs was 10 μg. Mean ± SEM; n = 6-7 (A), n = 10 (B), n = 7-8 (C, D). Figures adapted from (Renko et 
al. 2018), under the terms of the Creative Commons Attribution 4.0 International. 
Interestingly, the concentration of dopamine metabolites in the striatal microdialysis samples 
collected at one week post NTF injections showed that DOPAC/HVA ratio was significantly reduced 
in rats injected with GDNF as compared to all other groups (Figure 5.2.B). This suggests that GDNF 
injection modulates the activity of dopamine metabolizing enzymes. Indeed, GDNF significantly 
increased the total COMT activity by 155% in the injected striatum as compared to vehicle-injected 
striatum and by 170% when compared to the non-injected striatum (Figure 5.2.C). GDNF also 
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dopamine in rats (Meiser et al. 2013), in the injected striatum by 27% as compared to the vehicle-
injected controls (Figure 5.2.D). 
5.1.3 Effects of exogenous neurotrophic factors on GABA release in the 
GPe (unpublished data) 
To test whether intrastriatally injected NTFs modulate the GABAergic neurotransmission in the 
striatopallidal or striatonigral projection pathways, we collected microdialysis samples from the 
GPe and SNr of freely-moving rats at one and three weeks after the NTF injections. To stimulate 
GABA release, the MSN nerve terminals were depolarized by administering high concentration of 
potassium through the microdialysis probe. According to the pilot experiment, the overall 
extracellular concentration of GABA did not differ significantly between the treatment groups at 
one or three weeks post injection, nor were there any significant effects on stimulus-evoked GABA 
output (Figure 5.3.). At three weeks post injection, there seemed to be a tendency toward 
increased potassium-evoked release of GABA in CDNF-injected animals, but this difference did not 
reach statistical significance. We also measured the amount of GABA in the GPe tissue samples 
collected one week after the intrastriatal NTF injections, but no significant differences were found 
between the groups. GABA release in the SNr could not be reliably quantified because the 
concentration of GABA in the dialysates was at the limit of quantitation of the HPLC system and 
sometimes even below it (we used 1 mm long membranes for the SNr microdialysis). 
 
Figure 5.3. GABA release in the GPe measured with brain microdialysis one and three weeks after an 
intrastriatal injection of neurotrophic factors. There were no significant differences in GABA release 
between the treatment groups at one week (A) or three weeks (B) post injection. The dose of each 
NTF was 10 μg. Results are shown as % of the baseline; mean ± SEM; n = 4-6. 
5.1.4 Distribution of CDNF after nigral injection (II) 
To characterize the diffusion properties of supra-nigrally injected CDNF (3 μg) in naïve rats, the 
brains were collected for immunohistochemical analysis at 2, 6 and 24 h after the injection. We 
observed robust CDNF staining throughout the ipsilateral midbrain including the SNpc at 2 and 6 
h post injection, but not anymore at the 24-h time point (Figure 5.4.A-C). Clear CDNF labelling was 
also detected in the hippocampus and amygdala as well as thalamic and hypothalamic regions. 
There was no CDNF signal observed in the striatum at any of the time points. Additionally, 
increasing the injection volume from 1 to 4 μl while keeping all other parameters, such as the 
amount of CDNF, constant resulted in larger diffusion volume of CDNF around the SNpc at the 2-
Week 1









































































h time point as shown in the representative sagittal images of the CDNF staining (Figure 5.4.D). 
These qualitative data suggest that CDNF readily diffuses to the brain areas surrounding the SN 
but is eliminated within 24 h after the nigral injection. 
 
Figure 5.4. Diffusion of human CDNF (hCDNF) after an injection to the substantia nigra (SN) of intact 
rat brain. (A-C) Representative hCDNF immunostaining on coronal sections collected 2, 6 or 24 h after 
a nigral hCDNF (3 μg/4 μl) injection. CDNF readily diffuses in the brainstem, in particular around the 
SN, to the hippocampus, amygdala, thalamus and hypothalamus within 2 to 6 h after the injection. The 
panel on the right shows the rostro-caudal levels of the stained sections. (D) Representative hCDNF 
immunolabelling on sagittal sections collected 2 h after a nigral hCDNF injection in the concentration 
of 3 μg/1 μl or 3 μg/4 μl. CDNF diffuses farther with the 4-μl injection volume. The arrowheads indicate 
the approximate injection sites (added afterwards to the original figure); n = 2 at each time point or 
volume. Figures adapted from (Albert et al. 2019), under the terms of the Creative Commons 
Attribution 4.0 International. 
To further elucidate the localization of CDNF after the nigral injection, the midbrain sections were 
double stained for CDNF and TH or PV. We observed colocalization of CDNF with TH-ir neurons in 
the SN, while the colocalization with PV-ir neurons was not evident. Multiple TH-ir cells were 
detected in the nigral area of each brain, and approximately two thirds of them had CDNF-ir 
puncta inside their cell body on the injected side (Figure 5.5.). Although these observations are 






Figure 5.5. Immunofluorescent double staining for human CDNF (hCDNF) and tyrosine hydroxylase 
(TH) in the substantia nigra (SN). Representative confocal images from a rat brain injected with hCDNF 
(3 μg) to the SN and perfused 2 h later (right panel). Control side images (left panel) are taken with 
identical settings to account for possible background staining. White arrows on the injected side 
indicate hCDNF-ir puncta (cyan dots) within TH-ir cells (magenta) demonstrating the colocalization of 
hCDNF with dopamine neurons. Scale bars 10 μm; n = 6. Figures adapted from (Albert et al. 2019), 
under the terms of the Creative Commons Attribution 4.0 International. 
When 125I-labeled CDNF was injected to the SN and several brain areas were dissected 24 h later, 
no radioactivity was detected in distant brain areas such as the striatum, globus pallidus or cortex 
suggesting the absence of axonal transport to these areas (Figure 5.6.). The highest radioactivity 
after the nigral injection of 125I-CDNF was measured in the ipsilateral STN. Concurrent 
administration of either 2000 or 10 000-fold molar excess of unlabeled (“cold”) CDNF to the SN 
together with 125I-CDNF to compete for the active transport mechanisms did not block the spread 
of 125I-CDNF to the STN. 
 
Figure 5.6. Spread of 125I-labeled CDNF after an injection to the substantia nigra (SN) of intact rat 
brain. Percentage of the total radioactivity (=summed radioactivity in all brain areas measured) in the 
ipsilateral (left panel) and contralateral (right panel) brain areas measured from tissue samples 24 h 
after the nigral injection of 125I-CDNF (5 ng). For a subset of animals, 2000 (10 μg) or 10 000-fold (50 
μg) molar excess of cold (unlabeled) CDNF was injected together with 125I-CDNF. No transport into the 
striatum or other brain areas was detected. 125I-CDNF spread into the ipsilateral STN, but this spread 
was not affected by the excess of cold CDNF. FCTX, frontal cortex; CTX, cortex; STR, striatum; HC, 
hippocampus; GP, globus pallidus; STN, subthalamic nucleus; mean ± SEM; n = 5-6 per brain region. 





5.2 Activation of neuronal pro-survival signaling pathways by 
RET agonists 
To facilitate the comparison of pharmacological properties between RET agonists and positive 
controls (GDNF and NRTN), the molar concentrations of the ligands used in different in vitro 
experiments are provided in Table 5.1. From this comparison it is obvious that the potencies of 
GDNF and NRTN are at the level of four orders of magnitude larger than those of BT-compounds 
in the phosphorylation assays, which reflect the increase in protein phosphorylation status after a 
short-term (15 min) exposure to the ligands. In the neuronal survival and protection assays in 
cultured dopamine neurons, the potency differences are at the level of one to three orders of 
magnitude, because the integrated effect of prolonged (5 days) RET activation allowed to use 
much lower ligand concentrations. Direct potency and efficacy comparisons based on these 
experiments, however, must be done with caution due to putative differences in experimental 
conditions, such as transfection efficiencies of GFRα co-receptors, which may have an impact on 
the intensity readouts. 
Table 5.1. Comparison of molar concentrations used in in vitro experiments in Studies III and IV. 
Assay Ligand Concentration Effect 
RET phosphorylation in MG87RET 
fibroblasts 
BT13 25-100 μM + 
BT44 18-75 μM + 
GDNF 6.6 nM + 
NRTN 4.2 nM + 
Akt phosphorylation in MG87RET 
fibroblasts 
BT13 25-100 μM ? 
BT44 36-75 μM + 
GDNF 6.6 nM + 
NRTN 4.2 nM + 
ERK phosphorylation in MG87RET 
fibroblasts 
BT13 25-50 μM + 
BT44 7.5-75 μM + 
GDNF 6.6 nM + 
NRTN 4.2 nM + 
Survival of cultured dopamine 
neurons (wt) 
BT13 0.1-1 μM + 
BT44 7.5 nM - 3.5 μM + 
GDNF 0.33 nM + 
Survival of cultured dopamine 
neurons (RET knockout) 
BT13 1-5 μM – 
BT44 7.5-75 nM – 
GDNF 0.33 nM – 
Protection of cultured dopamine 
neurons against MPP+ induced 
cytotoxicity (wt) 
BT13 1 μM + (Mahato et al. 2020) 
BT44 75 nM + 
GDNF 0.33 nM + 
Protection of cultured dopamine 
neurons against MPP+ induced 
cytotoxicity (RET knockout) 
BT13 0.1-1 μM – (Mahato et al. 2020) 
GDNF 0.33 nM – (Mahato et al. 2020) 
+, significant increasing effect compared to vehicle; –, no significant effects compared to vehicle; ?, no quantitative 





5.2.1 RET agonists phosphorylate RET and induce intracellular signaling 
cascades (III and IV) 
A novel small molecule RET agonist BT13 stimulated the phosphorylation of RET in immortalized 
MG87RET fibroblasts transfected with GFRα1 or GFRα2 co-receptors as demonstrated by 
representative Western blot images (Figure 5.7.A and B). The effect of BT13 was concentration 
dependent and did not require the presence of GFRα co-receptors since RET phosphorylation was 
also elicited in GFP-transfected MG87RET fibroblasts incubated with BT13 (Figure 5.7.C). This 
suggests that BT13 functions as a direct RET agonist. 
When the downstream effects of BT13 were investigated, we saw that RET phosphorylation 
activated the intracellular targets Akt and ERK which are imperative for neuronal survival and 
neurite outgrowth (Figure 5.7.D-F). Akt and ERK phosphorylation also seemed to be dependent on 
the concentration of BT13 but independent on the expression of GFRα1/2. 
 
Figure 5.7. BT13 induces phosphorylation of RET and activates its downstream targets Akt and ERK 
in MG87RET fibroblasts. Representative Western blots show the increased level of RET 
phosphorylation in GFRα1 (A), GFRα2 (B) and GFP-transfected (C) cells in response to BT13 in a 
concentration-dependent manner. BT13 also increased the phosphorylation of Akt and ERK in a 
concentration-dependent manner in cells transfected with GFRα1 (D), GFRα2 (E) and GFP (F). GDNF, 
NTRN and soluble GFRα1/GDNF complex produced expected responses when used as positive controls 
for GFRα1, GFRα2 and GFP transfected cells, respectively. Their concentrations are provided in ng/ml. 
IP, immunoprecipitation; WB, Western blotting; GAPDH, glyceraldehyde-3-phosphate dehydrogenase. 
In line with the in vitro data, BT13 (750 μg) increased the level of phosphorylated ERK (pERK) and 
ribosomal protein S6 (pS6; downstream target of Akt) when injected into the mouse striatum. 
pERK and pS6 immunolabelling was significantly enhanced in the BT13-injected striata as 
compared to the vehicle-injected striata (Figure 5.8.). GDNF (5 or 10 μg) was used as a positive 







Figure 5.8. BT13 activates intracellular survival-promoting signaling pathways in the mouse brain. 
(A) Representative images of pERK and pS6 immunostained striatal sections collected after an 
intrastriatal injection of GDNF (10 μg), BT13 (750 μg) or vehicle. (B) Relative optical density of pERK 
labeling in the dorsal striatum as compared to the vehicle-injected side. BT13 (750 μg) increased the 
level of pERK (*p = 0.048; t(2) = 4.38). GDNF elevated the level of pERK at the dose of 5 μg (*p = 0.027; 
t(2) = 6.00) and 10 μg (**p = 0.009; t(3) = 6.19). (C) Relative optical density of pS6 labeling in the dorsal 
striatum as compared to the vehicle-injected side. BT13 (750 μg) increased the level of pS6 (*p = 0.040; 
t(3) = 3.47). GDNF elevated the level of pS6 at the dose of 5 μg (**p = 0.004; t(2) = 15.23). Significant 
differences between the vehicle and BT13/GDNF-injected sides were determined with paired two-
tailed Student’s t-test. Scale bar 200 μm; n = 3-4. 
 
Figure 5.9. BT44 induces phosphorylation of RET and activates its downstream targets Akt and ERK 
in MG87RET fibroblasts. Representative Western blots show the increased level of RET 
phosphorylation in GFRα1 (A), GFRα2 (B) and GFP-transfected (C) cells in response to BT44 in a 
concentration-dependent manner. BT44 also increased the phosphorylation of Akt and ERK in a 
concentration-dependent manner in cells transfected with GFRα1 (D) and GFRα2 (E). In GFP-
transfected cells, BT44 seemed to phosphorylate only ERK but not Akt (F). GDNF and NTRN (ng/ml) 
served as positive controls in cells transfected with GFRα1 and GFRα2, respectively. IP, 







Analogously to the parental compound BT13, BT44 activated RET and its downstream target 
pathways in MG87RET fibroblasts. BT44 stimulated RET phosphorylation in cells transfected with 
the co-receptors GFRα1 and GFRα2 as well as in GFP-transfected cells suggesting a direct, co-
receptor independent, agonistic mechanism (Figure 5.9.A-C). BT44 also induced the 
phosphorylation of Akt and ERK in GFRα1-RET and GFRα2-RET expressing fibroblasts (Figure 5.9.D 
and E). Interestingly, in GFP-transfected cells, BT44 induced ERK phosphorylation but did not have 
a clear effect on Akt phosphorylation (Figure 5.9.F). 
5.2.2 RET agonists promote the survival of cultured midbrain dopamine 
neurons (III and IV) 
Both BT13 and BT44 supported the survival of primary dopamine neurons in vitro as compared to 
vehicle. The number of TH-ir cells was increased in BT13 (0.1 and 1 μM), BT44 (7.5, 75 and 3500 
nM) and GDNF (10 ng/ml » 0.33 nM) -treated midbrain cultures from wild-type, but not from RET 
knockout, mice indicating that the survival-promoting effect of BT13 and BT44 on dopamine 
neurons was RET dependent (Figure 5.10.A-D). BT13 (1 μM) (Mahato et al. 2020) and BT44 (75 
nM) also protected MPP+ -challenged dopamine neurons in culture with a similar efficacy as GDNF 
(10 ng/ml » 0.33 nM) (Figure 5.10.E). 
 
Figure 5.10. BT13 and BT44 promote the survival of cultured dopamine neurons from wild-type, but 
not from RET knockout, mice and protect them against MPP+ -induced cell death. (A) The number of 
TH-ir cells in wild-type midbrain cultures on 5th day in vitro (DIV) presented as percentage of the 
vehicle-treated samples. BT13 0.1 μM (****p < 0.0001), BT13 1 μM (***p = 0.0002) and GDNF 10 ng/ml 
(*p = 0.021; Dunnett after repeated measures ANOVA; F2.35,16.46 = 6.55, p = 0.006) increased the number 
of TH-ir neurons in the culture. N = 8. (B) The number of TH-ir cells in RET knockout midbrain cultures 
on 5th DIV presented as percentage of the vehicle-treated samples. N = 8. (C) The number of TH-ir cells 
in wild-type midbrain cultures on 5th DIV. BT44 7.5 nM (***p = 0.0008), BT44 75 nM (**p = 0.006), 
BT44 3500 nM (**p = 0.004) and GDNF 10 ng/ml (***p = 0.0009; Dunnett after repeated measures 
ANOVA; F6,18 = 5.734, p = 0.0018) increased the number of TH-ir neurons as compared to the vehicle. 
N = 4. (D) The number of TH-ir cells in RET knockout midbrain cultures on 5th DIV. N = 2. (E) BT44 75 
nM (*p = 0.016) and GDNF 10 ng/ml (*p = 0.019; Dunnett after repeated measures ANOVA; F3,15 =  
5.410, p = 0.01) increased the number of surviving TH-ir cells in wild-type midbrain cultures exposed 
to MPP+ neurotoxin. N = 6. Mean ± SEM; the number of TH-ir cells is normalized to the total number 








5.3 Delivery of RET agonists into the striatum of 
hemiparkinsonian rats  
5.3.1 BT13 protects against motor dysfunction in 6-OHDA model of 
Parkinson’s disease (III) 
The neuroprotective effect of intrastriatally infused BT13 was compared with that of GDNF in a 
unilateral 6-OHDA model of PD in rats. The experimental design is presented in Figure 4.2.A.  
5.3.1.1 Motor deficits 
Amphetamine-induced rotational behavior was similar in all treatment groups at two weeks 
following the toxin administration (Figure 5.11.A). In animals infused with BT13 (3-6 μg/24h) and 
GDNF (3 μg/24h), the number of ipsilateral turns was significantly reduced at four and six weeks 
after the lesion as compared to the vehicle infusion (Figure 5.11.B and C). Noteworthily, there was 
spontaneous recovery in the turning behavior of vehicle-treated rats at four (p = 0.085 for 2 weeks 
vs. 4 weeks: t(11) = 1.895) and six weeks post lesion (p = 0.034 and p = 0.020 for 2 weeks vs. 6 
weeks: t(10) = 2.460 and 4 weeks vs. 6 weeks: t(10) = 2.756, respectively; paired two-tailed 
Student’s t-test), an observation that is accordance with previously published data on this 
particular toxin administration scheme (Penttinen et al. 2016). 
 
Figure 5.11. BT13 normalizes amphetamine-induced turning behavior in a time-dependent manner 
in 6-OHDA lesioned rats. (A) Effect of BT13 and GDNF infusions on amphetamine-induced turning 
behavior at two weeks post lesion. (B) At four weeks post lesion, the number of turns was lower in 
BT13 3-6μg/24h (*p = 0.013) and GDNF 3μg/24h (**p = 0.001) groups as compared to the vehicle group 
(Tukey HSD after one-way ANOVA; F2,53 = 7.344, p = 0.002). (C) The turning behavior was further 
reduced in BT13 3-6μg/24h (*p = 0.011) and GDNF 3μg/24h (**p = 0.007) groups as compared to the 
vehicle group at six weeks post lesion (Tukey HSD after one-way ANOVA; F2,51 = 5.882; p = 0.005). Mean 
± SEM; vehicle n = 11-12, GDNF 3μg/24h n = 15-16, BT13 3-6μg/24h n = 25-27. 
5.3.1.2 Dopaminergic neurons in the SNpc and fibers in the striatum 
The immunohistochemical assessment of nigral and striatal sections collected after the last 
behavioral test revealed that GDNF 3 μg/24h infusion partially protected TH-ir fibers in the 
lesioned striatum as compared to the vehicle treatment (Figure 5.12.A and D). BT13 3-6 μg/24h, 
however, failed to produce a significant protective effect on dopaminergic fibers. Neither BT13 



































































































































into the striatum can downregulate the expression of TH (Georgievska et al. 2004; Salvatore et al. 
2004), we used DAT as another dopaminergic marker to analyze the fiber density in the striatum. 
The density of DAT-ir fibers was comparable to that of TH-ir fibers in all treatment groups 
suggesting unaltered TH expression in the striatum (Figure 5.12.C and F). 
 
Figure 5.12. Effect of BT13 and GDNF on dopaminergic fibers in the striatum and cell bodies in the 
SNpc of 6-OHDA lesioned rats. Representative images of TH-ir fiber density in the striatum (A), TH-ir 
neurons in the SNpc (B) and DAT-ir fiber density in the striatum (C) in different treatment groups at six 
weeks post lesion. The dashed line in (A) shows the area in the dorsal striatum used for optical density 
measurements and in (B) the area used for stereological cell counting. The arrowheads denote the 
lesion side. (D) Quantification of TH-ir fiber density in the striatum. GDNF protected TH-ir fibers in the 
lesioned striatum as compared to the vehicle treatment (*p = 0.024; Tukey HSD after one-way ANOVA 
F2,51 = 3.708, p = 0.032). (E) Number of TH-ir cell bodies in the SNpc. (F) Densitometric quantification of 
DAT-ir fibers in the striatum. Scale bars: 1 mm (A and C) and 0.5 mm (B). Mean ± SEM; in TH staining 
(D and E) vehicle n = 11-12, GDNF 3μg/24h n = 15-16, BT13 3-6μg/24h n = 24-25; in DAT staining (F) 
vehicle n = 8, GDNF 3μg/24h n = 13, BT13 3-6μg/24h n = 19. 
5.3.2 BT44 shows neurorestorative potential in 6-OHDA model of 
Parkinson’s disease (IV)  
The neurorestorative effect of intrastriatally infused BT44 was studied in a rat model of PD with 
progressive unilateral 6-OHDA lesion (Penttinen et al. 2016) utilizing amphetamine-induced 
rotational behavior and limb-use asymmetry tests. The experimental design is presented in Figure 
4.2.B. Rats were assigned into equal treatment groups according to their amphetamine-induced 




5.3.2.1 Motor deficits 
Both GDNF 3 μg/24h and BT44 0.3 μg/24h were able to produce a functional recovery in 6-OHDA 
lesioned animals. Amphetamine-induced rotational asymmetry was significantly reduced in GDNF-
infused rats at six and 12 weeks post lesion and in BT44 0.3 μg/24h -infused rats at 12 weeks post 
lesion as compared to the vehicle-treated rats (Figure 5.13.B and C). Spontaneous limb-use 
asymmetry in the cylinder test, however, was not balanced by any of the treatment infusions 
(Figure 5.13.E and F). This is in line with earlier literature where GDNF therapy has been reported 
to induce functional recovery in amphetamine-induced rotation test but not in the cylinder test 
(Georgievska et al. 2002; Gasmi et al. 2007b; Yue et al. 2014). 
 
Figure 5.13. BT44 reduces amphetamine-induced rotations in 6-OHDA lesioned rats in a time-
dependent manner. (A) Amphetamine-induced rotation rate at two weeks (12 days) post lesion was 
used to assigned rats into equal treatment groups. (B) At six weeks post lesion, GDNF 3μg/24h 
alleviated amphetamine-induced rotational asymmetry as compared to PBS (#p = 0.025) and PG (*p = 
0.046; Tukey HSD after one-way ANOVA; F4,45= 3.638, p = 0.012). (C) At 12 weeks, BT44 0.3μg/24h 
significantly reduced the number of ipsilateral turns as compared to PBS (#p = 0.046) and PG (*p = 
0.010). GDNF-treated rats rotated significantly less than PBS (###p < 0.001), PG (***p < 0.001) and 
BT44 0.1μg/24h -treated rats (†††p < 0.001; Tukey HSD after one-way ANOVA; F4,44= 11.365; p < 0.001). 
(D) Rotation rate per 5 min at 12 weeks post lesion. From 60-min time point onwards, the turning 
response was smaller in BT44 0.3μg/24h -infused rats as compared to PBS (#p = 0.029) and PG -infused 
rats (**p = 0.003; Tukey HSD after repeated measures ANOVA; 60–120 min: F4,44= 8.491, p < 0.001). 
(E-F) There were no differences between the treatment groups in spontaneous limb-use asymmetry 
score measured in the cylinder test at six and 12 weeks post lesion. Mean ± SEM; n = 8-11. 
2 weeks (pre-treatment)











































































































































































Further analysis of the amphetamine-induced rotation rate per 5 min at 12 weeks post lesion 
revealed a distinct profile in the turning behavior of BT44 0.3 μg/24h -treated rats as compared to 
the other treatment groups (Figure 5.13.D). They seemed to have a faster and nearly full recovery 
from the strong amphetamine-response in the beginning of the experiment: from 60-min time 
point onwards, the rotation rate was significantly reduced in BT44 0.3 μg/24h group as compared 
to the vehicle groups. 
5.3.2.2 Dopaminergic neurons in the SNpc and fibers in the striatum 
The density of TH-ir fibers in the striatum was significantly higher in BT44 0.3 μg/24h and GDNF 3 
μg/24h -infused rats than in PBS-infused animals (Figure 5.14.A). In accordance with this, BT44 0.3 
μg/24h and GDNF 3 μg/24h seemed to increase the density of DAT-ir fibers in the striatum, but 
only the effect of GDNF 3 μg/24h was significant when compared to the vehicles (Figure 5.14.C). 
Intrastriatal infusion of GDNF, but not BT44, was also able to prevent the loss of dopamine neurons 
in the SNpc. The number of TH-ir and DAT-ir cell bodies in GDNF-treated rats was significantly 
higher as compared to the vehicle-treated rats (Figure 5.14.B and D). 
 
Figure 5.14. BT44 restores dopamine fibers in the striatum but is not able to protect dopamine 
neurons in the SNpc of 6-OHDA lesioned rats. (A) BT44 0.3μg/24h (#p = 0.025) and GDNF 3μg/24h (#p 
= 0.010) significantly increased the density of TH-ir fibers in the striatum as compared to PBS, while 
BT44 0.1μg/24h showed a trend for fiber restoration (p = 0.065; Tukey HSD after one-way ANOVA; F5,46 
= 3.671, p = 0.007). (B) The number of TH-ir cells was higher in the SNpc of GDNF-treated rats as 
compared to all other treatment groups (***p < 0.001 vs. PG; ###p < 0.001 vs. PBS; ††p < 0.01 vs. BT44 
0.1μg/24h and BT44 0.3μg/24h; Tukey HSD after one-way ANOVA; F5,48 = 8.898, p < 0.001). (C) The 
density of striatal DAT-ir fibers was higher in GDNF-treated rats as compared to PBS (##p = 0.001), PG 
(**p = 0.006) and BT44 0.1μg/24h -treated rats (†p = 0.046; Tukey HSD after one-way ANOVA; F5, 45 = 
4.746, p = 0.001). (D) GDNF-treated rats had a greater number of DAT-ir cells in the SNpc than PBS (#p 
= 0.012) or BT44 0.1μg/24h -treated rats (††p = 0.008; Tukey HSD after one-way ANOVA; F5, 46 = 3.752, 
p = 0.006). The brains of the lesion control group were analyzed at two weeks post lesion to verify the 
extent of the lesion at the time of the treatment initiation. Mean ± SEM; lesion control group n = 4, 

































































































































5.3.2.3 Correlation of TH immunohistological measures with amphetamine-
induced rotational behavior 
Due to the apparent discrepancies between amphetamine-induced turning behavior and TH 
immunohistological outcomes at 12 weeks post lesion, we analyzed the correlations of these 
measures quantitatively. Amphetamine-induced rotations showed low negative correlation with 
TH-ir fiber density in the striatum (Pearson’s r = -0.43, p < 0.01) and moderate negative correlation 
with TH-ir cell count in the SNpc (Pearson’s r = -0.64, p < 0.001) when data from all treatment 
groups were pooled together (Figure 5.15.A and B). Noteworthily, GDNF-treated rats rotated 
substantially less as compared to all other rats, but this behavioral improvement was not 
accompanied by fiber restoration in the striatum to the same extent. This is visualized in Figure 
5.15.A as a grouping of GDNF data points (black squares) close to the y-axis but not higher than 
the other data points. We also analyzed the correlation between the striatal fiber densities and 
nigral cell numbers from the pooled dataset and found a low correlation between these two 
histological read-outs (Pearson’s r = 0.45, p < 0.01) (Figure 5.15.C). 
 
Figure 5.15. Correlations between TH immunohistochemical measures and amphetamine-induced 
turning rate. (A) Amphetamine-induced turning rate at 12 weeks post lesion plotted against striatal 
TH-ir fiber density for each experimental animal. (B) Amphetamine-induced turning rate at 12 weeks 
post lesion plotted against nigral TH-ir neuronal number for each experimental animal. (C) TH-ir cell 
numbers in the SNpc plotted against TH-ir fiber densities in the striatum. r - Pearson correlation 
coefficient, all treatment groups analyzed together.  
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This work aimed to support the preclinical characterization of neurotrophic therapies for PD by 
testing the effects of unconventional NTFs, CDNF and MANF, in the non-lesioned rat brain and 
novel small molecule RET agonists, BT13 and BT44, in an animal model of PD. Patients await a 
disease-modifying treatment for their debilitating condition. Therefore, efforts have to be made 
to overcome the lack of translatability of NTF-based treatments that has overshadowed the field 
of research until today. 
The main outcomes suggest that exogenously administered GDNF, CDNF and MANF divergently 
modify dopamine release and dopamine synthetizing and metabolizing enzymes in the 
nigrostriatal system of the normal rat brain. We saw that nigrally delivered CDNF readily diffuses 
around the brainstem and colocalizes with TH-ir, but not PV-ir, neurons in the SN. No active 
transport of CDNF into distal brain areas was detected after a nigral injection. BT13 and BT44 were 
shown to activate RET and its downstream intracellular target pathways responsible for neuronal 
survival and regeneration in vitro. They also supported the survival of cultured midbrain dopamine 
neurons in a RET-dependent manner. BT13 promoted functional recovery in a neuroprotection 
model of PD, and BT44 alleviated motor impairment and showed potential to restore striatal 
dopaminergic fibers in a neurorestoration model of PD in rats. 
6.1 Effects of exogenously administered neurotrophic factors 
on dopamine release in the striatum 
A single intrastriatal injection of 10 μg of GDNF, CDNF and MANF has been shown to produce 
robust neuroprotective effects on nigrostriatal dopamine neurons at four weeks after the injection 
(Lindhom et al. 2007; Voutilainen et al. 2009). Also in normal rats, a single 10 μg -injection of GDNF 
into the SNpc was shown to elicit neurochemical changes on dopaminergic system that persisted 
for at least three weeks (Hudson et al. 1995). We set out to characterize the effects of GDNF, CDNF 
and MANF on dopaminergic neurotransmission at one and three weeks after the striatal delivery. 
Importantly, our experiments were conducted in freely-moving animals in order to avoid the 
confounding effects of anesthetics on neuronal functions (Marinelli and McCutcheon 2014; Müller 
et al. 2011). Our brain microdialysis results provide the first insight into the long-lasting and 
divergent biological effects of exogenously administered CDNF and MANF on nigrostriatal 
dopamine system in the normal rat brain. These are relevant data when considering these NTFs 
as a potential therapeutic approach for PD. It is important to confirm that they do not decrease 
the release of dopamine in the striatum, and therefore have apparent interactions with the 
dopaminergic medications of PD. 
We discovered that an intrastriatal injection of MANF significantly elevated stimulus-evoked 
dopamine output and enhanced DOPAC/dopamine turnover in the striatum one week after the 
injection. MANF may modulate presynaptic release mechanisms or storage pools of dopamine 




amphetamine) to evoke dopamine release, we pursued to dissect the contribution of these factors 
to the final output. Hypertonic K+ solution depolarizes nerve terminals and causes Ca2+-dependent 
exocytosis of vesicles close to the presynaptic membrane (Westerink et al. 1989). This pool of 
presynaptic dopamine is considered to be readily releasable.	 Amphetamine stimulus, on the 
contrary, gives an estimate of the total amount of dopamine stored in the synaptic terminals by 
depleting vesicular dopamine stores and causing Ca2+-independent release of dopamine 
(Westerink et al. 1989; Sulzer 2011). We saw an increase both in potassium- and amphetamine-
evoked dopamine overflow in MANF-injected rats.	Thus, MANF seems to replenish presynaptic 
dopamine stores and enhance Ca2+-mediated exocytosis or increase the proportion of readily 
releasable pool of vesicles. In primary neuron cultures and acute brain slices, GDNF has been 
shown to facilitate synaptic transmission by increasing the quantal size of dopamine release, 
potentiating Ca2+ influx and inhibiting A-type K+ channels (Pothos et al. 1998; Bourque and Trudeau 
2000; Yang et al. 2001; Wang et al. 2003). It is possible that MANF exerts corresponding 
modulatory effects on the synaptic terminals. The spatiotemporal resolution of microdialysis, 
however, is not good enough to draw conclusions about precise mechanisms behind the observed 
effects. For that, further studies focusing on the cellular-level mechanisms are needed. Studies 
with in vivo voltammetry would also offer a better temporal and spatial resolution to clarify the 
mechanisms of enhanced dopamine release in MANF-treated rats. 
As discussed below in chapter 6.4. MANF and CDNF have better diffusion properties in the brain 
parenchyma as compared to GDNF (Mätlik et al. 2017; Voutilainen et al. 2011, 2009). They can 
reach dopaminergic terminals in the whole striatum and enhance their function which can 
contribute to the overall dopamine outflow. GDNF, instead, readily binds to the heparan sulfate 
side chains of the extracellular matrix which mostly likely restricts its distribution close to the 
injection site and reduces the effects on distant nerve terminals. Increased sprouting of 
dopaminergic fibers in the striatum could also account for the enhanced dopaminergic 
neurotransmission in MANF-treated animals, but this seems unlikely since an earlier study 
demonstrated no effect of intrastriatal infusion of MANF on TH-ir fibers in the striatum of intact 
rats (Voutilainen et al. 2011). 
Microdialysis is a highly invasive method causing mechanical damage and gliosis around the 
sampling site (Benveniste and Hansen 1991). ER stress and inflammation are inevitable 
consequences of the mechanical insult. The capability of MANF and CDNF to mitigate ER stress 
and neuroinflammation could partly explain their augmented effects as compared to GDNF in the 
microdialysis experiment. Furthermore, the implantation of the guide cannula after the NTF 
injection disrupts the BBB. Hypothetically, this enables NTF-neutralizing antibodies to invade to 
the brain which can cause unexpected variation to the effects of the NTFs. 
It was unexpected that GDNF did not enhance stimulus-evoked dopamine release. By contrast, 
CDNF had a more pronounced effect than GDNF in spite of the fact that the half-life of exogenous 
GDNF in the brain has been estimated to be 3-4 days whereas the half-life of CDNF is only 
approximately 5.5 h (Granholm et al. 2000; Mätlik et al. 2017). We showed that COMT activity was 
increased after GDNF injection. It can be speculated that the smaller effect of GDNF on stimulus-





the clearance of extracellular dopamine. GDNF/RET signaling is also shown to function as a 
negative regulator of the cell surface trafficking of DAT (Boger et al. 2007; Kopra et al. 2017; Littrell 
et al. 2012; Zhu et al. 2015). This could partly explain why amphetamine-stimulated dopamine 
release was not enhanced in GDNF-treated rats. 
The recombinant NTFs used in Study I were produced in different cell lines which might have 
contributed to their divergent effects. GDNF was produced in E. coli, CDNF in Sf9 insect cells and 
MANF in mammalian Chinese hamster ovary cells. NTFs produced in mammalian cells may have 
stronger activity than NTFs produced in other cell lines. Proteins produced in insect or mammalian 
cells can be post-translationally glycosylated unlike proteins produced in bacterial cell lines. 
Glycosylation has an impact on the biological properties of recombinant proteins. According to 
mass spectrometer analysis, however, CDNF and MANF used in our experiment were not 
glycosylated making them comparable with GDNF in that regards. 
Finally, it is tempting to speculate that the differences seen in dopamine release may originate 
from other neurotransmitter systems. NTFs may well affect, for example, cholinergic interneurons 
or glutaminergic terminals in the striatum. Increased activation of presynaptic nAChRs or NMDA 
receptors on dopaminergic nerve terminals would facilitate the release of dopamine. Thus, it 
would be informative to measure stimulus-evoked release of other neurotransmitters such as 
glutamate and acetylcholine in the striatum after the injection of NTFs. 
6.2 GABA release in the globus pallidus after exogenously 
administered neurotrophic factors 
An essential question that remains is what are the effects of NTFs on other neuronal populations 
outside the nigrostriatal dopamine pathway (Aron and Klein 2011). The non-dopaminergic effects 
are equally important to be explored because they might cause adverse events in PD patients or 
give rise to positive therapeutic benefits alleviating, for example, the non-motor symptoms of PD. 
Despite its importance, this area of research has been overshadowed by the studies focusing on 
the dopaminergic effects of NTFs. The effects of NTFs on the GABAergic system, for instance, are 
substantive since they directly affect the output of the basal ganglia and motor control. Salvatore 
and colleagues (2009) reported long-lasting effects of a single unilateral injection of GDNF on 
striatal proteins regulating GABAergic neuronal function in the non-lesioned rat brain. They 
described for example bilateral changes in GABA synthesizing enzyme glutamic acid decarboxylase 
(GAD) 65/67 and increased levels of D1 receptor and phosphorylated DARPP-32 (dopamine and 
cAMP regulated phosphoprotein 32 kDa) in the contralateral striatum after the striatal delivery of 
GDNF. Patch clamp recordings from rat midbrain slices suggest that MANF can acutely increase 
GABA release and GABAA receptor-mediated inhibitory postsynaptic currents in dopamine 
neurons of the SNpc (Zhou et al. 2006). The physiological relevance of these phenomena, however, 
has remained obscure. 
To address the question whether GDNF, CDNF and MANF have divergent effects also on GABAergic 
MSNs, we performed another microdialysis experiment where we measured potassium-evoked 




and three weeks after an intrastriatal NTF injection. K+-stimulus caused a marked increase in the 
extracellular concentration of GABA in the GPe, but we did not detect significant differences 
between the treatment groups at either of the time points. Unfortunately, GABA concentration in 
the dialysates collected from the SNr was too low to be quantified reliably with our HPLC system. 
In the future experiments probing the SNr, either the perfusion rate of the dialysis solution has to 
be slower or the dialysis membrane has to be longer to yield higher concentration of GABA in the 
samples. No-net-flux microdialysis would also permit the determination of the actual extracellular 
concentration of GABA at the baseline. However, this method is not suitable for the detection of 
stimulus-evoked rapid concentration changes. 
Due to the lack of significant differences between the treatment groups, speculations on the 
possible effects of NTFs on GABAergic neurotransmission are avoided here. Overall, this pilot study 
should be repeated in order to draw reliable conclusions from the results. 
6.3 Effects of exogenously administered neurotrophic factors 
on dopamine synthesis and metabolism 
We provided novel data on the effects of CDNF and MANF on TH activity and the effect of GDNF 
on the activity of dopamine metabolizing enzymes COMT and MAO. To clarify if the elevated 
dopamine release in MANF-injected rats was due to enhanced synthesis of dopamine, we 
measured in vivo TH activity in the striatum one week after the intrastriatal NTF delivery. We saw 
significantly increased TH activity only in GDNF-injected rats. This observation is in accordance 
with earlier results showing increased TH phosphorylation and enzymatic activity in rats 
administered with exogenous GDNF or MEN2B mice with constitutively active RET (Beck et al. 
1996; Rosenblad et al. 2003; Georgievska et al. 2004; Salvatore et al. 2004; Mijatovic et al. 2008; 
Salvatore et al. 2009). Perhaps, out of the NTFs studied here, only GDNF has the ability to stimulate 
the phosphorylation of TH. It should be noted, however, that we investigated only one time point, 
and therefore the data are not sufficient to draw conclusions whether the NTFs can modify TH 
activity at different time points. It would be worth testing if MANF and CDNF are also able to 
modify the phosphorylation of TH as well as the time-dependence of the effects of NTFs on TH 
activity. Taken together,	 TH activity data could not provide an explanation for the increased 
stimulus-evoked dopamine overflow seen in MANF-treated rats. Other possible mechanisms are 
discussed above in chapter 6.1. 
An intriguing outcome from the microdialysis experiment was the significantly decreased 
DOPAC/HVA ratio in GDNF-injected rats. This phenomenon triggered us to further elucidate the 
effect of GDNF on the activity of COMT, MAO-A and MAO-B. Indeed, we detected increased COMT 
activity in the striatum of GDNF-injected rats together with reduced MAO-A activity which was, 
perhaps, a compensatory response to the increased COMT activity. This finding is well in line with 
an earlier study where a 10-μg nigral injection of GDNF elicited a dose-dependent increase in 
dopamine turnover measured as HVA/dopamine ratio in the SN and striatum tissue samples one 
week after the injection to normal rats (Hudson et al. 1995). The observed changes in COMT and 
MAO-A activity direct dopamine degradation towards 3-MT-mediated pathway and away from 





as compared to HVA. The putative changes in 3-MT levels would help to further clarify the effects 
of NTFs on the metabolic pathways of dopamine, but our HPLC system was not optimized to detect 
3-MT in the dialysates or tissue samples. 
LPS-induced microglia activation has been shown to enhance total COMT activity in the rat brain 
(Helkamaa et al. 2007).	In our study, we controlled the possibility for microglia activation due to 
the surgical procedure by comparing the vehicle-injected striatum to the non-injected striatum. 
No differences in COMT activity between the two hemispheres were detected. Thus, the observed 
effect on COMT activity is not due to the injection procedure per se, but rather related to the 
injected GDNF solution. However, the rhGDNF used in the study was produced in an E. coli cell 
line. Although it was tested by the manufacturer to be compliant for cell culture use in terms of 
LPS counts, we cannot exclude the possibility that there were some bacterial LPS residues in the 
product which could induce microglia activation and result in enhanced COMT activity. To confirm 
the results, GDNF originating from a mammalian cell line should be tested in the same setup and 
microglia activation after GDNF-injection should be ruled out using e.g. Iba1 (ionized calcium-
binding adapter molecule 1) immunohistochemistry. Furthermore, follow-up experiments should 
test whether GDNF injection has an effect on the expression level of COMT which could contribute 
to the increased enzyme activity. The time-dependence of COMT activation and the effects of 
MANF and CDNF on the activity of dopamine metabolizing enzymes would also be interesting to 
investigate in the future. 
The neurotrophic therapies should be compatible with the current PD medications that are 
described in chapter 2.3.5 and Table 2.2. Thus, the increased COMT activity after GDNF treatment 
is an important aspect to take into consideration if GDNF is administered to PD patients. This might 
call for adjustments to the existing dopamine-replacing drugs; for example, the dosage of a COMT 
inhibitor might need to be increased. The enhanced in vivo TH activity in GDNF-treated rats and 
elevated stimulus-evoked dopamine release in MANF-treated rats, on the other hand, could 
translate into reduced L-DOPA doses in PD patients. 
6.4 Spreading properties of neurotrophic factors after 
administration into the basal ganglia 
Insufficient brain distribution and bioavailability have limited the clinical benefits of the NTFs 
tested in phase II trials (Lapchak et al. 1998; Hamilton et al. 2001; Salvatore et al. 2006). Knowing 
the diffusion and transportation properties of a neurotrophic treatment is of paramount 
importance when delineating the optimal site of administration for a therapy that is intracranially 
delivered to a single site in a condition which afflicts normal neuroanatomical connections and is 
accompanied with disturbed axonal transport (Chu et al. 2012; De Vos et al. 2008; O’Keeffe and 
Sullivan 2018). Intrastriatally administered MANF has been shown to diffuse significantly better in 
the rat brain when compared to GDNF (Voutilainen et al. 2011, 2009). CDNF also diffuses readily 
and spreads to the cortical areas and hippocampus after an injection or infusion into the  striatum 
(Mätlik et al. 2017; Voutilainen et al. 2011). GDNF and CDNF have been demonstrated to undergo 
retrograde transport to the SNpc along nigrostriatal dopamine neurons when injected into the 




to be actively transported from the striatum to the frontal cortex but not to the SN (Voutilainen 
et al. 2009). 
Our pilot experiment suggested that a 3-μg injection of CDNF into the SN had comparable effects 
with a 10-μg striatal injection of CDNF on behavioral and histological read-outs in a 6-OHDA rat 
model of PD (unpublished data). Therefore, we wanted to further examine how CDNF behaves 
when injected into the SN; how well it diffuses into the surrounding brain areas, how different 
variables affect the diffusion properties, and is it transported or taken up by specific types of 
neurons. As expected, CDNF had a widespread diffusion in the brainstem of normal rats after the 
nigral injection. CDNF immunolabelling was detected at 2 and 6 h, but not anymore at 24 h post 
injection. This suggests that the exogenous CDNF was degraded between 6 and 24 h which goes 
well in line with the 5.5-h half-life of CDNF (Mätlik et al. 2017). The volume of distribution of 
injected CDNF was increased with the increased injection volume which is clearly an important 
factor to be optimized when the delivery protocol for a therapeutic protein is being established. 
A larger injection volume results in the diffusion of the protein to more distant brain regions which 
may give rise to enhanced therapeutic effects or emerge of adverse effects depending on the 
protein in question, the affected brain regions and the clinical condition.  
We saw similar punctate CDNF-ir staining inside the TH-ir neurons of the SNpc as was previously 
shown after striatal injection and retrograde transportation of CDNF to the SNpc (Mätlik et al. 
2017). CDNF did not seem colocalize with PV-ir neurons in the SNpc suggesting selective uptake 
into dopamine neurons. This can possibly contribute to the neuroprotective effects of CDNF on 
dopamine neurons and its favorable safety profile. Further experiments with quantitative 
outcomes, however, are needed to draw decisive conclusions of the localization of exogenously 
administrated CDNF.  
When radiolabeled CDNF was injected into the SN we observed prominent spread to the ipsilateral 
STN, but no active transport to the striatum or other distal brain areas. It is possible that upon 
cellular uptake CDNF is targeted to lysosomal degradation instead of axonal transportation when 
injected near the cell bodies as is the case with NGF (Butowt and von Bartheld 2001). 
Noteworthily, only one time point was analyzed after the injection of radiolabeled CDNF. As seen 
in the diffusion experiment, there is little CDNF immunoreactivity left in the brain at 24 h post 
injection, probably due to the short half-life of CDNF. It is possible that CDNF is transported from 
the SN but not detected in other brain areas 24 h after the injection anymore. Thus, it would be 
good to check if there are signs of active transport at earlier time points (e.g. at 2 h and 6 h) after 
the injection. Co-administration of unlabeled CDNF did not significantly reduce the radioactive 
signal in the STN suggesting that CDNF was passively diffused to this proximal nucleus instead of 
actively transported. Active transportation, however, cannot be completely ruled out because the 
prominent diffusion of radiolabeled CDNF to the area covering the STN potentially masks the 





6.5 Potential of neurotrophic factor mimetics as a therapeutic 
strategy for Parkinson’s disease 
Since the clinical proof-of-concept studies with NTFs have remained inconclusive, it is pivotal to 
look for novel neurotrophic strategies to protect the degenerating dopamine neurons and restore 
the impaired functionality of basal ganglia circuitry. There are several protein therapy related 
challenges that may limit the therapeutic use of NTFs for PD or other brain diseases. Firstly, 
proteins do not cross the BBB and therefore require surgical delivery into the brain which increases 
the costs and risks of the treatment. In the clinical studies with GDNF and AAV2-NTRN, the most 
common safety concerns have related to the intracranial drug delivery procedure and 
implantation of the infusion device (Lang et al. 2006; Marks et al. 2010; Whone et al. 2019). 
Secondly, the production of biological therapeutics for clinical use is not trivial. Special attention 
has to be paid to the batch-to-batch variations and stability of the recombinant protein. 
Additionally, the levels host cell contaminants or endotoxins (such as LPS) have to be carefully 
controlled. Thirdly, formation of neutralizing antibodies against the recombinant NTF treatment 
is a particular concern (Lang et al. 2006; Heiss et al. 2019). Anti-NTF antibodies can potentially 
limit the efficacy of the therapeutic protein and cross-react with the corresponding endogenous 
NTF causing its loss-of-function. Finally, low bioavailability and poor tissue penetration are well-
known issues with the GFL-therapeutics as discussed in the previous chapter. Small molecules that 
retain the neurotrophic activity of NTFs by activating the same receptors and signaling pathways 
provide an attractive approach to circumvent these protein therapy related challenges. 
Using virtual and cell-based screening methods a novel family of small molecule GFL mimetics, 
including BT13 and BT44, has been identified and optimized (Saarma et al. 2014; Sidorova et al. 
2017). These compounds seem to diffuse readily in the brain parenchyma and penetrate the BBB. 
They activate GFL-GFRα-RET signaling complex, but the exact mechanism of action is not 
elucidated yet. Molecular docking simulations have identified two possible binding sites: the 
putative allosteric modulation site in GFRα or the GFRα-interfacing surface of RET (Ivanova et al. 
2018). The latter would imply that the compounds act as a direct RET agonists. Recent results 
support their function as direct RET agonists because of their ability to phosphorylate RET and 
activate downstream signaling cascades also in the absence of GFRα co-receptors (Sidorova et al. 
2017; Viisanen et al. 2020; Study III; Study IV). BT13 and BT44 are first-in-class molecules with 
drug-like properties that selectively (see below) activate RET and its downstream survival-
promoting signaling pathways in vitro. This work demonstrated that they can markedly alleviate 
amphetamine-induced rotational behavior in a unilateral 6-OHDA lesion model of PD in rats. BT44 
also showed potential for restoring TH-ir fibers in the striatum of hemiparksinonian rats, but the 
neuroprotective effects on dopaminergic cell bodies in the SN remained unattained. BT13 and 
BT44 serve as promising lead compounds; with further optimization they can be developed into a 
novel disease-modifying therapy for PD. 
The potential off-target effects of BT44 were assessed in a panel of in vitro assays by an external 
company (Eurofins CEREP SA, France, see details Study IV supplementary data). BT44 (1 μM) did 
not affect the activity of selected ion channels, G-protein coupled receptors, transporters, kinases 




25% which, according to the company’s guidelines for result interpretation, reflects assay 
variability and indicates the lack of a significant effect of the test compound. Our data also show 
that BT44 only supports the survival of RET-expressing wild-type, but not RET knockout, dopamine 
neurons and fails to activate ERK-related signaling in TrkB-expressing murine fibroblasts lending 
support to the selectivity of BT44 for RET. 
BT44 promoted functional recovery in 6-OHDA lesioned rats. When we analyzed the 
amphetamine-induced turning rate per 5 min at 12 weeks post lesion, we saw an interesting 
feature in BT44 0.3 μg/24h -treated animals. They showed divergent time-dependence of the 
rotational asymmetry and seemed to recover faster from the amphetamine challenge when 
compared to other treatment groups. It can be speculated that BT44 alters dopamine dynamics. 
For example, reduced dopamine uptake through DAT or activity of dopamine metabolizing 
enzymes could account for slower clearance of dopamine from the extracellular space of the 
lesioned striatum, and consequently faster recovery from the amphetamine-induced turning 
response. Important to note that in Study III, BT13 was shown to acutely increase the level of 
extracellular dopamine in the dorsal striatum in mice. As mentioned earlier, RET signaling is 
suggested to negatively regulate DAT function and/or cell surface trafficking (Boger et al. 2007; 
Kopra et al. 2017; Littrell et al. 2012; Zhu et al. 2015). Moreover, it is possible that as a lipophilic 
compound, BT44 is able to diffuse into the non-lesioned hemisphere during the long infusion 
period where it could augment dopamine clearance from the extracellular space, for example by 
enhancing COMT-mediated degradation of dopamine as was shown to happen after GDNF 
administration in Study I. Further experiments assessing, for example, the effects of BT44 on DAT 
or COMT activity or its diffusion into the contralateral striatum are needed to explain the altered 
rotation rate profile. 
In the in vivo experiments, we encountered solubility problems related BT-compounds; they were 
insoluble to aqueous vehicles forcing us to use PG as a vehicle. Even with PG, the solution required 
heating and sonication in order to get the compounds thoroughly dissolved. We cannot be sure if 
any precipitation occurred in the infusion pumps or when the solution got in contact with aqueous 
extracellular fluid. These solubility issues should be resolved before proceeding to further in vivo 
experiments. The high-resolution 3D structure of GFRα1 and the model for GDNF-GFRα1 
interaction provide an opportunity for rational structure-based drug design (Leppänen et al. 2004). 
Novel molecules capable of binding to specific GFRα receptors with improved drug-like properties 
could help to overcome some of the difficulties related to the current BT compounds. After lead 
optimization, either BT-scaffold-based compounds or new GFL mimetics could be suitable for 
systemic administration. Compared to intracranial delivery it would be a less risky approach for 
large-scale clinical use and would help to overcome the problematic question about the most 
effective delivery site in the brain. However, the peripheral expression of GFRα and RET receptors 
should be considered when systemic administration of GFL mimetics is planned. Adverse effects 
can occur as a result of RET activation for example in the PNS, testis or thyroid gland. 
Apart from direct RET agonists, an attractive therapeutic approach for harnessing RET signaling 
pathways would be to develop selective positive allosteric modulators (PAMs) of GFRα1. The first 





animal models of PD (Tokugawa et al. 2003; Hedstrom et al. 2014). GFRα1-PAMs would potentiate 
the trophic effects of endogenous GDNF and provide major advantages over direct RET agonists: 
Firstly, they could reduce the risk of RET-induced adverse effects as compared to exogenous GDNF 
or direct RET agonists. The activation of RET would only occur in the presence of endogenous 
GDNF preserving the homeostatic regulation mechanisms of GDNF-GFRα1-RET signaling, and 
administration of unphysiological concentrations of GDNF would not be needed. Secondly, they 
could provide superior selectivity as compared to direct RET agonists owing to the limited 
expression of particular GFRα–RET pairs in different brain areas and other organs (Trupp et al. 
1997; Golden et al. 1998). Lastly, binding of a compound directly to RET on the surface interfacing 
with GFRα1 can potentially disrupt the signaling of endogenous GDNF. This partial antagonism 
could explain the submaximal efficacy of BT44 as compared to GDNF in our neurorestoration 
experiment (Study IV). In addition, continuous RET activation during the treatment infusion period 
might have caused downregulation of the receptor. In this case, subsequent withdrawal of the 
RET agonist would lead to an acute depletion of trophic support contributing to the lack of 
neuroprotective effect on nigral neurons. 
6.6 Methodological considerations 
6.6.1 Considerations relating to 6-OHDA lesion models 
In our neuroprotection experiment (Study III) evaluating the efficacy of BT13 in hemiparkinsonian 
rats, a single unilateral injection of 6-OHDA (16 μg) into the dorsal striatum resulted in relatively 
mild dopaminergic degeneration: in vehicle-treated rats, the density of TH-ir fibers in the striatum 
was reduced approximately by 55% and the number of TH-ir neurons in the SNpc by 27%, which 
correspond to the estimated state of the nigrostriatal system in PD patients at the onset of the 
motor symptoms, i.e. at early stage of the disease (Burke and O’Malley 2013). The lesion size was 
similar than the “regressive” lesion described by Penttinen et al. (2016). Because the size of the 
lesion was at the threshold of the motor manifestations, small changes at cellular level may have 
caused disproportionally profound functional improvement as seen with the almost completely 
vanished rotational behavior in GDNF and BT13 -treated rats (Björklund and Dunnett 2019). We 
also saw spontaneous recovery in terms of rotational behavior in vehicle-treated animals. This 
phenomenon is well-documented in the literature for rats with a small (0-30% loss of the SNpc 
neurons) or medium (30-75% loss of the SNpc neurons) 6-OHDA lesion (Stanic et al. 2003; Stanic 
et al. 2003b; Penttinen et al. 2016). The clear amphetamine-induced turning bias observed after 
two weeks is recovered by 10-16 weeks post lesion in animals with a medium-size lesion and even 
faster in animals with a small lesion. This functional recovery is associated with axonal regrowth, 
sprouting and phenotypic recovery of the nigrostriatal dopamine neurons (Blanchard et al. 1996; 
Finkelstein et al. 2000; Stanic et al. 2003). Spontaneous recovery is a confounding factor in our 
neuroprotection experiment implicating that the functional effects of BT13 have to be interpreted 
with adequate caution. The lack of effect on TH-ir and DAT-ir fibers in the striatum reinforces the 
view that the reduction in amphetamine-induced rotational behavior is not due to 
neuroprotection. Perhaps, a larger 6-OHDA lesion could have produced a more stable lesion with 




In the next experiment (Study IV), we wanted to utilize neurorestoration paradigm with a much 
more severe 6-OHDA lesion. In the neurorestoration model, it is possible to balance animals into 
experimental groups according to baseline rotation scores after the lesion (Figure 4.2.). This helps 
to control interindividual variation and reduce the groups sizes needed to see therapeutic effects. 
Of note, as BT13 was speculated to regulate DAT activity (Study III), we wanted to make sure that 
BT44 could not directly interfere with the neurotoxic effect of 6-OHDA which is dependent on 
DAT-mediated uptake into dopamine neurons. Most importantly, the delivery of the experimental 
compounds at the time when the lesion is already established reflects much better the clinical 
context in PD making the neurorestoration paradigm a more relevant model as compared to the 
neuroprotection paradigm. In addition, we wanted to produce a bigger and more stable lesion in 
order to get rid of spontaneous recovery and provide a larger window for the experimental 
therapeutics to produce their effects. 
The 6-OHDA delivery paradigm employed in our neurorestoration experiment, indeed, resulted in 
a much more severe lesion in agreement with the earlier results (Penttinen et al. 2016). In the 
lesion control group, the density of TH-ir fibers in the striatum was reduced approximately by 90% 
and the number of TH-ir cell bodies in the SNpc by 77% at two weeks post lesion. The number of 
TH-ir cells in the SNpc of PBS and PG -treated animals at 12 weeks post lesion was significantly 
lower as compared to the lesion control group indicating that the dopaminergic degeneration was 
not fully developed at the time of the treatment initiation but rather retrogradely progressing. It 
is well known that striatal denervation occurs rapidly after 6-OHDA injection into the striatum, but 
the cell bodies in the SNpc die gradually over several weeks or months (Björklund et al. 1997). The 
lesion size in the neurorestoration experiment reflects the state of the nigrostriatal system in 
advanced PD, i.e. the status of patients when intracerebral treatment procedures can be 
considered (Kordower et al. 2013). The neuronal damage was accompanied by persistent motor 
deficits as indicated by prominent amphetamine-induced rotational asymmetry and decrease in 
spontaneous contralateral forepaw use in the cylinder test in vehicle-treated rats. Regardless of 
the severe lesion, BT44 was able to induce delayed functional recovery in turning behavior and 
show small, but significant, restorative effect on dopaminergic processes in the striatum. 
Considering that the behavioral data from the cylinder test were not in line with the 
amphetamine-induced rotation data and no effects on dopaminergic cell bodies in the SNpc were 
observed, the neurorestorative potential of BT44 need to be confirmed in future experiments. It 
is recognized, that the aggressive lesion may have limited the neurorestorative effects of BT44 in 
our study. 
Earlier studies have shown that striatal 6-OHDA lesion can downregulate GFRα1 and RET 
expression in the nigrostriatal pathway up to one month post lesion (Marco et al. 2002; Kozlowski 
et al. 2004; Gavin et al. 2014). Due to the fact that the delivery of the RET agonists occurred during 
this period of time, the downregulation of RET can negatively affect their neuroprotective efficacy. 
The extent of the receptor downregulation in the disease model would be an important factor to 
clarify in the future before proceeding into large-scale efficacy studies in order to gain better 
understanding of the potency of the experimental compounds in vivo. The ability of GDNF to halt 
the degeneration of dopaminergic cell bodies is facilitated by its retrograde transport to the SNpc 





compounds (Lapchak et al. 1997; Tomac et al. 1995). Obviously, the considerably higher potency 
of GDNF as compared to BT-compounds as illustrated in Table 5.1 also accounts for its better 
efficacy in the neuroprotection and restoration experiments.  
The unilateral 6-OHDA lesion model is based upon the imbalance of the nigrostriatal system 
between the hemispheres. The effects of unilaterally delivered interventions are compared to the 
intact side of the brain. Thus, this model is not optimal for testing the effects of lipid soluble 
compounds that readily spread to the contralateral hemisphere after unilateral administration 
and potentially elicit effects there too. BT-compounds tested in our studies are very lipophilic. 
Their putative diffusion to the control side during the seven- or 14-day infusion may compromise 
the read-outs that are based on measuring the asymmetry between the hemispheres. 
6.6.2 Relevance of the behavioral tests in 6-OHDA lesion models 
6.6.2.1 Correlation between amphetamine-induced turning rate and nigrostriatal 
integrity 
Although amphetamine-induced rotation test has become the standard tool to monitor motor 
impairment and functional recovery in experiments with neuroprotective interventions, there are 
some important pitfalls that should be carefully considered in the future use of this test like 
Björklund and Dunnett (2019) have described in their critical reappraisal. We also analyzed the 
correlation between amphetamine-induced turning rate and the striatal TH-ir fiber density and 
nigral TH-ir cell number in the neurorestoration experiment (Study IV). In agreement with earlier 
reports, we did not find good correlations between these measures (Winkler et al. 1996; Kirik et 
al. 1998; Kozlowski et al. 2000; Voutilainen et al. 2009; Tronci et al. 2012; Björklund and Dunnett 
2019). 
Other neuronal circuits than nigrostriatal dopamine pathway may be responsible for the 
functional recovery seen in the experiment. For example, amphetamine induces dopamine release 
from dendritic vesicles in the SNr where dopamine primarily acts at presynaptic D1 receptors of 
the striatonigral MSNs facilitating GABA release (Rommelfanger and Wichmann 2010; Timmerman 
and Abercrombie 1996). This reduces the overactive firing of GABAergic SNr neurons projecting to 
the thalamus that is implicated in the motor imbalance of the unilateral 6-OHDA model. In our 
neurorestoration experiment, amphetamine-induced dendritic dopamine release in the SNr may 
have been augmented in GDNF-treated rats due to the significant preservation of dopaminergic 
cell bodies in the SNpc. Indeed, in vivo microdialysis measurements have also demonstrated 
enhanced amphetamine-evoked dopamine release in the SN of GDNF-treated rats (Hoffman et al. 
1997). Thus, GDNF-induced significant functional improvement in animals with advanced 
dopaminergic denervation can be mediated by increased dopamine release in the striatal output 
structures. The sparse remaining striatal innervation may have a minor contribution in this case 





In order to avoid amphetamine-evoked dopamine release in the extra-striatal structures as a 
possible confounding factor, it could have been beneficial to include apomorphine-induced 
rotational assessment in our behavioral test battery. The denervation of the striatum was at the 
level that is generally considered to be sufficient to cause supersensitization of the postsynaptic 
dopamine receptors which is a prerequisite for apomorphine-induced rotation test (Ungerstedt 
1971). This test has been reported to correlate better with the loss of both striatal TH-ir fibers and 
nigral TH-ir cell bodies in 6-OHDA lesioned mice as compared to amphetamine-induced rotation 
test (Grealish et al. 2010). Apomorphine-induced turning behavior also had a better capacity to 
discriminate mice according to the extent of their nigrostriatal damage. 
6.6.2.2 Other behavioral tests 
Amphetamine-induced rotation test is a practical experiment to assess motor asymmetry and 
functional recovery in neuroprotection studies. PD patients, however, show a more complex 
repertoire of motor deficits than can be recapitulated with simple drug-induced motor tests. 
Therefore, behavioral tests allowing quantification of spontaneous motor and sensorimotor 
functions would provide more informative outcomes (Dunnett 2005). It is recommended to 
combine amphetamine-induced rotation test with at least one other test measuring spontaneous 
motor behavior (Björklund and Dunnett 2019). For 6-OHDA lesioned rats, paw-use asymmetry 
measured with the cylinder, stepping or staircase test, and for 6-OHDA lesioned mice e.g. 
sensorimotor behavior in the corridor test, would be profitable adjuncts. 
For these reasons, we also analyzed spontaneous forepaw-use asymmetry using the cylinder test 
in our neurorestoration experiment (Study IV). Despite significant recovery in the amphetamine-
induced turning behavior, neither GDNF nor BT44 were able to normalize forepaw use in the 
cylinder test. These data are in accordance with earlier reports where GDNF protein injection or 
gene therapy into 6-OHDA-lesioned striatum significantly alleviated amphetamine-induced 
turning behavior but showed no effects in the cylinder test (Georgievska et al. 2002; Gasmi et al. 
2007b; Yue et al. 2014). Also in 6-OHDA lesioned mice, the behavioral deficits observed in the 
cylinder test showed poor correlation with amphetamine-induced turning behavior as well as with 
the integrity of the nigrostriatal pathway (Grealish et al. 2010). It should be noted, that not only 
the total extent of striatal dopaminergic denervation, but also its regional distribution affects the 
functional output and magnitude of the motor impairment (Kirik et al. 1998; Björklund and 
Dunnett 2019). Amphetamine-induced turning rate is known to be particularly sensitive to 
changes in dopaminergic innervation within the dorsomedial and dorsolateral parts of the 
striatum, whereas the ventrolateral parts of the striatum have more pronounced control on 
movement initiation, sensorimotor orientation and skilled motor behavior. Since our treatment 
infusions were directed into the dorsomedial striatum, they might have had limited effects on the 
ventrolateral striatum, and thus on spontaneous forepaw use in the cylinder test. 
Notably, most of the behavioral tests used to assess the non-motor symptoms of PD are not 
particularly designed for parkinsonian animals (Asakawa et al. 2016). We are lacking specific tools 
for the assessment of non-motor symptoms especially in rodent models of PD. Development of 





neglected field of research. Apart from the behavioral test, also other approaches can be 
considered to follow longitudinal functional changes in animal models of PD. For example, in vivo 
electrophysiology offers another approach to detect functional changes in various neuronal 
circuits in freely-moving animals. 
6.6.3 Validity of the disease models 
The encouraging preclinical results with NTF-based therapies have failed to translate into positive 
outcomes in clinical trials. To enable successful clinical translation of disease-modifying 
treatments, we should take a critical look at the limitations of the current preclinical models. Are 
the results obtained with these models relevant in terms of the clinical condition?	As experimental 
animals do not naturally develop PD, the disease has to be artificially induced by targeting one or 
few pathological processes of the disease.  
A major obstacle in developing effective disease-modifying therapies for PD is the lack of animal 
models that fully recapitulate the pathological and functional disease progression and the 
phenotype of PD (Paul and Sullivan 2018). The current animal models typically mimic only one or 
few aspects of the disease. The traditional neurotoxin-based (e.g. 6-OHDA and MPTP) animal 
models, for example, reproduce the degeneration of nigrostriatal dopamine neurons and 
neuroinflammation but fail to replicate several other crucial features such as the accumulation of 
α-syn containing protein inclusions. The mechanism of the neuronal insult is also different from 
the human disease. One of the important characteristics of human PD is that the pathology 
progresses over decades. Neurotoxins, instead, produce an acute lesion leaving little time for 
compensatory mechanisms to take place. The genetic animal models of PD seem to exhibit good 
construct validity as they are based on mutations that cause genetic forms of the human disease. 
However, they fail to produce a clear parkinsonian phenotype in terms of neurodegeneration and 
motor symptoms. 
Traditionally, the neurotoxin-induced animal models are focused on insulting the nigrostriatal 
dopamine neurons. This, indeed, offers a good approach to model motor dysfunctions but does 
not take into consideration the widespread nature of the disease. PD pathology is not restricted 
to the nigrostriatal dopamine system but affects multiple neuronal populations and 
neurotransmitter systems, which also give rise to the numerous non-motor symptoms of PD and 
should be better considered in preclinical drug development (Olanow et al. 2015b). Overall, the 
neurotoxin models serve as good tools for testing symptomatic treatments but might not be as 
useful in the development of disease-modifying therapies. 
One common issue with the rodent models of PD is the routine use of young adult animals as 
experimental subjects. Metabolism, plasticity and neuronal function in the young brain differ from 
those of the aged brain which makes the translation to PD patients even harder. Perhaps, 
establishment of disease models in aged animals could partly help to overcome this translatability 
problem. Another common problem relates to the timing of a neurotrophic therapy (Paul and 
Sullivan 2018). Studies where the therapy is administered after the nigrostriatal pathway has 




clinical scenario where a substantial nigrostriatal damage already exists at the time when the 
therapy can be initiated. In the majority of the preclinical studies, however, NTFs have been 
administered before or shortly after the lesion. Thus, there is a mismatch with clinical trials where 
the NTF interventions are mostly tested in patients with advanced PD. 
Since most animal models tend to reproduce only few features of human PD, it is essential to test 
potential treatments in a combination of different disease models. In addition to neurotoxin-
based models, α-syn-based models should be part of the preclinical testing. Neuroinflammation, 
as one important aspect of the PD pathobiology, also deserves more attention. Furthermore, 
dopamine neurons generated from PD patient-derived induced pluripotent stem (iPS) cells should 
be included in the battery of preclinical PD models. They harbor the full human-specific metabolic 
and regulatory pathways, and thus provide a valuable tool to investigate dopamine metabolism 
and mechanisms of dopaminergic degeneration (Meiser et al. 2013). Other possible platforms to 
be used in drug development include, for example, organoids, 3D cell constructs and organ-on-a-
chips. The importance of such new platforms is growing, and they will help us to replace some of 
the in vivo experiments according to 3R principles. 
If neurotrophic therapies will enter the clinical use, they will most probably be used in combination 
with standard PD medications. Therefore, it is of outmost importance to evaluate their efficacy in 
animal models together with other anti-parkinsonian treatments.	For example, GDNF delivery into 
the lateral ventricle of MPTP-lesioned marmosets was shown to reduce the severity of L-DOPA-
induced dyskinesias (Iravani et al. 2001). These type of co-administration experiments are 
warranted to improve the translatability of preclinical NTF studies. 
6.7 General discussion 
PD is a common neurodegenerative disorder with complex pathobiology and multitude of genetic 
and environmental risk factors (Kalia and Lang 2015). The diagnosis is preceded by a several years 
or even decades long prodromal phase, during which the characteristic parkinsonian Lewy 
pathology progresses from the periphery into the brain. Eventually, patients become afflicted by 
cardinal motor symptoms that arise from the progressive loss of nigrostriatal dopamine neurons. 
Equally importantly, several other neuronal populations are also affected which contributes to 
various non-motor symptoms of PD. The current treatments mainly target the motor impairment 
by replenishing reduced dopaminergic neurotransmission within the striatum. None of them, 
however, is capable to modify the neurodegenerative process or slow down the progression of 
the disease. Novel disease-modifying agents are urgently needed. NTFs and their biological effects 
mimicking small molecule compounds hold promise for this quest, but more preclinical work is 
required to further characterize their mechanisms of action, confirm their neuroprotective 
potential and uncover their effects on other brain cells than nigrostriatal dopamine neurons. It is 
not clear, for example, whether exogenous NTFs directed to the nigrostriatal dopamine system 
have significant effects on the non-motor symptoms of PD. Systemically administered NTF 
mimetics with widespread target engagement in all afflicted brain areas could potentially help to 





PD is a clinically heterogeneous disorder. There are many ways to classify various subtypes of PD, 
for example based on motor symptoms (e.g. tremor-dominant vs. non-tremor-dominant), 
cognitive features, age at onset, rate of progression or various combinations of these (Marras and 
Lang 2013). The different subtypes are believed to have distinct etiologies and pathogenesis. 
Better understanding of those would allow the identification of novel therapeutic targets and 
open avenues for the development of effective and safe disease-modifying therapies. 
GDNF and NRTN have been considered as the most promising candidates for the first neurotrophic 
therapy for PD based on the solid body of preclinical evidence. Failures in the phase II clinical trials, 
however, have raised questions whether RET is an optimal target receptor. In PD models induced 
by viral vector-mediated overexpression of α-syn, gene delivery of GDNF to the SNpc had no effect 
on the survival of dopamine neurons or motor impairment (Lo Bianco et al. 2004; Decressac et al. 
2011). Importantly, α-syn overexpression was shown to downregulate the transcription factor 
Nurr1 and its downstream target RET diminishing the intracellular response to GDNF (Decressac 
et al. 2012). Nurr1 and RET expression was also found to be reduced in nigral neurons in PD 
patients suggesting that α-syn-induced downregulation of RET might account for the negative 
results of GDNF in the α-syn overexpressing animal models and its limited efficacy in the clinical 
trials (Chu et al. 2006; Decressac et al. 2012). It should be noted, however, that there are also 
contrasting reports showing no downregulation of Nurr1 or RET in PD patients (Bäckman et al. 
2006; Su et al. 2017; Walker et al. 1998). Formation of α-syn aggregates may also impede the 
axonal transport of GDNF like it has been shown to impair the transportation of BDNF signaling 
endosomes (Chung et al. 2009; Volpicelli-Daley et al. 2014). This is an important factor to consider 
when planning the future experiments and deciding the administration sites of NTFs. 
Gain-of-function mutations in Ret gene causing the inherited cancer syndromes MEN2 and familial 
medullary thyroid carcinoma have triggered concerns regarding the oncogenic potential of RET 
activation (Plaza-Menacho et al. 2006). However, with an intermittent dosing scheme, the 
activation of RET would not be continuous like in the RET-related cancers which would help to 
manage the risk for tumors. Important to note, that in a recent study investigating the long-term 
effects of GDNF overexpression from the endogenous locus, continuously increased activation of 
GDNF-RET signaling did not elicit adverse effects or tumors (Turconi et al. 2020). Intermittent 
delivery also results in smaller cumulative doses as compared to continuous dosing schemes 
(Whone et al. 2019). This further helps to avoid potential safety risks. Target engagement in a 
pulsatile fashion may also offer benefits over continuous receptor stimulation in terms of ligand-
dependent receptor desensitization that potentially reduces the responsiveness of target tissues 
to a NTF therapy (Lohse 1993). 
Due to the abovementioned issues, it is vital to continue looking also for other, RET-independent 
opportunities for a disease-modifying therapy. Here, unconventional NTFs CDNF and MANF have 
shown great promise in preclinical studies. However, our knowledge of their biological role and 
mechanism(s) of action is still limited (Lindahl et al. 2017). The discovery of their putative 
receptors would enable better understanding of their physiological functions and development of 




6.7.1 Importance of biomarker development 
It is imperative to develop better diagnostic tools and novel biomarkers in parallel with disease-
modifying therapies to allow earlier intervention with neuroprotective agents, and consequently 
an improved therapeutic outcome. With the current diagnostic criteria, PD is identified only upon 
the manifestation of the motor symptoms which occurs several years after the neurodegenerative 
process has started (Miller and O’Callaghan 2015; Parnetti et al. 2019). This hinders the attempts 
to intervene at the	earliest phase of the disease when there is still a sufficient number of surviving 
dopaminergic neurons and axons that are capable to respond to the therapy. A reliable prodromal 
biomarker could provide a prolonged time frame, during which disease-modifying candidates 
could be administered to halt or slow down the cell loss. Currently, this time frame is not very long 
from the diagnosis to virtually complete loss of dopaminergic fibers in the putamen (4 to 5 years) 
(Burke and O’Malley 2013; Kordower et al. 2013). The earlier the NTF-based therapy can be 
initiated, the better efficacy it is expected to have as was demonstrated in the clinical trial with 
AAV2-NRTN (Olanow et al. 2015). In an effort to enable enrolment of patients at the earliest stage 
of PD into clinical trials of neuroprotective therapies, the International Parkinson and Movement 
Disorder Society task force has developed research criteria for prodromal PD (Berg et al. 2015). 
Identification of individuals in the prodromal phase would also facilitate the clarification of the 
disease mechanisms and progression. On the other hand, there is a greater risk for misdiagnosis, 
particularly with atypical parkinsonian syndromes, at the early stages of the disease (Tolosa et al. 
2006). 
PD should not be conceptualized as a unitary disorder (Berg et al. 2014). It comprises a spectrum 
of subtypes with distinct etiologies, pathological processes and therapeutic needs. Validated 
biomarkers would help to stratify patients according to their individual form of the disease. More 
precise diagnosis would pave the way for better understanding of the pathological processes in 
each subtype and more personalized disease management. Importantly, disease subtyping would 
contribute to the development of more translational disease models and design of more 
successful clinical trials with stratified inclusion criteria. The failed attempts to find 
neuroprotective strategies for PD may stem from the reductionist approach in the conducted 
clinical trials which have paid little attention to the variability of the disease at the individual level 
(Espay et al. 2017). 
Currently, UPDRS is used for longitudinal follow-up of the disease progression based on episodic 
and subjective clinical evaluations. Thus, drug development decisions in clinical trials rely on 
sparse datapoints contributing to frequent and costly failures. There is a need for reliable 
longitudinal biomarkers. Development of digital biomarkers, for example, may help to address 
many of the current diagnostic shortcomings in an economical fashion. They would allow an 
objective approach to continuously track fluctuations in motor and non-motor symptoms during 
patients’ daily life. The resulting rich real-world datasets may prove to be highly predictive in 
assessing clinical improvement in PD studies and permit personalized therapeutic adaptations. 
Ideally, preclinical drug development would already be accompanied with a translatable 





and regular patient monitoring. This kind of translatable biomarker would help to predict the 
effects of an intervention in a patient population based on preclinical tests in animal models. For 
example, imaging modalities would be suitable for translatable biomarkers because they provide 
a direct approach to measure specific neurofunctional properties and the same methodology can 
be applied both to experimental animals and humans. 
6.7.2 Issues with the clinical studies 
Despite promising outcomes in preclinical studies and open-label phase I trials, none of the 
controlled double-blind phase II trials have reported clear clinical benefit for intracranial GDNF or 
NRTN therapy in patients with moderate or advanced PD (Hegarty et al. 2017). Negative outcomes 
from these proof-of-concept studies have raised questions whether NTFs in general are 
translatable into an effective disease-modifying therapy or whether the trials have been 
conducted sub-optimally. If the NTF hypothesis is still valid, the limitations of the studies should 
be carefully appraised. 
The importance of conducting placebo-controlled double-blind trials should be underlined. 
Marked placebo effect is a well-described phenomenon in PD trials, especially when neurosurgical 
procedures are involved, which may explain the efficacy differences between the open-label and 
controlled double-blind trials (Goetz et al. 2008; Alterman et al. 2011). Therefore, no conclusions 
should be drawn from the open-label studies that are not properly controlled for the placebo 
effect. 
Patients enrolled in the phase II trials may have been too advanced to benefit from the NTF 
therapy (Olanow et al. 2015). Dopamine neurons are so profoundly degenerated and 
dysfunctional at the later stages of PD that they might not be capable of responding to the therapy 
anymore. Indeed, greater benefits have been observed in a subgroup of patients who received 
AAV2-NRTN therapy less than five years after the diagnosis (Bartus 2015; Olanow et al. 2015). In 
the future, it might be necessary to recruit patients at an earlier stage of the disease which 
complicates weighing the risks against the benefits. 
Transport of intraputamenally delivered GDNF or NRTN to the dopaminergic cell bodies in the 
SNpc is thought be necessary for their pro-survival effects. Thus, the feasibility of treating 
advanced PD patients with these factors is questioned because the putamenal innervation is 
almost completely disappeared within 4-5 years post diagnosis (Kordower et al. 2013). This 
denervation potentially contributes to the impaired retrograde axonal transport, as reported in 
AAV2-NRTN-treated patients enrolled in the clinical trial more than five years post diagnosis 
(Bartus et al. 2011; Bartus et al. 2015). 
There are some indications of clinical benefits at the later time points of the trials suggesting 
delayed and sustained effects for NTFs (Love et al. 2005; Marks et al. 2010; Patel et al. 2005). Thus, 
a longer-term follow-up might be required to detect possible clinical improvements. Ethical 
aspects, however, need to be considered in order to avoid excessively long exposure to placebo 




It has been suggested that technical differences in the drug delivery systems and infusion 
protocols partly contributed to the varying results between the phase I and phase II trials 
(Salvatore et al. 2006; Sherer et al. 2006; Morrison et al. 2007). Furthermore, explanations for the 
lack of efficacy in the phase II trials can also include insufficient dosage, heterogeneous or 
inadequate distribution of GDNF and NRTN in the target tissue and formation of neutralizing 
antibodies (Tatarewicz et al. 2007). 
6.7.3 Future directions 
Despite holding great therapeutic potential for PD, it might well be that NTFs are not sufficient 
alone to combat neurodegeneration and restore neuronal function. Combination therapies may 
offer an opportunity to maximize the benefits of NTFs. Coadministration of different NTFs seems 
to be more efficient in protecting, repairing and activating dopamine neurons than the delivery of 
a single NTF (Voutilainen et al. 2017). NTFs could provide additive therapeutic benefit also when 
administered in conjunction with other treatment strategies. Usually, synergistic therapies help to 
reduce the dose of each individual treatment, and thus mitigate the risk for possible adverse 
effects. 
It is becoming evident that the underlying pathological processes such as Lewy pathology or the 
augmented neuroinflammatory state have to be resolved in order to achieve favorable conditions 
for neuroregeneration. Only then, neurotrophic therapies would have a better opportunity to 
promote neuronal survival. Thus, it would be worthwhile to study the effects of NTFs in 
conjunction with, for example, experimental anti-α-syn antibodies that reduce the spread of α-
syn aggregates in the brain. Chronic neuroinflammation is one of the key elements in PD 
pathogenesis contributing to the neuronal dysfunction and degeneration. Reactive microglia are 
the primary mediators of neuroinflammation. Astrocytes, in turn, regulate the microglial 
responses by secreting factors that reduce their phagocytic activity and production of ROS. 
Therefore, combining anti-inflammatory (or immunomodulatory) treatments with trophic factors 
may open new avenues to induce regenerative processes in PD. Interestingly, experiments in 
cultured midbrain microglial cells identified GDNF as one of the major astrocyte-derived factors 
regulating their activation in a GFRα1 receptor -dependent manner (Rocha et al. 2012). CDNF and 
MANF have also been shown to reduce the secretion of pro-inflammatory cytokines from glial cells 
suggesting an important regulatory role in neuroinflammation (Zhao et al. 2013; Zhu et al. 2016; 
Neves et al. 2016). Thus, they might provide synergistic benefits if administered together with 
other NTFs (Voutilainen et al. 2017). 
The promising safety outcomes in the first-in-human study with CDNF encourage its further clinical 
development. It will be most interesting to see quantitative data on the clinical efficacy of 
intraputamenally delivered CDNF in PD patients. Our Studies I and II provide support for the clinical 
development of CDNF and MANF. The main outcomes in Study I suggest that NTFs have diverging 
effects on dopamine release and metabolizing enzymes in the normal rat brain. It was promising 
to see that CDNF and MANF did not decrease dopaminergic neurotransmission in the striatum. 
Thus, they would be most probably compatible with the current dopaminergic medications of PD. 





attention in possible clinical trials in the future in terms of the compatibility of GDNF therapy with 
the existing medications of patients, in particularly with COMT-inhibitors. More extensive 
preclinical experiments determining the effects of NTFs on dopamine neurochemistry in a time-
dependent manner should be performed. In addition, their coadministration together with 
standard symptomatic PD medications should be studied in animal models of PD to support the 
clinical development. 
NTFs are protein therapeutics which complicates their clinical use and restricts them to more 
advanced disease conditions due to the need for intracranial administration. The initiation of the 
treatment at a later stage of the disease can potentially reduce their neuroprotective potential. 
To overcome these limitations, we have developed small molecule NTF mimetics that could be 
suitable for peripheral administration at an earlier phase of the disease. Indeed, BT13 and BT44 
seemed to induce functional recovery in one commonly used animal model of PD when infused 
into the brain at the time or few weeks after the neurotoxin lesion (Studies III and IV). These RET 
signaling activating compounds serve as promising leads that deserve further development. First, 
their pharmacochemical properties should be improved to enable better solubility into aqueous 
vehicles and longer half-life in the brain. Secondly, their potency should be increased in order to 
avoid need for micromolar concentrations, and consequently reduce the risk for unspecific off-
target effects. Higher efficacy would also be desirable in order to better reveal their 
neuroprotective potential. Lastly, the mechanism of direct RET agonism reduces their specificity 
and increases the risk for antagonized endogenous GFL-GFRα signaling. Therefore, the 
development of the next generation compounds towards GFRα PAMs would most likely improve 
their specificity and safety profile.  
With the improved GFL-mimicking drug candidates, the neuroprotective efficacy after peripheral 
administration should be tested in proper dose-response studies using several well-validated PD 
models to gain a more comprehensive picture of their effects on PD pathology. A critical question 
that remains is whether they would work in α-syn-based PD models where Nurr1 and RET may be 
downregulated (Decressac et al. 2012). As we learned from Studies III and IV, the behavioral read-
outs did not correlate optimally with the histological read-outs measuring the integrity of the 
nigrostriatal dopamine system. Therefore, more attention should be paid to validate the animal 
models and behavioral assessments properly in pilot experiments before applying them into large-





The main objective of this work was to clarify the functional effects of intracranially delivered 
GDNF, CDNF and MANF on the nigrostriatal dopamine system in the normal rat brain and to 
examine the neuroprotective potential of novel small molecule RET agonists in a 6-OHDA rat 
model of PD. Generally, the results support the preclinical characterization of CDNF, MANF and 
RET agonists as potential neurotrophic therapies for PD. 
The principal findings and conclusions of this thesis are:  
1. Intrastriatal injection of MANF enhances stimulus-evoked dopamine release and 
DOPAC/dopamine turnover in the striatum of normal freely-moving rats. GDNF-injection, 
instead, increases in vivo TH and COMT activity and decreases MAO-A activity in the 
striatum of normal rats. These divergent and long-lasting effects of exogenously 
administered NTFs on dopamine neurochemistry are noteworthy when considering their 
compatibility of with the existing dopaminergic medications of the patients. 
2. CDNF readily diffuses in the brainstem but is not transported to distal brain areas after an 
injection to the SN of intact rats. Nigrally injected CDNF also colocalizes with TH-ir, but not 
with PV-ir, neurons in the SN. These data suggest dopaminergic selectivity of CDNF and 
facilitate the selection of optimal delivery site and protocol for CDNF. 
3. Small molecule RET agonists BT13 and BT44 induce the phosphorylation of RET and 
activate the downstream pro-survival signaling pathways Akt and ERK. They promote the 
survival of cultured midbrain dopamine neurons in a RET-dependent manner. BT13 
stimulates striatal dopamine release in vivo and improves functional recovery in a 6-OHDA 
rat model of PD. BT44 alleviates amphetamine-induced motor dysfunction in 6-OHDA 
lesioned rats and shows potential to restore striatal TH-ir fibers. Unlike GFLs, BT13 and 
BT44 are able to cross the BBB. They serve as promising lead compounds but require 
further drug design and development in terms of their efficacy and pharmacochemical 
properties. 
Taken together, these results shed light on the functional effects and distribution properties of 
exogenously administered NTFs on the nigrostriatal dopamine system in the intact rat brain. This 
work also provides a proof-of-principle for small molecule RET agonists mimicking the 
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